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resumo 
 
 
A Doença de Alzheimer (DA) é a doença neurodegenerativa mais prevalente a 
nível mundial, e a principal causa de demência na população sénior. O 
processamento anormal da Proteína Precursora de Amilóide de Alzheimer 
(PPA) e a produção aumentada do seu fragmento beta amilóide (Aβ) 
constituem eventos centrais na patogénese da DA, o que tem fomentado a 
investigação da PPA. Esta tem sido descrita como uma proteína envolvida em 
processos celulares determinantes, como adesão, migração, diferenciação, e 
sobrevivência celular. Como tal, devido à necessidade imperativa de 
caracterizar as suas funções biológicas, a investigação de proteínas que 
interagem com a PPA é de vital importância. Recentemente, diversas 
proteínas foram identificadas no nosso laboratório como putativos interatores 
da PPA, através da técnica de Yeast Two Hybrid (YTH). De entre estes, o fator 
de crescimento de ligação à heparina semelhante ao fator de crescimento 
epidermal (HB-EGF) revelou-se um interessante alvo de estudo.  
O HB-EGF é um membro da família do fator de crescimento epidermal (EGF) 
com capacidade de ligação à heparina, que se destaca pelas suas 
capacidades de estimular o crescimento e diferenciação celulares, tendo sido 
proposto como um relevante fator trófico para o desenvolvimento e 
manutenção do sistema nervoso central (SNC). Na verdade, o HB-EGF é mais 
abundante no SNC do que o próprio EGF, o que sugere que o HB-EGF é o 
principal ligando neuronal para o recetor do EGF (EGFR). O HB-EGF é 
sintetizado como um precursor de 208 aminoácidos (pre-proHB-EGF), sendo 
exposto na membrana celular como um precursor transmembranar de 20-30 
kDa, o proHB-EGF. Esta forma é subsequentemente proteoliticamente 
processada, gerando um péptido solúvel que é libertado para o meio 
extracelular (sHB-EGF). Curiosamente, o HB-EGF apresenta atividades 
biológicas parácrinas, autócrinas e justácrinas. 
O presente trabalho teve como principal objetivo a validação da interação entre 
a PPA e o HB-EGF, primeiramente alcançado através da técnica de YTH, que 
revelou também que a interação entre as duas proteínas não é mediada pelo 
domínio intracelular da PPA. Esta interação foi subsequentemente confirmada 
por ensaios de GFP-Trap pull-down em cultura de células de mamífero, e a 
sua relevância fisiológica estudada através de estudos de co-localização e 
sinalização celulares, usando células HeLa transfectadas com os cDNAs da 
PPA e do HB-EGF. Apesar do papel funcional do complexo PPA/HB-EGF não 
ter sido determinado, os resultados obtidos sugerem que as duas proteínas 
interagem física e funcionalmente, influenciando a sinalização mediada por 
cada uma delas separadamente, como a ativação da via de sinalização MAPK 
que verificámos ser também induzida pela PPA. Adicionalmente, descrevemos 
uma nova interação proteica entre a PPA e uma forma precursora do EGF, e 
demonstrámos que a PPA atua de forma sinérgica com o EGF. Estes 
resultados levam a uma maior compreensão da biologia da PPA, uma proteína 
importante na fisiologia cerebral e na fisiopatologia da DA. 
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abstract 
 
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder 
worldwide and the leading cause of dementia in the elderly. Abnormal 
processing of Alzheimer’s amyloid precursor protein (APP) and increased 
generation of its amyloid beta (Aβ) fragment are central events in the AD 
pathogenesis, propelling major studies on APP biology. APP is thought to be 
involved in important processes such as cell adhesion, survival, migration and 
differentiation. Therefore, because of the imperative need to study APP 
biological functions, the search for APP-binding partners has stand out. 
Recently in our laboratory, a plethora of putative APP-binding proteins was 
unraveled through the use of the Yeast Two Hybrid (YTH) system. Among 
them, the heparin-binding epidermal growth factor-like growth factor (HB-EGF) 
has emerged as an interesting target of study.  
HB-EGF is a heparin-binding member of the EGF family of growth factors that 
stimulates growth and differentiation. It has been purposed has an important 
trophic factor in the developing and adult central nervous system (CNS), being 
expressed at much higher levels than EGF in the CNS, which indicates that 
HB-EGF may serve as a major ligand for EGFR in neurons. HB-EGF is 
synthesized as a pre-pro-form of 208 amino acids in length and is expressed at 
the cell surface as a 20-30kDa type I transmembrane precursor, named proHB-
EGF. This larger membrane-anchored precursor is then proteolytically 
processed, generating the mature soluble HB-EGF (sHB-EGF) that is released 
to the extracellular medium. Very interestingly, HB-EGF presents autocrine, 
paracrine and juxtacrine biological activities, with proHB-EGF evidencing 
unique biological characteristics distinct from sHB-EGF.  
In the work here described, we first validated the APP/HB-EGF interaction by 
yeast co-transformation, and unraveled that the interaction is not mediated by 
the APP intracellular domain (AICD). We further confirmed it as an in vivo 
interaction by GFP-Trap pull-down assays and accessed the physiological 
relevance of this novel interaction through co-localization and signaling studies 
in HeLa cells transfected with the APP-GFP and HB-EGF cDNAs. Although the 
functional role of the APP/HB-EGF complex was not determined, results 
suggest that these proteins physically and functionally interact, having potential 
value in regulating each other signal pathways, with a role for APP in inducing 
the activation of the MAPK signaling being evidenced. In addition, a putative 
novel interaction with a proEGF species was also detected and APP was 
shown to act synergistically with EGF to activate the MAPK signaling. These 
results deepen our understanding of the APP biology, a crucial protein in 
cerebral physiology and AD pathophysiology. 
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1 Abbreviations 
AD Alzheimer’s disease 
ADAM  A disintegrin and metalloprotease 
Ade Adenine 
AICD APP intracellular domain   
APLP APP-like protein 
APP Amyloid precursor protein 
AR Amphiregulin 
Aβ Amyloid beta-peptide 
BCA Bicinchoninic acid 
Bcl-6  B cell lymphoma 6 
BSA Bovine Serum Albumin 
BTC Betacellulin 
cDNA Complementary deoxyribonucleic acid 
CNS  Central nervous system 
CSF Cerebrospinal fluid 
CTF C-terminal fragment 
DG Dentate gyrus 
 
DO Dropout 
DT  Difteria Toxin 
DTR  Difteria Toxin Receptor 
ECL  Enhanced chemiluminescence 
EGF Epidermal growth factor 
EGFP Enhanced Green Fluorescent Protein 
EGFR 
 
Epidermal Growth Factor Receptor 
ER  Endoplasmic Reticulum 
 
ErbB  
 
Erythroblastic Leukemia Viral Oncogene Homolog 
ERK Extracellular signal regulated kinase 
GAL4 Gal4 transcription factor 
GAL4-AD Gal4 activation domain 
GAL4-BD Gal4 DNA binding domain 
GFLD Growth factor-like domain 
GFP Green Fluorescent Protein 
GPCRs  G-protein coupled receptors 
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HBD Heparin binding domain 
HB-EGF  Heparin-binding Epidermal Growth Factor-like Growth Factor 
HB-EGF-C  HB-EGF cytoplasmic segment 
HeLa  Henrietta Lacks immortalized cell line 
His Histidine 
HSPG Heparan sulfate proteoglycans 
JM  Juxtamembrane 
JNK  c-Jun N-terminal kinase 
KPI Kunitz protease inhibitor 
LB Loading Buffer 
LB medium Luria Bertani growth medium 
Leu Leucine 
LGB Lower Gel Buffer 
LiAc Lithium acetate 
LPA  Lysophophatidic acid 
MAPK 
 
Mitogen-activated protein kinase 
MDC9   Metalloprotease/disintegrin/cysteine-rich protein 9 
MMP  Metalloproteinase 
mRNA  Messenger ribonucleic acid 
NE  Nuclear envelope 
NFKB  Nuclear Factor-Kappa B 
NRDc  N-arginine dibasic convertase 
O/N Overnight 
OD Optical Density 
ORF  Open Reading Frame 
PBS Phosphate buffered saline 
PI3K  Phosphatidylinositol 3-Kinase 
 
PKC Protein Kinase C 
PLCγ  
 
Gamma isoform of phospholipase C 
PLZF  Promyelocytic leukaemia zinc finger protein 
PM  Plasma Membrane 
PMA  Phorbol-12-myristate-13-acetate 
P-MAPK Phosphorylated MAPK 
PPIs Protein-protein interactions 
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PS1 and PS2 Presenilin-1 and -2 
P-STAT3 Phosphorylated STAT3 
QDO Quadruple Dropout 
rpm Rotation per minute 
RT Room Temperature 
sAPP Secreted APP 
SD Supplement dropout medium 
SDS Sodium dodecylsulfate 
SDS-PAGE Sodium dodecylsulfate - Polyacrilamide gel electrophoresis 
SEM Standard error of the mean 
sHB-EGF  Secreted HB-EGF 
SMC  Smooth muscle cells 
STAT  Signal Transducer and Activator of Transcription 
SVZ 
 
Subventricular zone 
TBS Tris-buffered saline solution 
TBS-T TBS supplemented with Tween detergent 
TDO Triple Dropout 
TEMED Tetramethylethylenediamine 
TGF-α  Transforming growth factor-α 
TGN  Trans-Golgi-network 
TM  Transmembrane 
TPA  Phorbol ester 12-O-tetradecnoylphorbol-13-acetate 
Trp Tryptophan 
UGB Upper gel buffer 
WB  Western Blot 
YPD Yeast Peptone Dextrose 
YTH Yeast Two Hybrid 
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2 Introduction 
2.1 Alzheimer’s disease (AD) 
Alzheimer’s disease (AD), first described by the neuropathologist Alois Alzheimer in 
1906, is a slowly progressive disorder characterized by an insidious onset and progressive 
cognitive impairment, loss of memory, and abnormal behavior, leading to a vegetative state 
and ultimately death. AD has become the most common age related neurodegeneratation, 
accounting for 50-60% of the cases of dementia. It is generally sporadic, with a late-onset, 
affecting people over the age of 65. However, around 5% of AD patients develop the disease 
phenotype at a much younger age (40 to 50 years old) and are classified as early-onset, most 
of which being familial cases (1). These are mainly caused by missense mutations in the 
amyloid precursor protein (APP), and in presenilin-1 and -2 (PS1 and PS2) genes (2). Abnormal 
processing of APP and increased generation of the amyloid beta (Aβ) peptide are central 
events in the AD pathogenesis (3), but mutations and polymorphisms in multiple genes, along 
with non-genetic factors, are likely to contribute to sporadic AD pathogenesis (2).  
2.1.1 Neuropathological phenotype 
The major AD pathological hallmarks are the progressive deposition of protein 
fragments in senile plaques and the appearance of neurofibrillary tangles (1–4). The combined 
consequences of the pathological changes lead primarily to massive neuronal and synapse loss 
at specific brain regions involved in learning, memory and emotional behavioral, such as the 
hippocampus and cortex (5). These morphological alterations lead to AD characteristic 
changes, namely cortical atrophy and concomitant enlargement of ventricles and sulci, 
particularly in the frontal, temporal and parietal lobes (Figure 1). 
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Figure 1 - Representation of a cross-section of brain coronal sections. Left: image of a healthy brain; right: 
Alzheimer’s brain. Note the shrinkage particularly at the hippocampus (dark blue circles) and the widening of the 
ventricles (light blue circles). Adapted from http://www.healthplexus.net/article/neurobiology-aging (Jun 2013). 
The senile/amyloid plaques are extracellular deposits of Aβ peptides, which are a 
product of the APP proteolytic cleavage (detailed in section 2.2.3). The Aβ peptides are 
organized in 7-10 nm-thick fibrils intermixed with non-fibrillar forms of the peptide. In 
addition, mature plaques (Figure 2) contain degenerating axons and dendrites, and are 
surrounded and invaded by microglia and reactive astrocytes, indicating an inflammatory 
component in the neurodegenerative process (3,5).  
The neurofibrillary tangles are intraneuronal lesions consisting of 10-nm-thick paired 
helical filaments (Figure 2). The main component of these filaments is the 
hyperphosphorylated form of the microtubule-associated protein Tau. Tau 
hyperphosphorylation favours its dissociation from microtubules and stimulates its self-
assembly into paired helical filaments that in turn assemble into neurofibrillary tangles (3,5). 
2.1.2 The amyloid cascade hypothesis 
The amyloid hypothesis states that overproduction of Aβ caused by the imbalance 
between the production and clearance of Aβ in the brain, and its aggregation into senile 
plaques is a primary event in AD pathogenesis, triggering an inflammatory response, synapse 
loss, neuronal dysfunction, cell death, and gradual cognitive decline (Figure 2) (2,5–8). 
Although the extracellular accumulation of insoluble fibrillar Aβ was previously considered a 
key causative element in AD, recent evidence suggests that soluble Aβ oligomers, which are 
  SACS/UA 2013 
Unraveling the APP/HB-EGF Interaction  11 
the precursors of the fibrils, are the actual neurotoxic components contributing to 
neurodegeneration and consequently dementia (2,5,6). 
 
 
Figure 2 - The putative amyloid cascade, which is still controversial in some of the correlations it defends, states 
that Aβ generation induces a set of detrimental mechanisms known to be involved in AD pathogenesis, and 
ultimately leads to the cognitive and behavioral abnormalities observed in AD patients. Reproduced from reference 
(9). 
The amyloid hypothesis generated several predictions that have been the basis for 
most work on the AD pathogenesis and on researching for a biomarkers-based diagnosis. 
Nonetheless, several of its predictions are still controversial. Therefore, understanding the 
normal physiological APP functions remains an issue of major scientific and clinical interest. 
2.2 Alzheimer's β-amyloid precursor protein (APP) 
As mentioned, the Aβ peptide was found to be a cleavage product derived from the 
transmembrane domain of a large precursor protein, APP. For that reason, APP has become 
one of the most studied proteins in the field of AD research (1), and after more than 15 years 
of intense research, understanding it remains a major scientific and intellectual challenge.  
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When studying APP (or its homologs) in cell cultures, many researchers have focused 
on specific fragments and/ or subdomains of APP, to which several functions have been 
attributed (10). Briefly, APP is thought to be involved in important processes such as cell 
adhesion, synaptic contact, cell survival, neurite outgrowth, cell migration and differentiation, 
and in memory regulation (7). APP has also been implied in protease inhibition (11) and in pro- 
and anti-apoptotic functions (3). The APP protein, as well as the plethora of functions 
correlated to it, will be further described below.  
2.2.1 APP characterization and gene family  
In mammalian, APP is part of a larger gene family that includes APP-like proteins 1 and 
2 (APLP1 and APLP2) (1,3,12–14). APP is a ubiquitously expressed type I transmembrane 
glycoprotein (1–3,12,13,15,16), present in many cell and tissue types, including astrocytes, 
microglia, endothelial cells, smooth muscle cells and all peripheral cells; however, it is detected 
predominantly in neurons (2,11,17,18). It is encoded by a single gene located on chromosome 
21 (21q21) that contains 18 exons, of which exons 7, 8 and 15 can be alternatively spliced (1–
3,12,13,15,18). Alternate splicing of the APP transcript generates 8 isoforms, ranging from 365 
to 770 amino acids (11,12,15). Among the 8 APP isoforms, the predominant transcripts are 
APP695 (exons 1–6, 9–18), whose encoding cDNA lacks the gene sequence from exons 7 and 8, 
APP751 (exons 1–7, 9–18) lacking exon 8, and APP770, encoded with all exons (Figure 3).  
 
 
Figure 3 - Schematic representation of the APP gene and its three major isoforms. The human APP gene contains 19 
exons. Alternative splicing produces the three major isoforms shown. The relative sizes of exons and introns are not 
drawn to scale. Reproduced from reference (2). 
The three transcripts encode multidomain proteins with a single membrane-spanning 
region and differ only in the size of their extracellular sequence. APP isoforms are expressed in 
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a cell-type specific manner, with APP695 being the predominantly transcript in neuronal tissue, 
whereas APP751 and APP770 are mainly expressed in non-neuronal cells, such as brain glial 
cells (1,2,4,5,11–14,19). Each isoform exists in immature (N-glycosylated) and mature 
(sulfated, N- and O-glycosylated) forms (20). Aβ is derived from the region of the protein 
encoded by parts of exons 16 and 17 (2).  
As illustrated in Figure 4, the APP protein is composed of a large glycosylated 
extracellular portion, a hydrophobic transmembrane domain, and a short C-terminal 
cytoplasmic domain, referred to as the APP intracellular domain (AICD) (1–3,10,12).  
 
 
Figure 4 - (A) Schematic representation of the human APP695 holoprotein, including the relative position of the -, 
- and -secretase cleavage sites. (B) Schematic representation of the functional domains arrangement in APP: the 
E1 region consists of the N-terminal growth factor-like domain (GFLD) and the following copper-binding domain 
(CuBD). The E1 region is linked via the acidic region to the carbohydrate domain, which contains the two N-
glycosylation sites of the ectodomain (red spheres). The carbohydrate domain can be subdivided into the E2 
domain, also called central APP domain (CAPPD), and a linker or juxtamembrane domain. The carbohydrate domain 
is followed by the transmembrane and the APP intracellular domain (AICD). Aβ indicates the amyloid β-peptide 
sequence. The Kunitz-type protease inhibitor domain (KPI), which is present in APP751 and APP770, and the Ox2 
sequence, which is present in APP770, are shown above their insertion site. Adapted from reference (10).  
The APP extracellular sequence (or ectodomain) can be regarded as a string of several 
individual functional domains (Figure 4). The APP N-terminal head (a.a. residues 23–128) starts 
with a 17- residue signal peptide and is followed by the E1 domain, which contains: a growth 
factor-like domain (GFLD), a copper-binding domain (CuBD) and a zinc-binding motif (10,13). 
The GFLD is a cysteine-rich domain that constitutes one of the APP heparin-binding sites, and 
seems to be critical for neurite outgrowth and MAP kinase activation (10,21). Immediately 
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adjacent to this, is a hydrophobic surface patch; such patches are quite often key players in 
protein–protein interactions, and may provide a ligand binding site and/or an APP–APP 
dimerization interface (10,22). CuBD, comprising residues 124–189, may regulate APP 
proteolysis or act as a metallotransporter; copper binding to this domain affects the APP 
dimerization state, leading to lower Aβ production (21). Zinc-metal binding to APP modifies its 
conformation and interferes with APP binding to extracellular matrix components (3).  
The N-terminal APP domain (E1 plus acidic) is able to stimulate neurite outgrowth, and 
is similar to a region identified in a couple of growth factors; thus, some authors suggest that 
this head domain by itself is responsible for the APP growth factor-like properties (10).  
The acidic region precedes the Kunitz protease inhibitor (KPI) domain that is missing in 
APP695, and an OX2 domain, only present in APP770. The KPI motif has the ability to inhibit 
serine proteases such as trypsin, chymotrypsin and factors XIa and IXa of the coagulation 
cascade, functioning in blood coagulation. KPI-containing APP isoforms seem to be more 
amyloidogenic and their abundance increases in AD brains (1,2). Following the KPI motif, there 
is a carbohydrate domain, which can be divided into the E2 domain [also called central APP 
domain (CAPPD)], and the linker (or juxtamembrane) region. The E2 domain is also interesting, 
since it contains a couple of substructures that might provide interaction sites for binding 
partners (10).  Importantly, the E2 domain possesses a putative growth-promoting motif called 
“RERMS” (3,10,13,21), and a highly conserved heparan sulfate proteoglycan (HSPG)-binding 
site. The E2 domain of APP is also able to form an antiparallel dimer in solution. Dimerization 
and dissociation of APP might regulate various APP functions. It has been hypothesized that 
cell-bound APP form dimers in trans-regulating cell–cell adhesion, whereas monomeric APP 
may act either as a growth factor receptor, when still bound to the cell membrane, or as a 
growth factor itself once it is released by α-secretase cleavage into the external milieu (10). 
Moreover, the strong homology and conserved domain organization between APP and the APP 
family members APLP1 and APLP2, imply that not only homo-oligomerization but also hetero-
oligomerization might be possible, as demonstrated recently (10,22). Dynamic alterations of 
the APP ectodomain between monomeric, homodimeric and heterodimeric status could at 
least partially explain some of the variety in the functions of APP. 
The Aβ domain comprises the 28 residues just outside the membrane plus the first 12-
14 residues of the single membrane-spanning domain (TM). It contains additionally zinc, 
cooper and heparin binding sites, and a RHDS motif (amino acids 5-8 of Aβ) that appears to 
promote cell adhesion.  
Near to its C-terminal region, APP has one 23-residue hydrophobic stretch that serves 
to anchor APP to internal membranes (e.g. ER, Golgi, trans-Golgi network and endosome) and 
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to the plasmalemma (4). Furthermore, the cytoplasmic region of APP, named APP Intracellular 
C-terminal domain (AICD) contains several consensus motifs (e.g. the YTSI and the YENPTY 
protein-sorting domains) that regulate its trafficking, and appears to have a role in signal 
transduction through interaction with several proteins (3,10,23,24). When liberated by 
proteolytic cleavage, AICD can be nuclear targeted and form protein complexes with 
transactivating properties (23,25).  
The two mammalian APP homologs, APLP1 and APLP2, are also transmembrane 
proteins and share conserved structures with APP, including a large extracellular domain 
containing the E1 and E2 domains and a short intracellular domain (Figure 5). Although these 
three proteins are functional and structurally related, only APP generates the amyloidogenic 
fragment Aβ, since the transmembrane domain is not conserved among APP and APLPs (1–
3,12–15). In addition, APLP1 does not possess the KPI domain (Figure 5) (1,12,13). Similarly to 
APP, APLP2 is expressed ubiquitously, while APLP1 is only expressed in the brain and is only 
found in mammals (1,12,13). However, given the sequence identity between the three genes, 
it is not unexpected that the mammalian APP homologs play redundant activities in vivo (13).  
 
Figure 5 - Schematic overview of domain structure of APP family proteins. All APP family members share con- 
served E1 and E2 extracellular domains, an acidic domain (Ac) and the YENPTY motif in the carboxyl terminus. Note 
that Aβ is unique for APP. HBD, Heparin binding domain; CuBD, Copper binding domain; KPI, Kunitz-type protease 
inhibitor domain. Adapted from reference (26). 
2.2.2 APP intracellular trafficking 
APP is a transmembrane protein that is dynamically sorted through the membranes of 
intracellular organelles and the plasma membrane (PM) (23). APP traffic (Figure 6) is tightly 
regulated and during this process APP can be cleaved by specific proteases. APP is co-
translationally translocated into the endoplasmic reticulum (ER) via its signal peptide, and then 
post-translationally modified (“matured”) and trafficked through the Golgi apparatus to the 
trans-Golgi-network (TGN) and to the cell surface, via the secretory pathway.  Classical N- and 
O-glycosylation occur during transit through the ER and Golgi. Phosphorylation and tyrosine 
sulfation in the late Golgi and at the cell surface further increases the structural complexity of 
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APP and APP-like proteins (3,4,7,11,13,14,16,27). APP is indeed a phosphoprotein with several 
putative phosphorylation sites in both the intracellular and extracellular domains, and APP 
phosphorylation plays an important role in regulating APP trafficking and processing (19). 
In neurons, APP is subjected to the constitutive secretory pathway and after sorting in 
the Golgi it undergoes fast axonal transport to presynaptic terminals (12,28). However, only a 
small portion of APP is localized to the PM, most of it remaining in the Golgi, where the highest 
concentration of APP is found at steady state (7,13). From the TGN, APP can be transported in 
TGN-derived secretory vesicles to the PM, or be directly to an endosomal compartment (Figure 
6, step 1). Clathrin-associated vesicles mediate both these steps. In the PM, where α-secretase 
is present, APP can either undergo non-amyloidogenic processing or be re-internalized by 
endocytosis, via its YENPTY motif (Figure 6, step 2). Once endocytosed, APP can be processed 
in the endosomal-lysosomal pathway. From late endosomes, APP can either be degraded in 
lysosomes or recycled by vesicles back to the PM or to the TGN (Figure 6, step 3). APP comes in 
contact with BACE1 in the endosome and the TGN, which promotes its amyloidogenic 
processing and subsequent Aβ generation (7,11,12,14,16,23,27,28). Aβ is either then dumped 
into the extracellular space, following vesicle recycling, or is degraded in lysosomes (12). The 
endocytosis process is determinant for Aβ generation, as 80% of Aβ release is blocked by 
preventing surface endocytosis (12). Although most APP must pass through the cell surface as 
part of its processing, this step is very rapid, and few APP is on the surface at a given time 
point (estimated half-life for surface-expressed APP is less than ten minutes) (3,12). Why some 
surface APP is internalized into endosomes and some proteolyzed directly by α-secretase is 
unclear. Finally, to complete the APP cycling loop, retrograde transport occurs between 
endosomes and the TGN, mediated by a complex of molecules called the Retromer (12,27).  
  SACS/UA 2013 
Unraveling the APP/HB-EGF Interaction  17 
 
Figure 6- Intracellular APP trafficking. Nascent APP molecules (black bars) mature through the constitutive secretory 
pathway (step 1). Once APP reaches the cell surface, it is rapidly internalized (step 2) and subsequently trafficked 
through endocytic and recycling compartments back to the cell surface (step 3) or to the TGN. A small fraction is 
also degraded in the lysosome. Nonamyloidogenic processing mainly occurs at the cell surface where α-secretases 
are present. Amyloidogenic processing involves transit through the endocytic organelles where APP encounters β- 
and γ-secretases. Reproduced from reference (29). 
Concerning the complexes involved in APP transport, the NPXY (asparagiNe-Proline-
any-tYrosine) amino acid motif (YENPTY domain) governs the targeting of proteins to clathrin-
coated vesicles (12,23,24). Several proteins, including members of the Fe65 and of the X11 
families have been identified as clathrin adaptor proteins mediating the binding of the APP 
NPXY motif to clathrin coats, and therefore acting as regulators of APP endocytosis (11,23,30). 
2.2.3 APP proteolytic processing 
As described above, APP undergoes proteolysis both during and after its trafficking 
through the constitutive secretory pathway (4,13). APP proteolytic processing is a very 
important physiological process, since it generates several fragments that are actually 
biologically active peptides, as it will be further discussed. 
The full-length APP is sequentially processed by at least three proteases termed α-, β- 
and γ-secretases, via two major mutually exclusive pathways (Figure 7). β- and α-cleavage sites 
are located close to the membrane region, between residues 596 and 597 of APP695. γ-
cleavage site is located within the transmembrane domain, between residues 711-712 or 713-
714. The α- and β-cleavages are mutually exclusive events, defining the processing pathway 
that APP undergoes.  
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In the Nonamyloidogenic Pathway, APP is sequentially cleaved by α-secretase and γ-
secretase. α-cleavage occurs at the Lys16–Leu17 bond within the Aβ peptide sequence (Fig. 1), 
releasing a large soluble N-terminal fragment (sAPP-α) and a membrane-bound C-terminal 
fragment (CTF) consisting of 83 amino acids (C83). The 10kDa C83 is further cleaved by γ-
secretase (a complex whose catalytic component are presenilins) to release a non-pathogenic 
p3 peptide (3 kDa product) and the AICD, both of which are degraded rapidly (1–4,6,12,13). In 
the Amyloidogenic Pathway, APP is primarily processed by β-secretase at the first residue (β-
cleavage site) or at the 11th residue (so called β’ site) of the Aβ peptide sequence, yielding 
soluble sAPP-β and generating a membrane-tethered CTF consisting of 99 amino acids (C99). γ-
secretase further cleaves the 12kDa C99 to release AICD and the 4kDa Aβ peptide (1–
4,6,12,13,24). Figure 7 is a schematic representation of the APP cleavage sites and its 
proteolytic products. Aβ is indeed a normal soluble cellular metabolite comprising two 
predominant forms with different COOH-termini length, Aβ40 and Aβ42. Of note, comparable 
levels of Aβ are detected in both cerebrospinal fluid and plasma in sporadic AD and healthy 
subjects throughout life, and intracellular Aβ40 is innocuous (2). 
 
Figure 7- Schematic Diagram of APP proteolytic processing and its metabolic derivatives. (b) Nonamyloidogenic 
processing of APP involving α-secretase followed by γ-secretase cleavage. (c) Amyloidogenic processing of APP 
involving BACE1 followed by γ-secretase is shown. Both processes generate soluble ectodomains (sAPPα and sAPPβ) 
and identical intracellular C-terminal fragments (AICD). Adapted from reference (12). 
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2.2.4 Functions of APP and its fragments 
 Full-length APP  2.2.4.1
The in vivo gain- and loss-of-function phenotypes associated with the APP family of 
proteins in model systems are consistent with a role for APP in the development of the 
peripheral and central nervous systems, relating to synapse structure and function, as well as 
in neuronal migration or adhesion. These may be mediated either by the full-length protein or 
by its proteolytic products (13). Indeed, the search for a physiological role of full length APP is 
inseparably linked to the functions of APP cleavage products (6).  
Cell Surface Receptor. Mainly due to its highly similar structure to Notch, APP has 
been proposed to function as a cell surface receptor (13). Studies have reported that certain 
ligands, including Aβ, F-spondin, Nogo-66, netrin-1 and BRI2, bind to the extracellular domain 
of APP, resulting in modulated APP processing and sequential downstream signals (1,3,13). 
However, it is unclear whether any of the candidates are bona fide ligands and definitive 
evidence supporting a physiological role of APP as a cell surface receptor is still lacking (13). 
Cell and Synaptic Adhesion. APP is widely accepted as a protein contributor to cell 
adhesion via its extracellular domain. The E1 and E2 regions of APP were reported to interact 
with extracellular matrix proteins and heparin sulfate proteoglycans, supporting its role in cell-
substratum adhesion. For example, APP co-localizes with integrins on the surface of axons and 
at sites of adhesion, and it was recently shown that APP and integrin-β1 do interact (13). 
Furthermore, the E1 and E2 regions were found also to interact with themselves, in parallel or 
anti-parallel, forming homo- (with APP) or hetero-dimers (with APLPs), with the trans-
dimerization promoting cell-cell adhesion (1,13,22). Further, heparin binding to the E1 or E2 
regions was reported to induce APP dimerization (13). Of note, recent studies suggest that 
homodimerization can be also promoted by the GxxxG motif near the luminal face of the 
membrane (13). The “RHDS” tetra-peptide motif between the sAPP C-terminus and the Aβ 
sequence also appears to promote cell adhesion (13). Recent studies in which trans-cellular 
APP/APLP interaction induced presynaptic specializations in co-cultured neurons, also suggest 
APP/APLPs as synaptic adhesion molecules (SAM) (1,13,31). Both the extracellular and 
intracellular domains of APP are required to mediate the synaptogenic activity (13,31). 
 APP Ectodomain - sAPPα 2.2.4.2
Synaptotrophic and Neuroprotective Functions. In most studies, APP overexpression 
shows a positive effect on cell health and growth, functions that can be reproduced by the 
soluble ectodomain, which is released by APP cleavage. sAPP has been shown to modulate cell 
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growth, motility, neurite outgrowth, and cell survival (12). Interestingly, sAPP-α alone is able to 
rescue most of the abnormalities of APP deficient mice, implying that most of the physiological 
functions of APP are conducted by its extracellular domain (1,6).  
The constitutively secreted sAPP-α is neuroprotective, protecting neurons against 
oxygen-glucose deprivation and excitotoxicity (1,6,12,24). Several lines of evidence point also 
to a neurotrophic role, a function that may be related to APP adhesive properties described 
above, either in its full-length form or as a secreted molecule (sAPP). Thus, APP may exert 
these activities in both autocrine and paracrine fashions, the later via sAPP-α (13). 
sAPP-α acts as a growth factor in dividing cells of epithelial origin, and regulates the 
proliferation of embryonic and adult neural stem cells (1,3,6,12,13). The RERMS sequence of 
APP is the region that appears to have growth-promoting properties (3). sAPP-α was also 
shown to promote neurite outgrowth, synaptogenesis as well as cell adhesion (1,6,12,13,24). 
sAPP promotes neurite outgrowth in neural stem cells, in a function where APLP2 (but not 
APLP1) was redundant (13). The biologically relevant sites for these actions appears to be the 
APP two heparin-binding domains (6,12). In vivo studies also shown that sAPP-α can improve 
cognitive function and synaptic density in animal models, promoting learning and memory 
(1,6,13). Because sAPP levels have been reported to be reduced in individuals with AD, the loss 
of its trophic activity and pro-survival mechanisms may contribute, at least in part, to the AD 
neurodegeneration (13).  
 APP Ectodomain - sAPPβ 2.2.4.3
Axonal Pruning and Degeneration. Although there are only 17 amino acids 
difference between sAPPβ and sAPPα, sAPPβ lacks most of the synaptotrophic and 
neuroprotective effects that have been associated with sAPPα. A recent study suggested that 
sAPP-β can be cleaved to generate an N-terminal fragment that is a ligand for the Death 
Receptor 6 (DR6), activating caspase 6, which further stimulates axonal pruning and neuronal 
cell death (Figure 8) (1,6,13).  
 APP Ectodomain - Aβ 2.2.4.4
Aβ is secreted constitutively by normal cells in culture and detected as a circulating 
peptide in the plasma and cerebrospinal fluid (CSF) of healthy humans and other mammals (4). 
The physiological and pathological functions of Aβ have been extensively investigated because 
of its central role in AD. Studies have demonstrated that Aβ overproduction results in a 
neurodegenerative cascade leading to synaptic dysfunction, neuronal tangle formation and 
eventually neuron loss in the pathologically affected brain regions. Among the various Aβ 
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peptides generated by the multiple-site cleavages of secretases, Aβ42 is the most toxic specie, 
being more hydrophobic and amyloidogenic. Most mutations related to hereditary familiar AD 
either increase Aβ generation or the ratio of Aβ 42/ Aβ 40 (1,6,14), suggesting that elevated 
levels of Aβ42 relative to Aβ40 is critical for AD pathogenesis (1,14). In AD patients Aβ42 levels 
in the CSF are reduced, which reflects the reduced clearance of Aβ through the CSF and 
increased accumulation in amyloid plaques (6). 
Although excessive Aβ causes neurotoxicity, some studies have shown that Aβ40 
protects neurons against Aβ 42-induced neuronal damage and is required for the viability of 
central neurons (1). Moreover, it has been showed that the Aβ peptide itself plays an 
important role in synaptic physiology, regulating synaptic scaling  and synaptic vesicle release 
(12). In addition, two groups recently reported that low doses of Aβ can positively modulate 
synaptic plasticity and memory by increasing long-term potentiation, revealing a novel 
physiological function of Aβ under normal conditions (1,14). 
 APP Intracellular Domain  2.2.4.5
The high degree of sequence conservation between the intracellular domains of APP 
proteins predicts that it is a critical domain mediating APP function. Indeed, this relatively 
short cytoplasmic domain contains phosphorylation sites as well as multiple functional motifs 
and multiple binding partners that contribute to trafficking, metabolism, and possibly cell 
signaling functions of APP (13).  
Phosphorylation and Protein-Protein Interaction. Depending on the exact cleavage 
site of γ-secretase, AICD may have 59, 57, 53 or 50 residues. However, because AICD is quickly 
degraded after γ-cleavage, the biochemical features and physiological functions of AICD in vivo 
are difficult to study. There are several conserved regions located on AICD: a YTSI (653–656 
residues) sorting motif near the cell membrane, a VTPEER (667–762 residues) helix capping 
box and a YENPTY (682–687 residues) motif that regulates APP trafficking and mediates the 
interaction between APP/AICD and phosphotyrosine-binding domain containing proteins (1). 
The YENPTY domain regulates clathrin-coated pit internalization through a series of binding 
partners. Mutation at this site alters endocytosis of APP and diminishes Aβ production (12). 
Some of the AICD-binding proteins identified, including kinesin light chain (KLC), Fe65, Shc, 
JNK-interacting protein (JIP), Numb, X11, Clathrin and mDab1, were found to share one or 
several common phosphotyrosine-binding domains that specifically interact with this YENPTY 
motif (1,13). Other proteins, such as protein interacting with APP tail 1 (PAT1), suppressor of 
variegation, enhancer of zeste, Trithorax (SET) and 14-3-3c, are believed to bind to the YTSI or 
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VTPEER motif of AICD (3). AICD, therefore, may have different functions when interacting with 
its’ various binding partners (1).  
AICD also contains three phosphorylation sites, including two threonine residues at 
654 and 668 and a serine residue at 665. AICD has been found to be phosphorylated by PKC, 
calcium-calmodulin dependent-kinase II, GSK3-b, Cdk5 and c-Jun N-terminal kinase (JNK) at the 
Ser/Thr sites mentioned above, which may affect APP localization, conformation, processing or 
the binding of AICD-interacting proteins, thus affecting the function of AICD (1,12,13).  
Cell Signaling. The generation of AICD is very similar to that of many other signaling 
molecules, such as NICD, which is also generated by γ-cleavage, is translocated to the nucleus 
and mediates gene transcription important for development. AICD seems to function in a 
similar fashion, with a role for AICD in gene transactivation being supported by several studies. 
The most widely accepted mechanism is that AICD, together with Fe65 and Tip60, forms a 
transcriptionally-active complex. Fe65, a cytoplasmic adaptor protein, binds to the YENPTY 
motif of AICD and mediates an indirect interaction between AICD and the histone 
acetyltransferase Tip60, stabilizing AICD. This complex regulates the expression of genes such 
as KAI1, Neprilysin, LRP1, p53, GSK-3β, EGFR, and APP itself (1–3,6,7,12,13). In addition, 
cellular Ca2+ homeostasis is modulated by AICD-induced mediated transcription (1,13). 
Apoptosis. Many studies have documented that AICD is cytotoxic and that over-
expressing different AICDs (C31, C57, C59) in Hela, H4, N2a or PC12 cell lines, as well as 
neuronal cell lines, induces cell death (1,13,32). Results indicate that this AICD-induced 
cytotoxicity may be mediated by its interacting proteins or by its target genes such as GSK-3β. 
However, C31, a short form of AICD generated by caspase cleavage, has been reported to 
directly activate caspase 3 in the tumor cell death process (1,13,32). C31 also appears to 
induce a caspase-independent toxicity by selectively increasing Aβ42.  
Figure 8 summarizes some of the functions attributed to APP proteolytic fragments. 
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Figure 8 - Schematic representation of the correlation between APP processing metabolic derivatives and some of 
their functions. ex, extracellular; PM, plasma membrane; cyt, cytosol. Reproduced from reference (6). 
2.2.5 APP-binding proteins 
A very useful way to approach APP function, besides addressing its functional domains 
and motifs, is the identification of its protein binding partners (10). Protein-protein 
interactions (PPIs) are fundamental to all cellular processes and they are often very useful to 
infer the function of a target protein.  
APP can actually bind to a large number of proteins (Table 1). Proteins that were 
reported to bind APP, but are also known to be quite generally involved in protein processes 
such as maturation or endocytosis, were not included in the overview. 
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Table 1 - Various protein interactions and functions of APP. 
Function APP Domain Binding Partners 
Surface Receptor 
CAPPD F-spondin 
Aβ, undefined ApoE 
Undefined Aβ 
Adhesion 
molecule 
Cell/substratum 
Undefined, Aβ 
ECM (laminin, 
collagen, etc) 
E1 (GFLD) Fibulin-1 
E1, E2 HSPG 
AICD Fe65 
Cell/cell 
CAPPD CAPPD 
E1 E1 
Regulator of 
neuronal 
processes 
Neurite outgrowth 
sAPP APP/Integrin? MAPK? 
Aβ Undefined 
Dendritic arborization 
CAPPD Undefined 
AICD (C99) Abl, profiling, JIP 
Synaptogenesis 
sAPP Undefined 
Undefined, AICD Fasciclin II, X11/Mint 
Synaptic plasticity sAPP Undefined 
Neuronal excitability sAPP Undefined 
Axonal transport cargo receptor AICD JIP 
Regulator of neuronal stem cell 
division 
sAPP Undefined 
Signaling 
molecule 
GPCR signaling pathway AICD G(o) 
Kinase-mediated signaling 
cascades 
AICD Abl, Shc/Grb2, JIP, Dab 
sAPP MAPK, STAT3, NFkB 
Gene transcription AICD 
Fe65, Fe65L, JIP, 
Mint/X11, Numb 
Regulator of calcium homeostasis 
Aβ, undefined Undefined 
AICD Undefined 
Regulator of metal homeostasis CuBD Cu2+ 
Regulator of cell 
survival/death 
Neurotrophic sAPP Undefined 
Neurotoxic 
Aβ Undefined, APP 
AICD casp (C31) Caspases, APP-BP1 
AICD (C59, C57) Undefined 
AICD (a.a. 649-664) Undefined 
ECM, extracellular matrix; HBD, heparin-binding domain; HSPG, heparin sulfate proteoglycans; SVZ, 
subventricular zone 
 
It is interesting to note that many of the proposed functions of APP (Table 1) and its 
derived fragments can be grouped into a series of common biological processes. For example, 
neurite outgrowth, dendritic arborization and synaptogenesis all require highly organized cell–
cell and cell–substratum interactions, to which APP indeed appears to contribute. From the 
table, it also becomes clear that both the extra- and intracellular APP regions are involved in 
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similar biological functions, like neurite outgrowth or arborization. It is tempting to speculate 
that holoAPP could function in these processes at both sides of the plasma membrane linking 
extracellular cues (e.g. ligand or substratum binding) to intracellular signaling pathways (via 
scaffolding proteins, Ca2+ regulation, interactions with the cytoskeleton and/or protein 
kinases). In this context, APP could function as a receptor-like modulatory protein in neuronal 
processes (10). 
 
Because of the imperative need to study in detail the APP proteome and better 
characterize APP functions, the search for APP-binding proteins has stand out in the 
laboratory. In a previous doctoral thesis developed at our laboratory, Dr. Sara Domingues has 
unraveled a plethora of putative APP-binding proteins, through the use of the Yeast Two 
Hybrid system in a brain cDNA library. The heparin-binding epidermal growth factor-like 
growth factor (HB-EGF) has emerged as a very interesting target of study. Among the known 
factors that regulate proliferation and neuronal generation, growth factors have been widely 
accepted as the most important mediators, which supported HB-EGF as our object of study. 
Additionally, several structural and functional features are shared between APP and HB-EGF 
proteins, which really made HB-EGF stand out. Of note, the identification of growth factor 
receptors binding to APP would also greatly support the growth factor hypothesis for APP. 
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2.3 Heparin-Binding Epidermal Growth Factor-Like Growth Factor 
(HB-EGF) 
2.3.1 Membrane-anchored growth factors 
Growth factors, a diverse group of polypeptides that regulate diverse processes from 
cell survival and proliferation to migration and programmed cell death, constitute a distinct 
subgroup in endocrinology (33–35). The biology of these factors differs somewhat from 
classical hormones as neither their site(s) of synthesis nor site(s) of action is restricted to 
defined tissues. Many growth factors probably operate in a paracrine fashion, binding to 
receptors in distant cells of the same tissue and, in certain instances, their action may be 
autocrine in nature, binding to receptors on the same cell (33). 
Recent studies revealed that several growth factors and cytokines are synthesized as 
membrane-anchored proteins, and that such membrane-anchored forms are not only the 
precursor forms of soluble factors but also biological active molecules. The epidermal growth 
factor (EGF) family of growth factors, tumor-necrosis factor-α (TNF-α) and the colony-
stimulating factor-1 are examples of ligands that are synthesized as membrane-anchored 
forms (36). Interestingly, the membrane-anchored forms have different biological activity from 
their soluble counterparts. In fact, membrane-anchored growth factors present distinct and 
unique features respecting their modes of action comparing to those of the soluble growth 
factors in the following respects:  (1) The membrane-anchored forms do not diffuse in fluids 
and thus, they act in a juxtacrine manner (i.e. through cell-cell contact) to signal neighboring 
cells. (2) Membrane-anchored growth factors can form a complex with other membrane 
proteins, and their activity can be regulated by associating molecules, as shown by proHB-EGF-
associating CD9 (mentioned later). (3) In addition, bidirectional signaling between membrane-
anchored growth factors and their receptors is also plausible (36).  
2.3.2 The Epidermal Growth Factor (EGF) family and their receptors 
Epidermal Growth Factor (EGF) is the founding member of the EGF superfamily of 
peptide growth and differentiation factors. Members of this group include EGF, HB-EGF, 
transforming growth factor-α (TGF-α), vaccinia growth factor (VGF), amphiregulin (AR), 
betacellulin (BTC), epiregulin, neuregulin-1 (NRG-1) - including the Neu differentiation factor 
(NDF), heregulin (HRG), acetylcholine receptor-inducing activity (ARIA), and glial growth factor 
(GGF) - and neuregulin-2 (NRG-2) (37). 
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Members of this protein family have highly similar structural and functional 
characteristics. These ligands have in common a motif of about 40–45 amino acids containing 
six cysteine residues, known as the EGF-like domain. The highly conserved six cysteine-residues 
of the EGF-domain form the consensus sequence CX7CX4CX10CXCX8C, with the six cysteine 
residues forming three intra-molecular disulfide bonds (C1–C3, C2–C4, C5–C6) (37). Another 
common feature of the EGF-family members is that they are synthesized as transmembrane 
precursor molecules which are then proteolytically processed to release the soluble mature 
growth factor from the cell surface (37). Besides these similarities, high binding affinity to their 
receptors and production of mitogenic responses in EGF-sensitive cells are also characteristic 
of the EGF-family members (33,35). 
The EGF-like growth factors achieve their effects by binding to and activating ErbB 
(Erythroblastic Leukemia Viral Oncogene Homolog) receptor tyrosine kinases. The ErbB 
receptors are class I transmembrane proteins and represent a subfamily of four closely related 
receptor tyrosine kinases: the EGF receptor (EGFR) also known as HER1/erbB1, HER2/erbB2 
also known as p185/neu, and more recently HER3/erbB3 and HER4/erbB4 (37–39). The four 
EGF receptor sub-types share a high degree of homology, most notably in the 290 amino acid 
cytoplasmic tyrosine kinase domain. Also conserved are two cysteine-rich regions in the 
extracellular ligand-binding domain. On the other hand, very little homology exists in the C-
terminal 100 amino acids which are essential for the activation of intracellular signal 
transduction pathways after ligand binding.  
EGF family ligands show specificity when it comes to binding and activating receptors. 
EGF, TGF-α and AR bind exclusively to HER1; NRG-1 and NRG-2 bind to HER3 and HER4 but 
activate only HER4; HB-EGF, BTC and epiregulin bind and activate both HER1 and HER4. HER2 is 
an orphan receptor, with no known ligand, whereas ErbB3 lacks functional intrinsic tyrosine 
kinase activity (35,37,38). Peptides that bind to EGFR compete with EGF for receptor binding 
and therefore they are referred to as EGF agonists or antagonist (34). 
 EGF and EGFR structure 2.3.2.1
Epidermal growth factor acts as a potent mitogen with a very important role in the 
growth, proliferation and differentiation of numerous cell types, with the deregulation of this 
gene, as well as of its receptor (EGFR), being associated with oncogenesis (39).  
Regarding cellular proliferation and neuronal generation, EGF was shown to promote 
cell proliferation in the subventricular zone (SVZ) and the dentate gyrus (DG) neurogenic brain 
niches, and the generation and migration of striatal-specific neurons following ischemic injury, 
being the EGFR signaling required. Other evidence showed that EGF exerts a neuroprotective 
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effect rather than a neurogenic effect in promoting recovery following traumatic brain injury 
(40). 
EGF is synthesized as a large precursor molecule that is proteolytically cleaved to 
generate the 53-amino acid mature epidermal growth factor peptide (39). This growth factor 
can be found in many human tissues including submandibular gland, parotid gland, and some 
other biological sources of EGF are platelets, macrophages, urine, saliva, milk, and plasma. The 
mature EGF receptor (EGFR/erbB1) is composed of a single polypeptide chain of 1186 amino 
acid residues and a substantial amount of N-linked oligosaccharides. A single hydrophobic 
membrane anchor sequence separates an extracellular ligand binding domain from a 
cytoplasmic domain that encodes an EGF-regulated tyrosine kinase (33). The extracellular 
domain of the EGFR is characterized by its capacity to bind EGF and EGF-like ligands with high 
affinity. Chemically, this portion of the receptor contains 10-11 N-linked oligosaccharide 
chains, an unusually high content of cystine residues (10%) that could give rise to as many as 
25 disulfides, and, in several cell lines, mannose phosphate. It is proposed that the region 
between the two half-cystine-rich clusters is involved in ligand binding (33). The hallmark of 
the cytoplasmic portion of this receptor is the sequence defining the tyrosine kinase domain, 
whose activity has a central role in the regulation of cell proliferation. Near the carboxyl 
terminus of the receptor are present four sites of EGF-dependent tyrosine 
autophosphorylation. Present data suggest that these COOH-terminal tyrosines define an 
autoinhibitory region that can be relieved by autophosphorylation. Cells exposure to EGF 
markedly induces the phosphorylation of Ser, Thr, and Tyr residues on the EGF receptor (33). 
 EGFR Signal Transduction  2.3.2.2
EGFR ligands act by binding the extracellular domain of this high affinity cell surface 
receptor. Upon ligand-binding, EGFR undergoes a transition from an inactive monomeric form 
to an active homodimer, or heterodimer if EGFR pair with another member of the EGFR family, 
a process known as transmodulation (33,38,39,41). Since in this process there is a cross-talk 
occurring between ErbB receptors, it allows a diversification of the nature of the intracellular 
signal elicited by a specific growth factor (34). EGFR dimerization then stimulates its intrinsic 
intracellular protein tyrosine kinase activity, resulting in auto-phosphorylation of several 
tyrosine residues within its cytoplasmic domain (e.g. Tyr 1092, 1172, 1197, 1110 and 1016). 
These phosphorylated tyrosine residues then act as docking sites for effector molecules (Figure 
9) eliciting downstream activation and signaling by several other transducers.  
In Figure 9, it is represented the EGF/EGFR signaling pathway. Upon EGF binding to EGFR, 
one of the activated adapter proteins, GRB2, is responsible for Ras activation, which in turn 
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activates the protein kinase activity of Raf. Raf initiates a cascade of phosphorylation events 
including the phosphorylation and activation of the MAPK kinase (MEK), which in turn 
phosphorylates MAPK (Mitogen-activated protein kinase, also called ERK - extracellular signal 
regulated kinase). MAPK activates a number of transcriptional regulators to induce cell growth 
and proliferation. PI3K (phosphatidylinositol 3-Kinase) is another major mediator of EGFR 
signaling that, once activated, phosphorylates membrane bound PIP2 (Phosphatidylinositol-
4,5-bisphosphate) to generate PIP3 (Phosphatidylinositol-3,4,5-trisphosphate). PIP3 binds to 
Akt, which in turn regulates the activity of various proteins that mediate cell survival.  
EGFR also activates PLCγ (Gamma isoform of phospholipase C), which hydrolyses PIP2 to 
generate IP3 (inositol trisphosphate) and DAG (1,2-Diacylglycerol). IP3 induces the release of 
Ca2+ from the ER to activate calcium-regulated pathways. DAG is the physiological activator of 
protein kinase C (PKC), which regulates NFKB (Nuclear Factor-Kappa B).  
Stimulation of EGFR induces also tyrosine phosphorylation of STAT1 and 3 (Signal 
Transducer and Activator of Transcription 1 and 3) leading to its nuclear translocation, where 
they are active in gene transcription. PAK activates JNK (c-Jun Kinase) that once activated enter 
the nucleus and causes phosphorylation of transcription factors such as c-Fos and c-Jun.  
EGFR also activates several other proteins including FAK (Focal Adhesion Kinase), Paxillin, 
Caveolin, E-Cadherin and Ctnn-Beta (Catenin-Beta). FAK1 take part in cell motility, whereas 
Caveolin, Cadherin and Ctnn-Beta are involved in cytoskeletal regulation. EGFR also 
translocates from the plasma membrane to other cellular compartments, including the nucleus 
where it directly regulates the expression of several genes in cooperation with other 
transcriptional regulators.  
This signal transduction will result in a variety of biochemical changes within the cell and in 
an increase in the expression of certain genes including the EGFR gene itself, ultimately leading 
to DNA synthesis and cell proliferation (36,38,41,42,44). 
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Figure 9 – Diagram showing key components of the EGFR signal transduction pathway. Upon ligand binding, 
activated EGFR recruits various cytoplasmic proteins, which transduce and regulate the EGFR function. Transduction 
by activated EGFR leads to downstream effect on proteins that are associated with cell proliferation, motility and 
survival, such as Ras, Raf and MAPK, PLC, PI3K, Akt, and STATs. The arrows point to signaling proteins that are 
subsequently recruited by upstream transducers, leading to several changes within the cell. Reproduced from 
reference (39). 
 
  SACS/UA 2013 
Unraveling the APP/HB-EGF Interaction  31 
2.3.3 HB-EGF as an EGF-family growth factor  
HB-EGF is a heparin-binding member of the EGF family of growth factors that 
stimulates growth and differentiation.  It was first identified as a 20±22 kDa glycoprotein in the 
conditioned medium of human macrophages (36,37). Like other members of the EGF family, 
HB-EGF is synthesized as a transmembrane protein (proHB-EGF) and can be cleaved at the 
plasma membrane to yield the 14-20kDa soluble HB-EGF (sHB-EGF) (36,37,41–43). Among the 
EGFR ligands, HB-EGF is notable for the number of proteins and other molecules with which it 
interacts, including transmembrane receptors, adhesion molecules, and transcriptional 
regulators (35). 
HB-EGF is expressed in a variety of tissues, predominantly lung, heart, skeletal muscle 
and brain, and in a large number of cultured cells including vascular endothelial cells and 
smooth muscle cells (SMC), monocytes/macrophages, skeletal muscle cells, renal mesangial 
cells, keratinocytes and tumor cells (36,37,41). HB-EGF is widely expressed in the central 
nervous system (CNS), including the hippocampus, cerebral cortex, thalamus, hypothalamus, 
basal ganglia, midbrain, olfactory bulb, and so on. HB-EGF is highly expressed in neurons, as 
well as astrocytes and oligodendrocytes (44–47). 
2.3.4 HB-EGF Physiological and Pathological role  
HB-EGF biological activities influence cell cycle progression, molecular chaperone 
regulation, cell survival, cell adhesion, and mediation of cell migration (37).  
Expression of proHB-EGF is detected in most tissues. This protein is involved in several 
developmental processes such as skeletal muscle cell development, heart muscle cell 
differentiation (37,41,44), and renal tubular formation (36,37,44), and in wound-healing and 
response to injury in the adult body (36,37,41,44). More recently, a role for HB-EGF in 
trophoblast survival (48), in neurogenesis stimulation (49,50) and as a neurotrophic factor (50) 
was supported by several studies. Among the pathological process in which HB-EGF plays a 
role, tumor growth, Smooth Muscle Cells Hyperplasia, Cardiac Hypertrophy and 
Atherosclerosis are the most prominent (36–38,41,44).  
2.3.5 Roles of HB-EGF in the CNS and higher brain function 
HB-EGF expression is much higher in brains of young animals than in adults, which is in 
accordance with its marked function during early developmental stages (44). However, HB-EGF 
is also considered to play pivotal roles in the adult nervous system (44–47). HB-EGF has been 
implicated in neuronal survival, glial/stem cell proliferation, and differentiation. Recently, a 
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research group has found that HB-EGF also enhances neurite outgrowth by activation of the 
ERK signaling pathway (50). This has never been reported for EGF, which suggests that HB-EGF 
may have more potent effects on the promotion of neurite outgrowth when compared to EGF. 
In fact, recent evidence has shown that HB-EGF is expressed at much higher levels than EGF in 
the central nervous system, indicating that HB-EGF may serve as a major ligand for EGFR in 
neuronal cells (44,50). Another study also reports that HB-EGF contributes to adult 
neurogenesis in the DG of the hippocampus (49). These reports suggest that HB-EGF may be 
one of the important contributors to neuronal development and synaptic plasticity in the 
hippocampus. Additionally, HB-EGF KO mice were impaired in spatial memory in the Morris 
water maze and in fear learning conditioning (51), which suggests that HB-EGF plays a 
significant, but yet to be fully identified, role in synaptic plasticity and memory formation. 
Several studies have also shown that HB-EGF appear to exert a neuroprotective effect and to 
modify neurogenesis after ischemic brain injury (44,52).  
Besides these several actions, HB-EGF affects the development and function of 
nigrostriatal dopaminergic neurons, as it was found to enhance the survival of midbrain 
dopaminergic neurons by activation of the MAPK and the Akt signal pathway (53).  
Finally, it was purposed that HB-EGF signaling may play a pivotal role in psychomotor 
behavior and neuronal transmission, and alterations affecting HB-EGF signaling could 
represent a contributing factor for the development of psychiatric disorders such as 
schizophrenia (44).  
In conclusion, evidences indicate that the HB-EGF signal may be an important trophic 
factor in the developing central nervous system and a contributor to higher brain functions 
(Figure 10). 
 
Figure 10  - HB-EGF roles in CNS and higher brain function. HB-EGF is widely expressed throughout the brain, being 
implicated in psychomotor behavior, cerebral ischemia, nigrostriatal dopaminergic neuron, memory, and synaptic 
plasticity. PFC, prefrontal cortex; Hipp, hippocampus; SN, substancia nigra; Ctx, cortex. Reproduced from (44). 
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2.3.6 HB-EGF gene 
 Gene structure 2.3.6.1
The HB–EGF gene locus has been mapped to the long arm of chromosome 5, at 5q23, 
in humans, and to chromosome 18 in mice (35,37). The longest form of a HB-EGF cDNA cloned 
so far is approximately 2.4 kb in length and corresponds in size to the predominant mRNA 
typically revealed by Northern blot analysis. The human and mouse HB-EGF genes encompass 
approximately 14 kb, and consist of 6 exons and 5 introns consistent with the overall gene 
structure of other ligands of the EGF family. The sequences contributing to the 208 amino acid 
ORF are found on exons 1–5 (Figure 11) (37). 
              Exon 1 Exon 2 Exon 3 Exon 4 Exon 5   Exon 6
16 74 133 185 aa
-261 46 47 220 221 339 400 555 556 645 646 2076 bases
 
Figure 11 – The 6 exons structure of HB-EGF. Adapted from reference (37). 
 
The expression of the HB-EGF gene is highly regulated by several transcriptional 
regulatory factors in a tissue-specific manner (37,41). A number of putative transcription factor 
binding sites were identified in the mouse and human HB-EGF promoters including binding 
sites for Sp1, AP1, Ets-2, NFkB and the muscle specific transcription factor MyoD. The HB–EGF 
promoter contains two E-box sequences, at -1606 bp and -510 bp upstream the transcription 
start site, respectively. The HB-EGF proximal E-box (at -510 bp) has been shown directly to be 
responsible for binding MyoD and activating the promoter. Further, the HB–EGF promoter 
contains two putative NFkB binding sites, a proved positive regulator of HB–EGF expression. In 
addition, platelet-activating factor, which has been considered to contribute to atherogenesis, 
activates HB-EGF gene expression in human peripheral blood monocytes (37). Several lines of 
evidence have suggested that HB-EGF is a direct transcriptional target downstream the 
Ras/Raf/MEK pathway, being upregulated by these MAPK pathway components, and playing 
an important role in the autocrine activation of signaling pathways in transformed cells. More 
recently, HB-EGF induction was proved to depend on the activation of two of the three major 
MAPKs, ERK and p38, and inhibiting either of them results in decreased HB-EGF expression. 
HB-EGF can be induced by a variety of stimuli, and in all cases its induction depends on the 
activation of MAPKs, a pathway that also contributes to EGFR gene transactivation (54). 
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2.3.7 HB-EGF Structure 
Although HB-EGF shares approximately 40% sequence identity in its C-terminal domain 
with EGF and TGF-α, determination of the primary peptide sequence of HB-EGF revealed the 
presence of an extended N-terminal domain that was absent in EGF and TGF-α (35,37). 
Notably, the N-terminal sequence of HB-EGF is enriched in basic amino acids that are positively 
charged at physiological pH and enable interaction with negatively charged heparin sulphate 
proteoglycans both on the cell surface and in the extracellular matrix (35). 
HB-EGF is synthesized by ER-bound ribosomes as a pre-pro-form of 208 amino acids in 
length and is expressed at the cell surface as a 20-30kDa type I transmembrane precursor, 
named proHB-EGF, consisting of an ectodomain, a single membrane-spanning domain and a 
cytoplasmic domain (37,38,55,56). Pre-proHB-EGF is composed by signal peptide (ORF1-23), 
propeptide (ORF24-62), mature HB–EGF (ORF63-149), juxtamembrane (ORF150-160), transmembrane 
(ORF161-184) and cytoplasmic (ORF185-208) domains (Figure 12). Within the mature HB-EGF 
domain, HB-EGF has an EGF-like domain (ORF103-150) (Figure 12) typical of all members of the 
EGF family, namely 6 conserved cysteine residues, which form three intra-molecular disulfide 
bonds (C1-C3 , C2.C4 , C5-C6) essential for HB-EGF mitogenic activity (37). The EGF-like growth 
factor domain alone is sufficient to elicit EGFR phosphorylation via autocrine, juxtacrine, and 
paracrine signaling pathways (55,56). Also within the mature HB-EGF domain, there is a 
Difteria Toxin (DT)-binding domain (ORF106-149) and a Heparin-binding domain (ORF93-113) (Figure 
12 B). The HB-EGF heparin-binding domain lies mostly N-terminal to the EGF-like domain but 
partially overlaps the first Cys residue in this domain. It contains two consensus sequences for 
heparin recognition, X-B-B-X-B-X and X-B-B-B-X-X-B-X (with B being basic amino acid). Within 
the 21-amino acid stretch, the highly basic sequences KRKKK93-97, KKR103-105 and RKYK110-113 
contribute the most to heparin-binding (37). It appears that the transmembrane HB-EGF 
associated with cells consists of ORF63– 208, suggesting that the HB-EGF propeptide domain is 
cleaved rapidly intracellularly after synthesis of the precursor or very rapidly once it has 
reached the cell surface (37,57), and the endopeptidase furin was implicated in this rapid 
constitutive cleavage at Arg62–Asp63 (37,58,59). 
This larger membrane-anchored precursor named proHB-EGF is then proteolytically 
processed, generating the mature or soluble HB-EGF (sHB-EGF) (Figure 12 A), which is released 
to the extracellular medium (36,37). Several N-terminal truncated isoforms of mature HB-EGF 
have been purified. The longest form contains 87 amino acids encompassing the sequence 
Asp63 –Pro149 of the ORF. The other three forms have as N-terminal amino acids Arg73, Val74 and 
Ser77, thereby yielding proteins of 76, 75 and 72 amino acids respectively, all of which 
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mitogenically active (37). The apparent molecular mass of cell-derived HB-EGF is about 14-20 
kDa, much larger than would be predicted for a protein of 73–87 amino acids. This discrepancy 
is in part due to HB-EGF being heavily O-glycosylated at glycosylation sites, such as Thr75 and 
Thr85. Discrepancies might also be due to highly positively charged domains in HB-EGF that 
retard the protein mobility in the SDS-PAGE (37).  
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Figure 12 - HB–EGF protein structure. A) Predicted amino acid sequence of the human HB-EGF open reading frame. 
The 87 amino acid form of mature HB–EGF is shown within the yellow box and the six cysteine residues of the EGF-
like domain are highlighted in green circles. B) Domain structure of pre-proHB-EGF is depicted including signal 
peptide, propeptide, mature HB-EGF, juxtamembrane, transmembrane and cytoplasmic domains. Also depicted are 
the EGF-like domain, Heparin-binding domain and the Diphtheria Toxin (DT)-binding domain within the mature HB-
EGF domain. Adapted from reference (37). 
2.3.8 Proteolytic processing of proHB-EGF (Ectodomain shedding) 
Post-translational modifications of transmembrane proteins are critical mediators of 
cellular processes such as proliferation, differentiation, migration, adhesion, and death. 
Membrane-anchored proHB-EGF undergoes a number of post-translational modifications 
ranging from O-linked glycosylation of the N-terminal ectodomain, N-terminal truncations, 
phosphorylation of the cytoplasmic domain and regulated cleavage of the entire ectodomain 
(35). Ectodomain shedding is the term used to describe the proteolytic cleavage that releases 
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the ectodomains of transmembrane proteins from cell surface into extracellular spaces (60), a 
process widely observed in growth factors, growth factor receptors, cell-adhesion molecules, 
extracellular matrix proteins and other membrane proteins (36,58). The processing of 
membrane-anchored EGFR ligands is essential for the complete repertoire of functions those 
ligands play in development, emphasizing the significance of ectodomain shedding for EGFR-
mediated signaling (60,61). Regulated processing of the juxtamembrane (JM) domain of 
proHB-EGF represents a critical control point in HB-EGF function since it converts the 
membrane-anchored non-diffusible form into the soluble protein that has a greatly expanded 
sphere of influence on surrounding cells and tissues, altering its actions from juxtacrine to 
paracrine (35,36).  
Ectodomain shedding of membrane-anchored growth factors and cytokines is primarily 
mediated by metalloproteinases that cleave within the ectodomain of the ligand, particularly 
by members of “a disintegrin and metalloprotease” (ADAM) family that also cleave APP to 
sAPP. Metalloproteinases inhibition prevents HB-EGF release induced by different stimuli, with 
the former being postulated to regulate HB-EGF ectodomain shedding (60,61). In order to the 
cleavage to take place, both proHB-EGF and the metalloproteinase need to be membrane-
anchored (61). Proteolytic cleavage at the proHB-EGF JM site yields at least two fragments, 
soluble HB-EGF (sHB-EGF) and the carboxyl-terminal fragment containing the transmembrane 
and cytoplasmic segments (HB-EGF-C) (Figure 13) (55,56,60). Release of soluble HB-EGF has 
been found to occur both constitutively and in a regulated manner. Monocytes/ macrophages 
and T lymphocytes are among the cell types that release HB-EGF constitutively. In the case of 
adherent cells such as MDA-MB-231 and Vero, the membrane-anchored precursor is the 
predominant form and processing is inducible, for example, by addition of phorbol esters (58). 
In mammalian cells, two membrane-anchored enzymes, ADAMs 10 and 17, have 
emerged as key molecules in the shedding of the seven ErbB1-ligands. ADAM17 is considered 
the principal ‘sheddase’ for HB-EGF, whereas ADAM10 was identified as the major ‘sheddase’ 
for EGF (35,41,62). A matrix metalloproteinase-3 (MMP-3) has also been implicated in the 
cleavage of HB–EGF in the juxtamembrane region, since it releases sHB-EGF from an insoluble 
substrate in vitro (37,58). So far, it has been reported that proHB-EGF can be processed by 
MMP-3, MMP-7, ADAM9, 10, 12, and 17 (60). 
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Figure 13 - Schematic representation of HB-EGF processing. HB-EGF is synthesized as pre-proHB-EGF by ER-bound 
ribosomes, and expressed at the plasma membrane as proHB-EGF. ProHB-EGF is cleaved at the juxtamembrane 
domain, yielding soluble HB-EGF and HB-EGF-C. Adapted from reference (55). 
 Regulation of proHB-EGF processing  2.3.8.1
Regulation of ectodomain shedding by different stimuli. Ectodomain shedding must 
be strictly regulated. Several stimuli, which include calcium ionophores, activation of G-protein 
coupled receptors (GPCRs) by lysophophatidic acid (LPA), and phorbol ester-mediated PKC 
activation are known to induce ectodomain shedding of HB-EGF by metalloprotease activation 
(Figure 14) (36,55,56,61–64). Activators of protein kinase C (PKC), such as phorbol ester 12-O-
tetradecnoylphorbol-13-acetate (TPA), were among the first identified activators of protein 
ectodomain shedding (36,59,61–64). Therefore, PKC is involved in the intracellular signaling 
pathway for proHB-EGF processing, with PMA inducing the loss of cell-surface associated 
transmembrane HB-EGF, the acquisition of cell resistance to DT, and release of the mature 
sHB-EGF into conditioned medium (61). Stimulation of G-protein-coupled receptors (GPCRs) 
also leads to proHB-EGF ectodomain shedding, and shed sHB-EGF, in turn, activates and 
further induces EGFR signaling, mediating the reported EGFR transactivation by GPCR 
signaling. Transactivation of EGFR-dependent pathways has been known to be critical for the 
mitogenic activity of GPCRs ligands such as lysophosphatidic acid, endothelin and thrombin. It 
was shown that the sHB-EGF generated by GPCR-induced ectodomain shedding of proHB-EGF 
is the only growth factor mediating EGFR transactivation (36). Several growth factors, including 
sHB-EGF itself, may be involved in activation of receptor tyrosine kinases, activating the Ras-
MAPK pathway that also leads to proHB-EGF ectodomain shedding. 
Cellular stresses caused by inflammatory cytokines, reactive oxygen and osmotic shock 
can also induce ectodomain shedding (41). In addition, protein phosphorylation may also be 
involved in the regulation of this process, since it was observed that tyrosine phosphorylation 
and phosphatase inhibitors promote shedding (61). The cochaperone BAG-1 (an antiapoptotic 
protein) that binds to HB-EGF C-terminus, also increases the secretion of soluble HB-EGF. 
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Furthermore, Nardilysin, a metalloendopeptidase and linker protein, potentially regulates HB-
EGF ectodomain cleavage by binding to ADAM17 (64). 
 
Figure 14 - Model of proHB-EGF ectodomain shedding induction. ADAM proteins are activated by various stimuli 
including GPCR signaling, PKC activation, and binding of cytoplasmic docking proteins, which lead to proHB-EGF 
processing yielding sHB-EGF and HB-EGF-C. Adapted from reference (60). 
Regulation of proHB-EGF shedding by signaling pathways. ProHB-EGF ectodomain 
shedding is regulated by at least two distinct intracellular signaling pathways, including the PKC 
pathway and the Ras-MAPK pathway. 
It has been shown that the regulated processing of proHB-EGF requires PKCδ and 
MDC9 (metalloprotease/disintegrin/cysteine-rich protein 9), a member of the ADAM family of 
metalloproteases which is a PKCδ-specific binding protein. Importantly, MDC9 overexpression 
results in the shedding of the proHB-EGF ectodomain (63). PKCδ may trigger proHB-EGF 
shedding by binding and subsequent phosphorylation of the cytoplasmic domain of MDC9, 
recruiting MDC9 to the proximity of proHB-EGF (63). The direct interaction with PKCδ supports 
the hypothesis that MDC9 is the initial protease in the TPA-induced mechanism of ectodomain 
proHB-EGF shedding (63). 
In many types of mammalian cells, the Ras-MAPK cascade is the main mitogenic 
signaling pathway, and MAPK activation is essential for cell growth (65). PMA is known to 
induce MAPK activation and this activation was shown to precede HB-EGF shedding, 
comprising an intermediate step in the shedding mechanism (61). As an inducer of proHB-EGF 
shedding, MAP kinase may be a mediator of sustained and amplified growth factor activity. 
One of the hypothesis is that HB-EGF binds to its receptor, which in turn activates MAPK, 
leading to cell proliferation but also to the release of more growth factor from the proHB-EGF 
membrane-anchored precursor, resulting in an autocrine amplification loop (61). Since it has 
been demonstrated that Raf-1 induces proHB-EGF shedding via the MAPK cascade, it was 
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postulated that the activation of the MAPK cascade by PMA is in part due to the activation of 
certain PMA-responsive PKC isoforms that activate Raf-1. Therefore, results suggest that HB-
EGF-induced binding to ErbB receptors regulates proHB-EGF shedding via Raf-1/MEK/ERK 
signaling pathway (61), and MAPK (p42 and p44) activation was shown to mediate the serum 
starvation-induced HB-EGF cleavage (61). 
Another suggested novel regulator of proHB-EGF shedding is the degree of cell 
adhesion and spreading. Surprisingly, it was observed that when cells are placed into 
suspension, PMA failed to induce shedding, with the ability of PMA to induce proHB-EGF 
shedding being fully restored after plating suspended cells on fibronectin. However, this 
inability of PMA to induce the cleavage of proHB-EGF in suspended cells was not due to an 
impaired activation of the MAPK, suggesting that MAPK activity is necessary but not sufficient 
to promote proHB-EGF shedding, since cell adhesion is also required. The degree of cell 
spreading also appears to regulate proHB-EGF shedding. It was observed that when cells are 
plated on increasing fibronectin densities, the extent of PMA-induced shedding of proHB-EGF 
increases in proportion to the degree of cell spreading (61). 
In summary, activation of the Ras-MAPK pathway promotes G1 phase progression in 
the cell cycle, and MAPK activation can induce proHB-EGF shedding in a process that is 
dependent on cell adhesion and spreading, suggesting that the cellular architecture and 
cytoskeleton may play a role in this signaling pathway (61,65). 
2.3.9 Mature HB-EGF: Autocrine and Paracrine biological activities 
Mature HB-EGF is a potent stimulator of cell proliferation and migration. It has a broad 
spectrum of activities, but in particular it targets fibroblasts, SMC and epithelial cells. HB-EGF is 
a potent mitogen for a number of cell types including mouse 3T3 fibroblasts, SMC, epithelial 
cells, keratinocytes, hepatocytes, renal tubule cells, and breast and ovarian carcinoma cells. 
HB-EGF is also a potent stimulator of cell motility, being also chemotactic for SMC, fibroblasts 
and keratinocytes (36,37,41), and stimulating intensive random migration (chemokinesis) of 
astrocytes (37). On the other hand, HB–EGF is not mitogenic for endothelial cells, unlike other 
heparin-binding growth factors such as Fibroblast Growth Factor-1 and -2 (FGF-1 and -2) and 
Vascular Endothelial Growth Factor (VEGF) (36,37,41). Noticeably, the HB-EGF mitogenic 
activity on SMC is much stronger than that of EGF, and it appears to involve interactions with 
heparan sulfate proteoglycans in the extracellular matrix (37). 
HB–EGF might also stimulate cells indirectly by inducing the transcription of other 
growth factors and growth factor receptor genes. For example, in SMC, HB-EGF stimulates an 
increase in the mRNA levels of the SMC mitogens Platelet-derived Growth Factor (PDGF) and 
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FGF-2. HB-EGF also induces an increase in the mRNA levels of other EGF-like ligands such as 
TGF-α, AR and BTC in keratinocytes, epithelial cells and colon adenocarcinoma cells. Induction 
of macrophage colony-stimulating factor (M-CSF) receptor gene expression in SMC by HB-EGF 
suggests it has a role in the phenotypic change of SMC to macrophage-like foam cells in 
atherosclerosis (37). 
2.3.10 Transmembrane HB-EGF (proHB-EGF): Juxtacrine activities  
Although HB-EGF was first identified as a soluble growth factor, the existence and 
relative abundance of HB-EGF in its membrane-anchored form, the existence of protein 
complexes of proHB-EGF with other membrane proteins, and its localization at cell-cell contact 
sites suggest that proHB-EGF is not only a precursor for sHB-EGF but also plays some role in 
intercellular interactions. In fact, proHB-EGF has unique biological characteristics distinct from 
sHB-EGF (36,37,41). Several properties of transmembrane HB-EGF, including juxtacrine growth 
factor activity and adhesion, DT-binding, and proteolytic processing to produce mature HB-EGF 
are depicted in Figure 15. Juxtacrine activity is a term coined to describe the interactions of an 
immobilized growth factor with neighboring cells in a non-diffusible manner. 
 
 
Figure 15 - Scheme of activities associated with the transmembrane form of HB–EGF. Transmembrane HB–EGF is 
depicted clockwise as a juxtacrine growth factor, as an adhesion molecule for the cells of the mouse blastocyst, as a 
target for proteolytic processing and as the receptor for DT. Interactions with EGFR and heparan sulfate 
proteoglycans (HSPG) are depicted. Reproduced from reference (37). 
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An important and apparently unique property of transmembrane HB-EGF is that it is 
the specific receptor for Diphtheria Toxin (DT), which explains its denomination as DTR 
(Difteria Toxin Receptor) (66). DT binds specifically to the EGF-like domain of transmembrane 
human HB–EGF (Asp106 –Pro149), with Glu141 being a critical residue for DT-binding and toxin-
sensitivity (37,67). Most mammalian cells expressing proHB-EGF are sensitive to DT, however, 
mice and rat are DT-resistant, since DT does not bind to their proHB-EGF due to amino acid 
substitutions in the EGF-like domain (36,67). After DT binding, the DTR/transmembrane HB-
EGF complex is internalized by receptor-mediated endocytosis and enters the cytoplasm, 
where the A-fragment of the toxin exerts its cytotoxicity (36,37). HB-EGF must be in the 
transmembrane form to convey DT toxicity. When cells possessing the transmembrane form 
are treated with phorbol ester, the precursor is processed to release mature HB-EGF and cells 
become DT-resistant (37,66). 
Transmembrane HB-EGF was also reported to stimulate juxtacrine tyrosine 
phosphorylation of EGFR/HER1 and proliferation (68), and acts as an adhesion factor, e.g. for 
blastocysts (69).  
There are also evidences suggesting that proHB-EGF has the ability to suppress the 
growth of cancer cells through up-regulation of EGFR, an effect completely opposite to that of 
sHB-EGF that always presents growth-promoting activity. In fact, proHB-EGF is expressed in 
various tissues that are not thought to be involved in cell proliferation, suggesting that its 
original function in vivo is not always promotion of cell growth. While both forms of HB-EGF 
induce EGFR phosphorylation, in the case of proHB-EGF the phosphorylation state is 
prolonged, which may explain the distinct actions (70). It was also observed that the prolonged 
EGFR stimulation possibly up-regulates the expression of the cyclin-dependent kinase inhibitor, 
p21, which leads to an increased resistance to apoptosis. Of note, the cell growth arrest and 
induction of p21 in tumor cells expressing high amounts of EGFR have been reported to be 
mediated by STAT1 (37,70). 
The juxtacrine activities of transmembrane HB-EGF are modulated by CD9, which acts 
as a co-factor for proHB-EGF juxtacrine activity (see in section 2.3.11.3) (36,37,68).  
2.3.11 HB-EGF receptors and proHB-EGF protein complexes formation 
 Tyrosine kinase receptors 2.3.11.1
HB-EGF, EGF, TGF-α and AR all stimulate qualitatively similar patterns of EGFR/HER1 
tyrosine phosphorylation suggesting that these ligands are functionally identical in activating 
SACS/UA 2013 
42   Luísa Filipe Henriques Martins de Bastos 
HER1. HB-EGF is also capable of activating HER4/ErbB4, a receptor first shown to be activated 
by NRG (37,42). High-affinity interactions with receptors are mediated via the 3-looped EGF-
like motif and result in receptor autophosphorylation and initiation of downstream signaling 
cascades. Interestingly, the biological outcomes evoked by HB-EGF binding to ErbB1 and ErbB4 
are distinct, with the former typically promoting proliferation (mitogenic function) and 
chemotaxis and the latter stimulating strong chemotaxis and migration but no proliferative 
response (37,42,43,50).  
Interactions between the membrane-anchored form of HB-EGF and the respective 
ErbB receptors expressed on adjacent cells also mediate both cell survival and intercellular 
adhesion functions (35).  
In complex systems, where several EGF receptor subtypes are expressed and 
heterodimerization occurs, HB-EGF can activate HER1 and HER4, as well as HER3 and HER2, by 
EGF receptor transmodulation (37). An interesting recent discovery is that HB-EGF plays a 
critical role in EGFR transactivation induced by G-protein-coupled receptor ligands, such as 
lysophosphatidic acid, endothelin-1, and angiotensin-II, being the ectodomain shedding of 
proHB-EGF required for this process (38,71). 
 Heparan sulfate proteoglycans (HSPG) 2.3.11.2
One functional difference and unique feature of HB-EGF is that, unlike EGF and TGF-α, 
it is a heparin-binding protein, showing a high affinity for heparin and heparan sulfate. The 
interaction of HB-EGF with heparin, in the form of HSPGs present on cell surfaces (Figure 16), is 
known to modulate HB-EGF binding to EGFR and activity at least for certain cell types, such as 
SMC and CHO cells (35–37).  For this, HB-EGF is a much more potent chemoattractant for SMC 
than EGF or TGF-α, and reduction of SMC surface HSPG levels reduces the chemotactic activity 
of HB-EGF to about the level of EGF and TGF-α, suggesting that interaction with HSPG 
enhances HB–EGF activity relative to EGF and TGF-α.  
Cell surface HSPG also modulates other transmembrane HB-EGF activity, particularly 
DT-binding activity. Cells expressing transmembrane HB-EGF/DT receptor, but deficient in cell 
surface HSPG were less sensitive to DT toxicity than were wild type cells and the DT-sensitivity 
was restored by addition of either Heparan Sulfate (HS) or heparin. Apparently, heparin 
increases DT-binding to the cells by increasing the affinity of HB-EGF/DTR for DT. 
In conclusion, binding of this growth factor to HSPG, which has lower affinity to HB-
EGF but exists in higher receptor/cell number when compared to the high affinity tyrosine 
kinase erbB receptors, results in an additional level of growth factor activity regulation (37). 
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 DRAP27/CD9 2.3.11.3
HB-EGF forms a complex with a cell-associated protein, DRAP27 (Figure 16), the 
monkey homologue of CD9, a tetraspan membrane protein that belongs to the 
transmembrane 4 superfamily (TM4SF) and that is suggested to be involved in cell growth, 
adhesion and migration (37,67). CD9 serves as a co-factor of proHB-EGF for DT binding and, 
therefore, greatly upregulates the binding of DT to proHB-EGF. Juxtacrine mitogenic activity of 
proHB-EGF is also upregulated by the association of CD9. This up-regulation of proHB-EGF 
activities occurs due to protein-protein interaction between proHB-EGF and CD9, which 
increases the number of effective binding sites for DT (35,36,67). This binding appears to 
stabilize transmembrane HB-EGF on the cell surface by preventing its processing and/or 
internalization (37). The second extracellular domain of CD9 and the EGF-like domain of 
proHB-EGF are essential for the proHB-EGF up-regulation. It was also showed that CD9 and 
also CD63, CD81, and CD82, can be found associated with proHB-EGF and integrin α3β1. 
However, among these TM4SF proteins, only CD9 up-regulated the DT binding activity of 
proHB-EGF (67). 
 Integrin α3β1 2.3.11.4
In addition to CD9, proHB-EGF forms a complex with integrin α3β1, a protein localized 
at cell-cell contact sites in epithelial cells (36,37). Together with integrin α3β1, transmembrane 
HB-EGF and CD9 were found to co-localize at cell–cell contact sites near adherence junctions 
(Figure 16). It seems that transmembrane HB-EGF binds to CD9, which in turn binds to integrin 
α3β1. Since EGF receptors are also localized to adherence junctions, the notion that proHB-EGF 
plays a role in intercellular communication in a juxtacrine manner at cell-cell contact sites is 
supported. In conclusion, it may be that direct interactions of juxtacrine growth factors, 
receptors and cell adhesion molecules control cell proliferation during the cell–cell adhesion 
process (37).  
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Figure 16 - Hypothetical model of the proHB-EGF complex. ProHB-EGF forms a complex with associated molecules 
including CD9, Integrin α3β1 and HSPGs at cell-cell contact sites. EGFR localized at cell-cell contact sites transmits 
growth stimulatory or inhibitory signals into the cells. Metalloproteases may also be localized at the site for the 
processing of proHB-EGF. Adapted from reference (36). 
 N-arginine dibasic convertase (NRDc) 2.3.11.5
Recently, NRDc, a metalloendopeptidase associated with the cytoplasm and the cell 
surface, was identified as a specific receptor for sHB-EGF, although not being one of the known 
members of the ErbB family (38,42,60). Its name derives from its in vitro substrate specificity, 
since it generally cleaves precursor polypeptides at the N-terminus of arginine (R) residues in 
dibasic sites. NRDc is mainly expressed in developing neural tissue and adult testis, heart and 
skeletal muscle, tissues that also express HB-EGF (42). 
Within the EGF family of ligands, NRDc was found to be a highly selective receptor for 
HB-EGF. This specificity suggests that there is a specific NRDc-binding domain within HB-EGF. 
In fact, evidence suggests that the interaction is mediated by the HB-EGF heparin-binding 
domain. Interestingly, NRDc was shown to enhance sHB-EGF-induced, but not EGF-induced, 
cell migration. Furthermore, this occurs in an EGFR/ErbB1-dependent manner, since EGFR 
inhibition totally abolishes HB-EGF-induced cell migration.  Therefore, although the mechanism 
by which NRDc induces cell migration is not known, it is certain that NRDc is a modulator of 
HB-EGF migration activity via ErbB1 (42). 
 Cytoplasmic tail interactors 2.3.11.6
Several binding partners for the cytoplasmic domain of proHB-EGF were identified, 
including the cochaperone BAG-1 and the transcriptional repressors promyelocytic leukaemia 
zinc finger protein (PLZF) and B cell lymphoma 6 (Bcl-6). As mentioned above, interaction 
between BAG-1 and proHB-EGF was found to lead to rapid secretion of sHB-EGF, decreased 
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cell adhesion, and increased resistance to apoptosis. Basically, this interaction augments the 
pro-survival function of proHB-EGF. Conversely, association between the C-terminal fragment 
of HB-EGF, that is liberated following ectodomain shedding, with PLZF or Bcl6, leads to nuclear 
export and degradation of these transcriptional repressors, respectively, and a resulting 
inhibition of their repressive activity (35,41,50).  
2.3.12 ProHB-EGF dual intracellular signaling  
 Mature HB-EGF-induced signaling 2.3.12.1
Soluble HB-EGF generated by proHB-EGF processing binds to EGFR and ErbB4 directly, 
and binds/activates ErbB2 and ErbB3 indirectly by receptor heterodimerization. This induces 
ErbBs signaling into cells and promotes G1-phase progression in the cell cycle by regulating the 
expression of cyclin D via the Ras-MAPK signaling cascade (Figure 17) (38,41,60).  
 
 
Figure 17 - Gene transcription control by HB-EGF-C and sHB-EGF. HB-EGF-C and sHB-EGF generated by proHB-EGF 
processing mediate signaling into the nucleus directly, and indirectly via ErbB receptors, respectively, and this dual 
intracellular signaling regulates gene transcription. Adapted from references  (60,72). 
Upon HB-EGF binding to the receptor, auto-phosphorylation occurs due to the 
intracellular tyrosine kinase activity of EGFR, HER2 and HER4. Phosphorylated tyrosine residues 
then serve as docking sites for intracellular proteins that direct downstream signaling 
pathways, including PI3K and MAPK cascades. Very recently, the downstream signaling 
circuitry that regulates the ability of HB-EGF to autoregulate, to induce migration, and to 
inhibit apoptosis of human trophoblasts has been examined (73). In human cytotrophoblast 
cell lines, HB-EGF induces a rapid, transient activation of the MAPK14, ERK and PI3K pathways 
(marked phosphorylation of MEK, MAPK14, ERK, and AKT is observed 15 min after treatment 
with HB-EGF), but a slower or delayed activation of the JNK pathway (occurring after 1h of 
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treatment). The authors verified that the presence of an inhibitor of PI3K or of any of the three 
MAPK pathways (MAPK14, MEK, or JNK), blocked the HB-EGF-induced increase in trophoblast 
migration (73). Interestingly, it was also reported that HB-EGF prevents apoptosis induced by 
oxygen fluctuations (Hypoxia/Reperfusion) by signaling through MAPK14 but not through the 
other kinases. Another very interesting finding was that HB-EGF signaling increases HB-EGF 
protein levels via the three MAPK pathways (but not PI3K) in hypoxia conditions (73). 
 HB-EGF-C-induced signaling  2.3.12.2
In addition to the well-known signaling pathways mediated by the extracellular EGF-
like growth factor domain, subsequent to shedding, the carboxyl-terminal cell-associated 
remnant, HB-EGF-C, is phosphorylated and migrates from the PM to the ER and nuclear 
envelope (NE), where it directly regulates gene expression (55,56) and functions as an 
intracellular signal coordinating cell cycle progression (Figure 17) (41,60,72).  
The interactions between HB-EGF-C and PLZF and Bcl-6 (55,56,60,72) evoke a novel 
intracellular signaling that is independent of EGFR activation. PLZF is localized in the nucleus, 
being a transcriptional repressor of several proteins and a negative regulator of the cell cycle 
by the suppression of cyclin A expression (60,72). HB-EGF-C translocates from the PM to the 
nucleus, where it binds to PLZF and triggers its nuclear export, which results in the prevention 
of cyclin A transcription suppression and allowing progression of the cell cycle into the S-phase 
(Figure 17, Figure 18) (60,65,72). This process also lead to Bcl6 degradation and attenuation of 
its negative regulatory activity on gene repression (Figure 18) (35,37,65). 
Therefore, proHB-EGF has two functional domains (HB-EGF and HB-EGF-C) affecting 
mitogenic signaling, and the coordination of the dual mitogenic signals generated by the 
processing may be important for cell cycle progression (60,72). BAG-1L, an isoform of BAG-1 is 
another potential binding protein of nuclear HB-EGF-C. While BAG-1 was first identified as a 
proHB-EGF cytoplasmic-binding protein in the cytoplasm and PM, its isoform BAG-1L possesses 
a nuclear localization signal and is localized in the nuclei of some cell types, being therefore a 
potential binder of nuclear HB-EGF-C (60).  
Recent experiments have indicated that the cytoplasmic region of proHB-EGF also acts 
to regulate the distribution of proHB-EGF at the plasma membrane. These findings indicate 
that the proHB-EGF cytoplasmic region is, unexpectedly, a multifunctional protein domain (60). 
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Figure 18 - Regulated processing and activity of HB-EGF. ProHB-EGF expressed on the PM undergoes ectodomain 
cleavage (A). Release of the mature, soluble protein facilitates both autocrine (B) and paracrine (C) activation of 
ERBB receptors expressed on the same or adjacent cells, respectively. ProHB-EGF can also activate ERBB receptors 
via juxtacrine signaling (D). The HB-EGF-C translocates to the nucleus (E) to effect either nuclear export (F) or 
degradation (G), respectively, of the transcriptional repressors PLZF or Bcl6. Reproduced from reference (35). 
It is then well accepted that HB-EGF-C is able to function in the nucleus, thus raising 
two intriguing questions: How is the newly synthesized proHB-EGF, which possesses ER 
retrieval activity, delivered to the PM? And how is HB-EGF-C targeted to the nucleus in 
response to shedding stimuli? In fact, HB-EGF shows bidirectional intracellular trafficking, 
anterograde and retrograde transport between the plasma membrane and ER (Figure 19), and 
is able to localize to five different subcellular compartments: the plasma membrane, Golgi 
apparatus, ER, nuclear envelope, and perinuclear vesicles.  
In a recent study, the shedding of proHB-EGF and the subsequent trafficking of the 
cleaved HB-EGF-C fragment were analyzed in relation to the cell cycle and accordingly, with 
cellular proliferation (65). It was observed that in the early G1 phase, proHB-EGF is localized to 
the PM, with its shedding occurring during late G1 phase, where proHB-EGF is localized to the 
cytoplasm, and the HB-EGF-C migration into the nucleus was observed at the beginning of 
early S phase. During the S and G2 phases, HB-EGF-C is localized to the nucleus. Following 
internalization of endogenous HB-EGF into the nucleus, endogenous PLZF translocation to the 
cytoplasm occurs late in S phase, with complete migration of PLZF into the cytoplasm occurring 
in the G2 phase (65). ProHB-EGF shedding, nuclear translocation of HB-EGF-C, and nuclear 
export of PLZF might thus be a main mechanism for cell cycle progression of normal cells (65). 
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Figure 19 - A working model for the intracellular trafficking of proHB-EGF and HB-EGF-C regulated by post-
translational modification. A, anterograde and retrograde transports. B, nuclear envelope targeting of HB-EGF-C. 
Since the newly synthesized proHB-EGF is sorted to the plasma membrane, it indicates that the ER/NE retrieval 
activity of HB-EGF-C is inactivated when proHB-EGF is synthesized. Evidences have shown that during or just after 
proHB-EGF is synthesized by ER-bound ribosomes, an epitope-masking posttranslational modification occurs in the 
cytoplasmic tail region - amino acids 199–208 - which suppresses ER retention/retrieval activity (185-198) via a 
conformational change. With ER targeting blocked, proHB-EGF is instead targeted to the plasma membrane. After 
exposure to shedding stimuli, a phosphorylation at S207 occurs in the carboxyl-terminal, which induces a 
conformational change and exposes the previously masked-epitope, which appear to regulate the activation of the 
retrograde transport to the Golgi apparatus and ER. Adapted from references (55,56). 
 
In synthesis, APP and HB-EGF have functions, a complex cellular processing, and 
signaling pathways that partially overlap, with a putative interaction between these two 
proteins being innovative and of major importance in APP and HB-EGF physiologies, besides its 
potential contribution to our understanding of the AD pathogenesis.  
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3 Aims of the thesis 
Given the several distinct roles that have been purposed for APP and its physiological 
relevance in developing and adult CNS, it is important to identify novel APP-binding proteins in 
order to better characterize APP function. From a large scale yeast two-hybrid screening of a 
human brain cDNA library using APP as bait, a novel promising APP interactor was identified, 
the EGF-like growth factor HB-EGF. Therefore, this master thesis focused on validating and 
characterizing the interaction between APP and HB-EGF, with the specific aims being: 
 To confirm the interaction between APP and HB-EGF by yeast co-transformation; 
 To validate the physiological APP/HB-EGF interaction ex vivo by GFP-Trap® pull-down 
assays; 
 To monitor the subcellular localization of the APP/HB-EGF complex in mammalian 
cells; 
 To evaluate the influence of APP and HB-EGF co-expression in MAPK and STAT3 
signaling; 
 To study the effect of APP:HB-EGF co-expression in the induction of cellular 
morphological changes. 
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4 Materials and Methods 
4.1 Yeast two Hybrid Screening 
4.1.1 YTH Screening workflow - Background 
The original two-hybrid system was based on the yeast GAL4 transcription factor, 
involved in galactose metabolism, and is known as the GAL4 system (74). The two functional 
domains of a transcriptional activator, the DNA-binding domain (BD) and the transcription 
activation domain (AD), can be split apart and each fused to one of a pair of putative partner 
proteins in order to reconstitute the activator’s ability to turn on a reporter gene. These two 
elements can be co-introduced into yeast strains modified with one or more reporter genes 
(the use of multiple reporter genes decreases the number of false positives obtained). These 
reporter genes have a binding site specific to the BD on their promoter region, causing the 
transcription of those genes to be dependent on the interaction between prey and bait 
proteins. Interaction of the BD-bait fusion with the AD-prey fusion, positions the AD in the 
proximity of the reporter gene, thus activating its transcription (75). 
The MATCHMAKER GAL4 Two-Hybrid System 2 (Clontech) was used to perform yeast 
two-hybrid screens according to the manufacturer’s instructions. The key components and 
features of the MATCHMAKER Two-hybrid System 2 (Clontech) are the reporter genes used, 
the yeast host strains, the optimized plasmids and the cDNA libraries, as detailed below. 
Reporter genes. The reporter genes used in this system are the MEL1 gene (coding for 
α-galactosidase that is secreted into the culture medium) and the auxotrophic reporter genes 
HIS3 and ADE2, which allow yeast cells carrying interacting proteins to grow in medium lacking 
histidine and adenine. Additionally, the YTH bait plasmid pAS2-1 and the library plasmid 
pACT2, which contain the TRP1 and LEU2 genes, respectively, allow for selection in medium 
lacking tryptophan and leucine. Hence, the high-stringency selection consists of medium 
lacking tryptophan, leucine, histidine and adenine, and also in the presence of X-α-Gal (5-
bromo-4-chloro-3-indolyl alpha-D-galactopyranoside). If the two proteins (bait and prey) 
interact, the reporter genes will be activated and the yeast will grow with a blue appearance of 
the colonies. The selection of positive clones with the “five” reporter genes was designed to 
reduce the number of false positives, thus allowing faster identification of true interactions 
with the bait protein. 
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Yeast host strains. The AH109 Saccharomyces cerevisiae strain was used, since it 
virtually eliminates false positives by using three reporters – ADE2, HIS3 and MEL1 – under the 
control of distinct GAL4-responsive upstream activating sequences (UAS) and promoter 
elements (TATA boxes). 
Plasmids. The Gal4 DNA-BD fusion vector pAS2-1 and the Gal4-AD fusion vector pACT2 
have multiple cloning sites that allow for the insertion of bait or library cDNA, respectively. 
They also carry a bacterial replication origin and an ampicilin resistance gene, for selection in 
bacteria. pAS2-1 contains the TRP1 gene for selection in Trp- auxotrophic yeast strains (AH109, 
Y187 or diploids) and pACT2 contains the LEU2 gene for selection in Leu- auxotrophic yeast 
strains (AH109, Y187 or diploids). Additionally, the YTH system includes yeast plasmids carrying 
Gal4-BD and Gal4-AD fusion cDNAs (pVA3-1 and pTD1-1) that provide controls for positive 
interactions, which were used to validate the method. 
Baits and prey for the YTH screening. Bait-1 cDNA, coding for full-length human APP 
(isoform 695) and Bait-2 cDNA, coding for the intracellular domain of human APP695 with 50 
amino acids, the AICD, had been previously PCR amplified and inserted in Clontech’s GAL4 
DNA-binding domain (GAL4-BD) expression vector pAS2-1, using NcoI/SmaI restriction enzyme 
sites, in frame with the GAL4 DNA-BD. The bait proteins were expressed as a fusion with the 
Gal4-BD in the yeast strain AH109.  
The Human Brain MATCHMAKER cDNA Library (Clontech) used to perform the YTH 
screen (previous work from Dr. Sara Domingues in our laboratory) is a high-complexity cDNA 
library, expressing fusions of the prey proteins with the yeast Gal4-AD vector pACT-2 and 
pretransformed into the S. cerevisiae Y187 host strain. 
YTH screening by Yeast Mating. A large scale yeast mating screening of several 
independent clones from human brain Matchmaker cDNA library (Clontech) was previously 
carried out in our laboratory (76). In this method, a yeast strain expressing the bait protein is 
mated with another yeast strain of opposite mating type pretransformed with the cDNA 
library. The diploid cells were plated in selective media with X-α-Gal and three reporter genes: 
HIS3, ADE2, and MEL1, allowing for the identification of the positive clones.  
HB-EGF was identified as a positive clone when using the full-length human APP 
(isoform 695) cDNA as bait, which has propelled its selection for validation and further 
functional investigation during the current project. Yeast plasmid DNA was then extracted 
from the positive clones using the breaking buffer method (Yeast Protocols Handbook, 
Clontech) and the pACT2-library plasmids were rescued by transformation in E. coli XL-1 Blue. 
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The library cDNAs were identified by partial sequencing of the library insert with a primer that 
targets the GAL4-AD (Clontech), using an ABI PRISM 310 Genetic Analyzer (Applied 
Biosystems). 
4.1.2 YTH cDNAs amplification and purification 
The pACT2, pAS2-1 (vectors alone), pVA3-1, pTD1-1 (positive controls), pAS2-1-APP, 
pAS2-1-AICD (baits 1 and 2) and pACT2-HB-EGF (prey) cDNAs were all subjected to bacterial 
transformation, DNA isolation by “Midiprep” and were ultimately purified by ethanol 
precipitation as follows.  
4.1.3 Bacteria transformation with plasmid DNA 
Preparation of E. coli XL1-blue competent cells.  A single colony of E. coli XL1-Blue was 
incubated in 10 ml of SOB medium at 37°C overnight. Then, 1 ml of this culture was used to 
inoculate 50 ml of SOB and the culture was incubated at 37°C with shaking at 220 rpm for 1-2 
h, until OD550nm=0.3. The culture was cooled on ice for 15 min and centrifuged at 4,000 g at 4°C 
for 5 min. The supernatant was discarded and then resuspended in 15 ml of Solution I 
(solutions in Appendix). After standing on ice for 15 min, cells were centrifuged at 4,000 g for 5 
min at 4°C and 3 ml of Solution II were added to resuspend the cell pellet. The cells were 
immediately divided in 100 µl aliquots and stored at -80°C. 
Bacteria transformation with plasmid DNA. E. Coli XL1-Blue competent cells were 
thawed on ice and the appropriate amount of DNA (plasmid DNA: 0.1-50 ng) was added to a 
100 µl aliquot of competent cells and gently swirled. Cells were incubated on ice for 30 min 
and then subjected to an heat shock at 42°C for 90 sec, followed by a quick cooling on ice for 2 
min. 900 µl of SOC medium was added to cells and a 45 min incubation at 37°C followed. The 
culture was then centrifuged at 14000 rpm for 30 sec, the supernatant was removed and the 
pellet was resuspended in the remaining volume (100 µl), and spread on the appropriate agar 
medium (LB/ampicillin or kanamycin agar plates). Plates were incubated at 37°C for 16-18 h. 
 Isolation of plasmid DNA from bacteria - Promega “Midiprep” 4.1.3.1
One colony of transformed bacteria with each cDNA was isolated, transferred to 3 ml 
of LB medium containing the appropriate antibiotic, and incubated for 16-18 h at 37°C with 
shaking (180 rpm). After bacterial growth, 250 µl of the culture was transferred to 250 mL of 
LB medium, also with the appropriate antibiotic, and again incubated overnight (O/N) at 37°C 
with agitation. Cells were then centrifuged at 5000 g, for 10 min (Beckman Avanti J-25 I - 
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Beckman Coulter), the supernatant was discarded and 6 ml of Cell Resuspension Solution was 
added. After resuspension, 6 ml of Cell Lysis Solution was added, gently mixed and incubated 
at RT for 3 min. Once the solution became clear and viscous, 10 ml of Neutralization Solution 
was added to the lysed cells and mixed. After precipitate formation, a PureYieldTM Clearing 
Column was placed into a 50 ml disposable plastic tube and the lysate was poured into the 
column. After 2 min incubation, the PureYieldTM Clearing Column was centrifuged at 1500 g for 
5 minutes (Eppendorf Centrifuge 5810R). Then, a PureYieldTM Binding Column was placed into 
a new 50 ml disposable plastic tube and the filtered lysate poured into it. Following an 
additional centrifugation step at 1500 g for 3 min, 5.0 ml of Endotoxin Removal Wash solution 
(with isopropanol added) was added to the PureYieldTM Binding Column. Another 
centrifugation at 1500 g for 3 min followed, and the flow-through was discarded. The column 
was then washed with 20 ml of Column Wash Solution (with ethanol added) and centrifuged 
once again at 1500 g for 5 min. The flow-through was discarded and the centrifugation step 
was repeated for an additional 10 min, to ensure the removal of ethanol. To elute the DNA, 
the column was transferred to a new 50 ml disposable plastic tube and 600 µl Nuclease-Free 
Water was added to the DNA binding membrane in the PureYieldTM Binding Column. The 
column was centrifuged at 1500-2000 g for 5 min one last time and the filtrate was collected 
and transferred to a microtube. 
 Purification of plasmid DNA by ethanol precipitation  4.1.3.2
Ethanol precipitation was also performed in order to concentrate nucleic acids as well 
as to increase DNA purification, which is essential for optimal transfections. Approximately 
1/10 volume of 3M sodium acetate (pH 5.2) was added to the DNA solution, to adjust the salt 
concentration. Then, 2.5 volume of ice-cold 100% ethanol was added, mixed and incubated 
O/N at -20°C to allow the DNA precipitate to form. The DNA was recovered by centrifugation 
(14000 g, 15 min, 4 °C), the supernatant was carefully discarded and the pellets rinsed with 
750 µl of ice-cold 70% ethanol (half of the tube capacity). The solutions were incubated for 15 
min, at -20 °C, and then centrifuged (14000 g, 5 min, 4 °C). The supernatant was once again 
removed and the pellet allowed to dry. After all traces of ethanol have disappeared, the DNA 
was resuspended in Milli Q water and stored at -20°C. The DNA concentration and the 260/280 
nm purity ratio was calculated by absorbance measurements. 
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4.1.4 Yeast transformation with plasmid DNA 
 Preparation of competent yeast cells  4.1.4.1
One yeast colony was inoculated into 1 ml of YPD medium in a microtube and vortexed 
vigorously to disperse cell clumps. The culture was transferred into a 250 ml flask containing 
50 ml of YPD and incubated at 30°C with shaking at 230 rpm overnight, until it reached the 
stationary phase with OD600nm>1. An amount of this culture (20-40 ml), sufficient to produce an 
OD600nm=0.2-0.3, was transferred into 300 ml YPD in a 2 L flask. The culture was incubated at 
30°C with shaking at 230 rpm, until OD600nm=0.4-0.6, and then centrifuged at 4000 g for 5 min 
at room temperature. The supernatant was discarded and the cells resuspended in 25 ml of 
sterile H2O. The cells were recentrifuged and the pellet resuspended in 1.5 ml of freshly 
prepared, sterile 1x TE/LiAc (lithium acetate solution). 
 Yeast transformation by the LiAc-mediated method  4.1.4.2
In a microtube, 200 ng of plasmid DNA were added to 100 µg of salmon testes carrier 
DNA. Then, 100 µl of freshly prepared competent cells were added to the microtube, followed 
by 600 µl of sterile PEG/LiAc (40% PEG 4000/ 1x TE/1X LiAc). The mixture was incubated at 
30°C for 30 min with shaking (200 rpm). After adding 70 µl of DMSO, the solution was mixed 
gently and then heat-shocked for 15 min in a 42°C water bath. The cells were chilled on ice for 
1-2 min and pelleted by centrifugation for 5 sec at 12,000 g and resuspended in 0.5 ml of 
sterile 1x TE buffer. Cells were then plated in the appropriate SD selection medium, and 
incubated at 30°C for 2-4 days, until colonies appeared. 
4.1.5 Bait and Prey auto-activation test  
In order to analyze the ability of the recombinant constructs to autonomously activate 
the reporter genes HIS3, ADE2 and MEL1, the bait plasmids pAS2-1-APP and pAS2-1-AICD, the 
prey plasmid pACT2-HB-EGF, and the pAS2-1 and pACT2 empty vectors were independently 
transformed into the AH109 yeast strain (Clontech), using the lithium acetate transformation 
method, as described above. The transformants were selected on medium without tryptophan 
(for APP, AICD and pAS2-1) and without leucine (for HB-EGF and pACT2), since the respective 
vectors contain the nutritional selection reporter genes TRP1 and LEU2. To verify that the 
Gal4-BD and the Gal4-AD fusion constructs do not intrinsically activate reporter genes, the 
transformants from the previous step were assayed for growth in medium lacking histidine and 
adenine and for blue appearance of the colonies in the presence of X-α-Gal. Briefly, the AH109 
yeast cells independently transformed were plated on SD/-Trp/X-α-Gal, SD/-Trp/-His/X-α-Gal 
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and SD/-Trp/-Ade/X-α-Gal (for baits), and on SD/-Leu/X-α-Gal, SD/-Leu/-His/X-α-Gal and SD/-
Leu/-Ade/X-α-Gal (for prey). The plates were incubated at 30°C for 2-4 days. 
4.1.6 Verifying protein interactions in yeast by co-transformation  
After testing APP, AICD and HB-EGF for HIS3, ADE2 and MEL1 reporter genes’ intrinsic 
activation, protein interactions were verified by co-transformation of the AH109 yeast strain 
with each BD-bait (full-length APP and AICD) and the AD-prey (HB-EGF), using the lithium 
acetate method described above. In parallel, the pAS2-1 and pACT2 empty plasmids were co-
transformed as an interaction negative control. A positive control is given by co-transformation 
of pVA3-1 and pTD1-1 vectors, which express the Gal4-BD-p53 and the Gal4-AD-SV40 large T 
antigen fusions, respectively. AH109 was thus co-transformed using the following plasmid 
pairs: pAS2-1/pACT2; pVA3-1/pTD1-1; pAS2- 1/HB-EGF-pACT2; APP-pAS2-1/pACT2; AICD-pAS2-
1/pACT2; APP-pAS2-1/HB-EGF-pACT2; AICD-pAS2-1/HB-EGF-pACT2. The co-transformants 
were selected in SD/-Trp/-Leu medium. To confirm protein-protein interactions (reporter 
genes activation), fresh colonies of the co-transformants were assayed for growth on SD/TDO 
(SD/-Trp/-Leu/-His) and SD/QDO (SD/-Leu/-Trp/-His/-Ade) plates, and later on SD/QDO/X-α-
Gal plate (SD/-Leu/-Trp/-His/-Ade/ X-α-Gal). 
4.2 APP-GFP and Myc-HB-EGF mammalian expression cDNAs 
The green fluorescent protein (GFP), obtained from Aequorea victoria, is widely used in 
transfection experiments to study the dynamics and characteristics of gene expression in a 
non-invasive manner. For this reason, the generation of GFP-fusion proteins is one of the 
favorite methodologies for immunofluorescence analysis. Wt APP cDNA (isoform 695) fused to 
GFP was already available at the laboratory, having been one of the constructs selected for 
performing the several studies in the scope of this master thesis. Briefly, parental APP cDNA 
was subcloned into the pEGFP-N1 vector (Clontech), a plasmid that encodes GFP. The result 
was a fusion gene of APP with GFP in its C-terminal (77,78). 
The HB-EGF clone cDNA was obtained from Human Brain Matchmaker cDNA library 
(Clontech), which contains fusions of the prey proteins with the yeast Gal4-AD vector pACT-2. 
The pACT2-HB-EGF DNA had been previously extracted from the positive clones obtained in 
the screening by large scale yeast mating and was rescued by transformation in E. coli XL-1 
Blue. 
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4.2.1 APP-GFP and pACT2-HB-EGF cDNAs amplification and purification 
Both constructs were amplified and recovered from E.coli XL-1 Blue. Isolation and 
purification of plasmid DNA was performed using the Promega Pure Yield Plasmid Midiprep 
System. Both DNAs were further purified by ethanol precipitation. These procedures were 
previously described in section 4.1.3. 
4.2.2 Generation of the Myc-HB-EGF construct 
The HB-EGF cDNA was digested and inserted into pCMV-Myc (Clontech), a mammalian 
expression vector containing the human cytomegalovirus (CMV) promoter and a Myc tag N-
terminal to the multiple cloning site (MCS). The Myc epitope tag was chosen due to its small 
size, unlikely to affect the tagged protein’s biochemical properties. The pCMV-Myc-HB-EGF 
construct was thus created from pACT2-HB-EGF, using standard cloning procedures (Table 2), 
having the insert been cloned in frame with the Myc coding sequence. 
Table 2 - Cloning strategy followed to obtain the pCMV-Myc-HB-EGF fusion construct.  
Vector and Insert 
DNA amplification in E.coli XL1-Blue 
DNA isolation by “Midiprep” 
Ethanol precipitation 
Simultaneous digestion with EcoRI and XhoI 
Incubation with alkaline phosphatase 
Restriction fragment analysis of DNA 
DNA extraction from the Agarose Gel 
Vector and Insert DNA purification 
Ligation of Vector and Insert 
Transformation of ligation mixtures into E.Coli XL1-Blue 
Isolation of plasmids from transformants by “Miniprep” 
Identification of insert-containing plasmids by restriction analysis 
DNA “Midiprep” 
 
 Plasmid DNA digestion with restriction enzymes 4.2.2.1
Firstly, to express a recombinant Myc-tagged HB-EGF protein, the plasmid DNA pCMV-
Myc (Clontech) was simultaneously digested with EcoRI and XhoI (both from New England 
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Biolabs, NEB) restriction endonucleases. The pACT2-HB-EGF DNA was simultaneously digested 
with the same restriction enzymes. For a typical DNA digestion the manufacturer’s instructions 
were followed. In a 1.5 ml microtube the following components were added:  
 100 µg/ml DNA  
 1x reaction buffer (specific for each restriction enzyme)  
 1 U/µg DNA of restriction enzyme 
 0.1 µg/µl BSA 
 Milli Q water to make the volume up to 20 µl 
The mixture was incubated at the appropriate temperature (37°C for both enzymes) for 4 
hours before further analysis. 
 Alkaline phosphatase treatment  4.2.2.2
In order to prevent self-ligation of pCMV-Myc vector molecules, the digested plasmid 
DNA was first incubated with shrimp alkaline phosphatase (SAP) (ROCHE) before ligation. 
According to the manufacturer’s instructions, the reaction mixture was adjusted with 1/10 
volume 10X concentrated dephosphorylation buffer, and incubated with 1 µl of SAP at 37°C for 
1 h. Finally, SAP was inactivated by heating the reaction mixture at 65°C for 15 min. 
 Restriction fragment analysis - DNA Gel Electrophoresis  4.2.2.3
The electrophoresis apparatus was prepared and the electrophoresis tank was filled 
with 1x TAE buffer to cover the agarose gel. The appropriate amount of agarose was 
transferred to an Erlenmeyer with 50 ml 1x TAE. The slurry was heated until the agarose was 
completely dissolved and allowed to cool to 60°C before adding 1,25 µl GreenSafe (Nzytech). 
The agarose solution was poured into the gel cast and the comb was positioned. After the gel 
became solid the comb was carefully removed and the gel immersed in the tank. The DNA 
samples were mixed with 6x loading buffer and the mixture was loaded into the slots of the 
submerged gel using a micropipette. Marker DNA was also loaded into the gel (1 Kb plus DNA 
ladder, Invitrogen). The lid of the gel tank was closed and the electrical leads were attached so 
that the DNA migrated towards the anode. The gel run at 90-100V until the bromophenol blue 
had migrated the appropriate distance through the gel. At the end, the gel was examined by 
UV light and analyzed on a Molecular Imager (Biorad). 
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 DNA extraction from Agarose Gels 4.2.2.4
The QIAquick Gel Extraction Kit Protocol (Qiagen) was used to extract and purify the 
cleaved pCMV-Myc and pACT2-HB-EGF plasmids from the agarose gel. Firstly, the DNA 
fragments were excised from the agarose gel with a clean, sharp scalpel, minimizing the size of 
the gel slices. Each gel slice was then weighted and 3 volumes of Buffer QG to 1 volume of gel 
(100 mg ~ 100 μl) were added. The sample was incubated at 50°C until the gel slice had 
completely dissolved. After checking the yellow color of the mixture, which corresponds to a 
pH<7.5, a QIAquick spin column was placed in a provided 2 ml collection tube. To bind DNA, 
the sample was applied to the QIAquick column, and centrifuged for 1 min. The flow-through 
was discarded and the QIAquick column was placed back in the same collection tube. Then, 0.5 
ml of Buffer QG were added to QIAquick column and centrifuged for 1 min, to remove all 
traces of agarose. To wash, 0.75 ml of Buffer PE were added to QIAquick column and 
centrifuged for 1 min. The flow-through was discarded and the QIAquick column was 
centrifuged for an additional 1 min. The QIAquick column was then placed into a clean 1.5 ml 
microcentrifuge tube and the DNA was eluted by adding 30 μl of Buffer EB to the center of the 
QIAquick membrane and centrifuging the column for 1 more min. All centrifugation steps were 
carried out at ~13,000 rpm in a conventional table-top microcentrifuge. 
 Vector and Insert DNA purification 4.2.2.5
The QIAGEN DNA Purification kit was used to purify the DNA fragments from the 
enzymatic reactions. It allowed DNA purification by using QIAquick spin columns (silica-
membrane-based columns). Briefly, 5 volumes of buffer PB (QIAGEN) were added to 1 volume 
of the solution to be purified and mixed. The spin column was placed in a collection microtube 
and the sample was applied to the column and centrifuged for 1 min at 12,000 g to bind the 
DNA. The flow-through was discarded and the column was washed with 0.75 ml of buffer PE 
(QIAGEN), centrifuged for 1 min at 12,000 g and the flow-through discarded. The column was 
placed back in the same microtube and centrifuged again to remove traces of washing buffer. 
Then, the column was placed in a clean microtube, 30 µl of Buffer EB (QIAGEN) were added 
and allowed to stand for 1 min. To elute the DNA, the column was centrifuged for 1 min at 
12,000 g. 
 Ligation of Vector and Insert  4.2.2.6
The T4 DNA ligase (NEB) was used to join the EcoRI/XhoI-digested pCMV-Myc and the 
HB-EGF fragment, in order to obtain the pCMV-Myc-HB-EGF construct. To carry out the ligation 
reaction, 50 ng of vector DNA from the previous step was transferred to a microtube with 
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three times the equimolar amount of insert DNA. 2 µl of 10x T4 DNA ligase buffer and 1 µl of 
T4 DNA ligase (New England Biolabs) were added to the reaction mix and H2O was added to a 
final volume of 20 µl. The reaction was carried out for 16 h at 16°C. An aliquot (5 µl) of the 
DNA ligation mixture was then subjected to bacterial transformation and plated onto 
ampiciline-containing selective media as described previously (section 1.1.3). 
 Isolation of plasmids from transformants - “Miniprep” 4.2.2.7
In order to screen for the recombinant plasmid in the transformants, the plasmid DNA 
was extracted from several isolated bacterial colonies by alkaline lysis “miniprep”, for 
subsequent restriction fragment analysis, as follows. A single bacterial colony was transferred 
into 3 ml of LB medium containing ampicillin (50 µg/ml) and incubated overnight at 37°C with 
vigorous shaking (220-250 rpm). 1.5 ml of this culture was transferred into a microtube and 
centrifuged at 12,000 g for 1 min at 4°C and the supernatant was discarded. The cell pellet was 
resuspended in 100 µl of ice-cold Solution I by vigorous vortexing. Then, 200 µl of freshly 
prepared Solution II were added to the microtube that was mixed by inverting several times. 
Keeping the microtube on ice, 150 µl of ice-cold Solution III were added and again the 
microtube inverted several times. After the microtube was allowed to stand on ice for 5 min, it 
was centrifuged at 12,000 g for 10 min at 4°C and the supernatant transferred to a clean 
microtube. The DNA was purified by ethanol purification as previously described (section 
4.1.3.2) and stored at -20°C. 
 Identification and purification of insert-containing plasmids 4.2.2.8
After plasmid DNA extraction from bacteria, the DNA was further analyzed by 
restriction digestion with the endonucleases EcoRI and XhoI and the restriction fragments 
submitted to electrophoretic analysis as described above. Once confirmed that the ligation 
procedure had been successful for the selected transformants, the pCMV-Myc-HB-EGF 
construct was once again amplified by bacteria transformation and isolated by Promega 
“Midiprep”, which yielded transfection-quality plasmid DNA. The manufacturer’s instructions 
were followed, as described previously in section 4.1.3. 
4.3 Mammalian cell asssays 
4.3.1 Culture and maintenance of the HeLa cell line 
Immortal cell lines are a very important tool for research into the biochemistry and cell 
biology of multicellular organisms. HeLa cells are an immortalized cell line derived from human 
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cervical epithelia cancer cells, originally taken from a cancer patient, Henrietta Lacks. Since this 
is an immortalized cell line, HeLa cells have evaded normal cellular senescence and instead can 
keep undergoing division, allowing their growth for prolonged periods in vitro. Indeed, this cell 
line was found to be remarkably durable and prolific, which made this cell line our choice for 
all the research experiments performed.  
HeLa cells were cultured in Dulbeco’s Minimal Essential Media supplemented with 1% 
Non-Essential amino acids (Gibco), 10% heat inactivated Fetal Bovine Serum (FBS; Gibco) and 
1% antibiotic/antimycotic (AA) mix (Gibco). Cultures were maintained at 37°C under 5% CO2 in 
a humidified incubator. Cells were subcultured whenever 80-90% confluence was reached. 
4.3.2 Transient transfection of the HeLa cell line with APP-GFP and Myc-
HB-EGF cDNAs 
In order to be able to study the effects of APP and HB-EGF activity and interaction 
through transient transfection experiments, HeLa cells were grown on plastic culture dishes 
(12-well, 6-well and 60 mm), having been seeded 24 h before transfection, so that cells could 
be around 70 to 80% confluence at the time of the transfection. The growth medium was 
changed immediately prior to the transfection procedure and HB-EGF, along with Wt APP-GFP 
cDNA, was transfected into HeLa cells. Single-transfection of HB-EGF and Wt APP-GFP cDNA 
was also performed for some experiments. As experimental controls, single-transfection of 
pEGFP-N1 and pCMV-Myc vectors, or co-transfection of both empty vectors (EGFP:Myc) was 
also accomplished.  
4.3.3 Transfection using the TurbofectTM Reagent  
All the transfection procedures were performed using the TurboFectTM reagent 
(Fermentas Life Sciences). The TurboFectTM transfection reagent is a cationic polymer that 
forms a positively charged complex with DNA that is easily endocytosed by eukaryotic cells. 
Briefly, for each well of a 12-well plate, 1 µg of cDNA was diluted in 50 µl of serum-free growth 
medium and for each well of a 6-well plate, 2 µg of cDNA were diluted in 100 µl of serum-free 
growth medium. When using a 60 mm plate, 4 µg were diluted in 400 µl of serum-free growth 
medium. After gently vortexing the plate, a ratio of 1.5-2:1 µl of TurboFectTM reagent was 
added to the DNA, mixed and incubated during 15-20 min at RT. It was then added to each 
well and mixed by gently agitating the plate. The cells were incubated at 37°C in a 5% CO2 
incubator. After 6 h the cell medium was changed, and at 24 h of total transfection time, cells 
were collected.  
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4.3.4 Cells stimulation with EGF 
Confluent cell monolayers were stimulated with 100 ng/ml of Human Epidermal 
Growth Factor (EGF; Cell Signaling). For signaling studies purposes, EGF was added 1 hour 
before cell collection 23h post-transfection. When the aim was to visualize the EGF effect on 
cells morphology through immunocytochemistry procedures, EGF was added to the cell 
medium 1 hour after transfection with plasmid DNA, and left until a total of 24h of 
transfection, after which cells were fixed. 
4.3.5 Protein synthesis inhibition with CHX 
HeLa cells independently transfected for 23h with the pCMV-Myc vector or the pCMV-
Myc-HB-EGF constructs were treated for 1h with 50 μg/ml cycloheximide (CHX; Sigma) in FBS-
DMEM, and harvested with 1% SDS. The total protein content of the cellular lysates was 
determined and samples subjected to western blotting, as described below, to evaluate the 
APP levels.  
4.4 Proteomic assays 
4.4.1 Cell collection and quantification of protein content (BCA) 
Transfected cells were harvested in 150 µl (12-well), 250 µl (6-well) or 550 µl (60 mm 
plate) 1% SDS for WB and boiled at 90°C for 10 min, followed by a 10 sec sonication period, 
and storage at -20°C. The cell collection procedure for GFP-Trap® Pull-Down Assay is slightly 
different and is described further ahead.  
The protein content of cell lysates was carried out using the Pierce's bicinchoninic acid 
(BCA) protein assay kit (Thermo Scientific), following the manufacturer’s instructions. The 
whole procedure was performed using a 96-well plate for spectrophomotmetric analysis. 
Standard samples were prepared using increasing known amounts of bovine serum albumin 
(BSA), as depicted in Table 3. The remaining samples were prepared by mixing 5 µl of the cell 
lysate with 20 µl 1% SDS. Duplicates of all samples were assayed by this method. 
Table 3 - Standards used in the BCA protein assay method. BSA, Bovine serum albumin solution (2 mg/ml). 
Standard BSA (µl) 1% SDS (µl) Protein Mass (µg) 
Blank 0 25 0 
P1 1 24 2 
P2 2 23 4 
P3 5 20 10 
P4 10 15 20 
P5 20 5 40 
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The working reagent was prepared by mixing the BCA reagent A with the BCA reagent 
B in a 50:1 proportion, and 200 µl of this mixture were added to each well. The plate was 
incubated for 30 min at 37°C, after which the absorbance at 562 nm was measured using a 
microplate reader (Infinite M200, Tecan). A standard curve was obtained by plotting BSA 
standard absorbance vs BSA concentration, and used to determine the total protein 
concentration of each sample. 
4.4.2 GFP-Trap Pull-Down assays 
For biochemical interaction studies, GFP-fusion proteins and their binding partners can 
be fast and efficiently isolated via pull-down of the GFP moiety with GFP-Trap® (Chromotek). 
Therefore, GFP-Trap Pull-Down assays were performed in order to confirm and further analyze 
APP binding to HB-EGF. After HeLa cells co-transfection with the APP-GFP and the Myc-HB-EGF 
cDNAs for 24h, cells were incubated with the DSP crosslinker (Pierce) for 45 min at room 
temperature. Then, cells were washed in 1x PBS and subsequentely collected with a scrapper 
in 1 ml of cold PBS with 1x PMSF solution. Samples were then centrifuged for 5 min at 3000 g 
(4°C), the supernatant was removed and 500 μl of freshly prepared lysis buffer was added to 
the pellet. The cell membranes were further disrupted by sonication for 10 s. Samples were 
maintained on ice for 30 min and vortexed twice, with 10 min intervals. Meanwhile, the GFP-
Trap beads (Chromotek) were washed 4 times in freshly prepared wash buffer, isolated by a 
magnet and kept at 4°C. After 30 min, the sample was centrifuged for 5 min at 10,000 g (4°C), 
and the supernatant transferred to a new microtube, being the pellet discarded. 25 μl of 
supernatant were transferred to a microtube with 12 μl of Loading Buffer/10% SDS, always 
keeping the sample on ice (“Cell Lysates”). 10 μl of supernatant were collected to perform BCA 
protein quantification in order to aliquot mass-normalized lysates. The volume of the mass-
normalized lysates was adjusted to 300 μL with freshly prepared dilution buffer and 5-10 μl of 
GFP-Trap beads were transferred to each sample, followed by an incubation step of 4h with 
orbital shaking at 4°C. The mixture was then subjected to magnetic separation with a magnet, 
the supernantant was fully discarded and the magnetic complexes magnetically washed with 
300 μl of wash buffer for 3 times. The magnetic complexes were then ressuspended in 100 μl 
of Loading Buffer/1% SDS (“Pull-Down”) and boiled for 10 min to dissociate the GFP-Trap 
beads from the protein complexes. Afterwards, the GFP-Trap was magnetically separated and 
the supernatant transferred to a new microtube. Lysates, supernatants and precipitates were 
then resolved in a 5-20% SDS–PAGE followed by immunoblotting. For the pull-down assays in 
60 mm culture dishes, an initial step was added in the beginning of the procedure to minimize 
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protein degradation, with cells being washed 2x in cold PBS and kept on ice in the first 10 min 
of incubation with the DSP cross-linker.  
4.4.3 Western Blot (WB) assays 
Mass-normalized samples were resolved by electrophoresis on a 5-20% gradient 
sodium dodecylsulfate polyacrylamide gel (SDS-PAGE). The samples were prepared by the 
addition of ¼ volume of loading gel (4x LB) buffer and subjected to electrophoresis, after what 
protein samples were electrotransferred to a nitrocellulose membrane.  
 Ponceau Red staining of protein bands 4.4.3.1
Ponceau Red staining is normally applied to assess successful electrotransfer of 
proteins to the nitrocellulose membrane. It can also be used as a loading control in an 
alternative to actin or β-tubulin, when these proteins levels vary with the experimental 
conditions. This type of staining is fast, inexpensive, nontoxic, and it is fully reversible in a few 
minutes (79). The nitrocellulose membranes were incubated in Ponceau S solution (Sigma 
Aldrich) for 7 min, followed by a wash with deionized water for making the protein bands 
clearly visible. Membranes were then scanned in a GS-800 calibrated imaging densitometer 
(Bio-rad), after which membranes were washed with 1X TBS-T and water for complete removal 
of the staining. 
 Immunodetection 4.4.3.2
Concerning the immunological detection, briefly, after transferring the proteins, 
membranes were first hydrated in 1X TBS for 10 min, and then blocked for unspecific antibody 
binding sites. This was ensured by incubating the membrane for 1-2 h with 5% non-fat dry milk 
(or BSA, according to the manufacturers’ instructions) in 1X TBS-T. Incubation with the primary 
antibody was performed according to the manufacturer indications, or according to previously 
optimized experiments with the incubation time ranging from 2 h to O/N incubation. After 3 
washes with 1x TBS-T, membranes were incubated for 2 h with the secondary antibody, 
diluted either in 3% non-fat dry milk or BSA in 1X TBS-T solution. Antibodies dilutions are 
further presented in Table 4. Membranes were subsequently washed 3 times with TBS-T 
before submission to signal development.  
Immunodetection was carried out using horseradish peroxidase-conjugated secondary 
antibodies, and membranes were submitted to signal development using either homemade 
enhanced chemiluminescence (ECL) or LuminataTM Crescendo (Millipore) reagents. Both of the 
reagents work as a substrate to horseradish peroxidase, producing a chemiluminescent signal. 
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In a dark room, membranes were incubated for 1 min at RT with ECL or for 5 min with 
LuminataTM Crescendo, and then an autoradiography film (GE Healthcare) was placed on the 
top of the membrane and placed inside an x-ray film cassette. The excess of detection reagent 
was drained off the membrane. After the exposure (with time varying depending on the 
protein being detected), the film was developed in developing solution (Sigma Aldrich), 
washed in water and fixed in fixing solution (Sigma Aldrich). The membrane was further 
washed with 1x TBS-T and deionized water before drying. The autoradiograms were scanned in 
a GS-800 calibrated imaging densitometer (Bio-Rad) and immunoreactive bands were 
quantified by densitometric analysis with QuantityOne software (Bio-Rad Laboratories), using 
Ponceau Red Staining as an internal control. 
 Antibodies used in WB assays 4.4.3.3
In the WB assays, several antibodies were used. The monoclonal anti-APP 22C11 
(Chemicon), directed against APP N-terminus, and the polyclonal anti-APP CT695 (Invitrogen) 
directed against APP C-terminus, both recognizing full-length APP, enabled the evaluation of 
APP and APP-GFP cDNA levels. The monoclonal anti-Myc-Tag (Cell Signaling Technology) and 
the polyclonal anti-HB-EGF antibodies (Antibodies online) were used to detect Myc-HB-EGF 
and HB-EGF.  
To evaluate the effect of HB-EGF and APP in MAPK/Erk signaling, two antibodies were 
used: the monoclonal anti-phospho-MAP Kinase (Millipore), directed against the 
phosphorylated Tyr185/Tyr187 residues, and the polyclonal anti-MAP Kinase (Millipore) 
antibody; both of these recognize the p44 and the p42 MAP kinases (ERK 1 and 2). 
To evaluate the effect of HB-EGF and APP in STAT3 signaling, two antibodies were 
used: the monoclonal anti-phospho-STAT3 (Millipore), directed against the phosphorylated 
Tyr705 residue, and the monoclonal anti-STAT3 (Cell Signalling Technology) antibody; both of 
these recognize the alpha and beta STAT3 isoforms. All the secondary antibodies, either 
recognizing mouse or rabbit IgGs, were goat antibodies labeled with horseradish peroxidase 
(GE Healthcare).  
The polyclonal anti-EGF and anti-EGFR antibodies were used to evaluate EGF and EGFR 
protein levels, respectively, and to test for interaction with APP. In Table 4 are represented the 
primary and secondary antibodies used, as well as their respective dilutions. 
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Table 4 - Antibodies used in the Western Blotting, respective target proteins and their sizes, and specific dilutions 
used. 
Target Protein Size (kDa) Primary Antibody Secondary Antibody 
APP (N-
terminal) 
100-150 Monoclonal 22C11 
(Chemicon); 
Dilution: 1:250 
Horseradish Peroxidase 
conjugated α-Mouse 
IgG; 
Dilution: 1:5000 
APP (C-
terminal) 
100-150 Polyclonal CT695 
(Invitrogen); 
Dilution: 1:500 
Horseradish Peroxidase 
conjugated α-Rabbit 
IgG; 
Dilution: 1:5000 
Myc-Tag 
NA Monoclonal Anti-Myc-Tag 
(9B11) (Cell Signaling 
Technologies) 
Dilution: 1:5000 
Horseradish peroxidase 
conjugated α-Mouse 
IgG; 
Dilution: 1:5000 
Phospho-
Thr185/Tyr187 
MAP kinase 
42 and 44 Monoclonal Anti-phospho-
MAP Kinase 1/2 (Erk 1/2) 
(Thr185/Tyr187), clone 
AW39 (Millipore) 
Dilution: 1:1000 
Horseradish peroxidase 
conjugated α-Rabbit 
IgG; 
Dilution: 1:5000 
MAP Kinase 
42 and 44 Polyclonal Anti-MAP Kinase 
1/2 (Erk1/2), CT (Millipore); 
Dilution: 1:1000 
Horseradish peroxidase 
conjugated α-Rabbit 
IgG; 
Dilution: 1:5000 
Phospho-
Tyr705 STAT3 
76 and 84 Monoclonal Anti-phospho-
STAT3 (Tyr705) (Millipore); 
Dilution: 1:3000 
Horseradish Peroxidase 
conjugated α-Rabbit 
IgG; 
Dilution: 1:1000 
STAT3 
76 and 84 Monoclonal Anti-STAT3 
(124H6) (Cell Signaling 
Technology); 
Dilution: 1:2000 
Horseradish Peroxidase 
conjugated α-Mouse 
IgG; 
Dilution: 1:2000 
HB-EGF (mature 
domain) 
14-30 Polyclonal Anti-HB-EGF 
(Antibodies-online); 
Dilution: 1:500 
Horseradish Peroxidase 
conjugated α-Rabbit 
IgG; 
Dilution: 1:1000 
EGF 
5.8/133 Polyclonal Anti-EGF (C-Term) 
(Antibodies-online); 
Dilution: 1:500 
Horseradish Peroxidase 
conjugated α-Rabbit 
IgG; 
Dilution: 1:1000 
EGFR 
180 Polyclonal Anti-EGFR 
(Millipore); 
Dilution: 1:500 
Horseradish Peroxidase 
conjugated α-Rabbit 
IgG; 
Dilution: 1:5000 
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4.5 Immunocytochemistry (ICC) assays  
In order to evaluate if and were APP and HB-EGF co-localize in mammalian cells, 
subcellular localization studies were carried out using HeLa cells. Immunocytochemistry of 
HeLa cells co-transfected with EGFP:Myc, APP-GFP:Myc, EGFP:HB-EGF, and APP-GFP:HB-EGF 
were performed. Besides these conditions, a set of immunocytochemistry analysis with 
transfected cells under sEGF influence was also performed. 
4.5.1 Sample preparation and immunodetection 
After 24h of transfection with the Turbofect Reagent, HeLa cells grown on coverslips 
were fixed with 4% paraformaldehyde in PBS for 30 min. Fixed cells were washed 3 times with 
1x PBS and permeabilized with a 0.2% TRITON PBS solution during 10 min. After another 3 
washes, cells were covered with 1x PBS/3% BSA blockage solution for 30 min. Cells were then 
incubated with the primary antibodies diluted in 1x PBS/3% BSA for 2 h at RT (respective 
dilutions are presented in Table 5). The antibodies were removed by washing 3 times with 1x 
PBS and the specific secondary antibodies were incubated for 1 h at RT (see Table 5). After 
another 3 washes with 1x PBS and one additional wash with deionized water, coverslips were 
mounted on microscope glass slides and embedded in VECTASHIELD® antifading-reagent, with 
or without DAPI for nucleic acid staining (Vector Laboratories). 
Fluorescence microscopy was carried out in a LSM 510 Meta confocal microscope 
(Zeiss) using an Argon laser line of 488 nm (green channel), a 561 nm DPSS laser (red channel), 
and a Diode 405-430 laser (blue channel). Images were acquired with a 63x water immersion 
objective.  
4.5.2 Antibodies used in ICC assays 
For the immunocytochemistry procedures, the monoclonal anti-Myc-Tag antibody (Cell 
Signaling Technology) and the polyclonal anti-HB-EGF antibody (antibodies-online) were used. 
These antibodies were used to visualize the co-localization of APP and HB-EGF and to analyze 
the effects of HB-EGF and APP-GFP overexpression in the cell. The secondary antibodies used 
were the anti-mouse and the anti-rabbit Texas Red-conjugated antibodies, the anti-rabbit 
Alexa Fluor 350, and the anti-mouse Alexa Fluor 488-conjugated antibodies (Molecular 
Probes). The list of the primary and secondary antibodies used for the immunocytochemistry 
procedures as well as their respective dilutions are present in Table 5. 
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Table 5 - Antibodies used in immunocytochemistry, respective target proteins and specific dilutions used. 
Target Protein /Epitope Primary Antibody Secondary Antibody 
Myc-Tag 
Monoclonal Anti-Myc-Tag 
(9B11) (Cell Signaling 
Technologies) 
Dilution: 1:5000 
Texas Red® Goat Anti-
Mouse IgG (Life 
Technologies) or Alexa 
Fluor® 488 Goat Anti-mouse 
(Molecular Probes) 
Dilution: 1:300 
HB-EGF 
Polyclonal Anti-HB-EGF 
(antibodies-online); 
Dilution: 1:100 
Texas Red® Goat Anti-
Rabbit IgG (Life 
Technologies); 
Dilution: 1:300 
4.6 Data analysis  
The protein bands resultant from the immunobloting procedures were quantified using 
the Quantity One densitometry software (Bio-Rad). Data from HB-EGF and APP-GFP cDNAs 
transfected cells were compared to cells transfected only with the pCMV-Myc and EGFP-N1 
empty vectors. All applicable data are shown as mean values ± SEM (standard error of the 
mean). The Student’s t-test was used to determine the significance of differences between 
population means. Statistical significance analysis was conducted by one way analysis of 
variance (ANOVA) followed by the Tukey test. 
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5 Results 
5.1  Confirmation of APP - HB-EGF binding by Y2H 
As previously mentioned, HB-EGF was identified as a positive clone in a large scale 
yeast mating, when using the full-length human APP (isoform 695) cDNA as bait, which 
propelled its selection for further investigation. 
Although the Y2H system offers numerous advantages comparing to biochemical 
methods, the novel PPIs identified by large-scale YTH screening should be validated, at first in 
the YTH system, and then confirmed by other methods, in order to exclude all classes of false 
positives. Therefore, from this point forward, our primary goal was to validate APP/HB-EGF 
interaction. Additionally, we also tested whether the interaction was mediated by the AICD 
using the yeast two hybrid system. 
5.1.1 Bait and prey autoactivation test 
Firstly, before studying any possible interactions between baits and prey, it was 
necessary to demonstrate that the bait and the prey proteins do not autonomously activate 
the reporter genes HIS3, ADE2 and MEL1, for example, due to intrinsic DNA-binding and/or 
transcriptional activation sequences.  
In order to address this topic, both bait plasmids (pAS2-1-APP and pAS2-1-AICD) and 
the prey plasmid (pACT2-HB-EGF) were independently transformed into the AH109 yeast strain 
and tested for growth in selective media lacking His and Ade.  
None of the bait plasmids neither the prey plasmid were able to drive the expression 
of the nutritional reporter genes HIS3 and ADE2, since no growth was detected (Table 6). 
Likewise, the colorimetric reporter gene MEL1 was not activated by any of the fusion 
constructs, since no blue color was detected in the SD/-Trp/X-α-Gal or SD/-Leu/X-α-Gal. The 
Gal4-BD fusion genes and the Gal4-AD fusion gene behaved similarly to the pAS2-1 and pACT2 
empty vectors, which were expressed as negative controls (Table 6).  
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Table 6 - Results of the baits and prey autoactivation tests. 
  Growth and Blue color 
  SD/-Trp/X-α-Gal 
or 
SD/-Leu/X-α-Gal 
SD/-Trp/-His/X-α-Gal 
or 
SD/-Leu/-His/X-α-Gal 
SD/-Trp/-Ade/X-α-Gal 
or 
SD/-Leu/-Ade/X-α-Gal 
Bait 
APP White colonies No growth No growth 
AICD White colonies No growth No growth 
Negative control 
(empty pAS2-1) 
White colonies No growth No growth 
Prey 
HB-EGF White colonies No growth No growth 
Negative control 
(empty pACT2) 
White colonies No growth No growth 
5.1.2 Validation of the APP/HB-EGF interaction by yeast co-transformation 
Once confirmed that APP, AICD and HB-EGF do not induce HIS3, ADE2 and MEL1 
reporter genes’ intrinsic activation, a yeast co-transformation assay was performed in order to 
confirm the interaction between APP and HB-EGF. Interaction of HB-EGF with the APP 
intracellular domain (AICD) was also tested, to shed light on the APP motif responsible for the 
interaction.   
pACT2-HB-EGF (prey plasmid) and both pAS2-1-APP and pAS2-1-AICD (bait plasmids) 
were successfully co-transformed in yeast strain AH109 and the co-transformants were tested 
in SD/TDO, SD/QDO and SD/QDO/X-α-Gal medium.  
The authenticity of the interaction between the HB-EGF clone and the full-length APP 
was confirmed by the ability to grow and turn blue on SD/QDO/X-α-Gal plates, which indicates 
expression of all the reporter genes HIS3, ADE2 and MEL1. In fact, the appearance was similar 
to the positive control that co-expressed the Gal4-BD-p53 and Gal4-AD-SV40 fusion proteins 
(Figure 20). The Gal4-BD and Gal4-AD empty vectors (pAS2-1 and pACT2) were co-expressed as 
a negative control, which, as expected showed no positive colonies (Figure 20, B). YTH tests 
were also carried out with yeast cells transformed with single bait or prey constructs. While all 
yeast constructs were able to grow on the YPD rich medium (data not shown), only co-
expression of BD-bait and AD-prey fusion proteins conferred survival on SD/QDO plates. Some 
colonies started to appear after 2-3 days, but the plates were incubated for 8 days (TDO) or 16 
days (QDO) to allow slower growing colonies to appear. According to the Clontech’s 
MATCHMAKER YTH System User Manual, true His+, Ade+ colonies are robust and can grow to 
more than 2 mm in diameter. The small, pale colonies that may appear after 2 days but never 
grow more than 1 mm should not be considered as positives clones.  
On the other hand, no growth of pAS2-1-AICD – pACT2-HB-EGF colonies neither in the 
triple DO nor in the quadruple DO was verified (Figure 20, B). This means that HIS, ADE2 and 
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MEL1 reporter genes were not activated and thus no interaction occurred between the Gal4-
BD and Gal4-AD. Hence, we can conclude that the interaction between APP and HB-EGF is not 
mediated by the APP Intracellular Domain. 
In conclusion, the results obtained showed that HB-EGF interacts with APP via APP 
domains other than the C-terminus of APP. 
 
 
 
Figure 20 - Qualitative confirmation of the interaction between APP and HB-EGF by Yeast co-transformation. (A) 
Growth of yeast cells co-transformed with APP and HB-EGF constructs was first analyzed by streaking into 
quadruple dropout (QDO; -Leu, -Trp, -His, -Ade). (B) Yeast cells co-transformed with pACT2-HB-EGF+pAS2-1-APP, 
pACT2-HB-EGF+pAS2-1-AICD, and with the plasmid positive (pvA3-1+pTD1-1) and negative (pAS2-1+pACT2) controls 
were grown on QDO medium with X-α-Gal to test for α-galactosidade activity.  
5.2 APP Interplay with HB-EGF 
The YTH presents some intrinsic limitations that should be considered. For this reason, 
and although several control procedures were performed, the validation of the detected 
interaction by other independent methods was imperative.  
5.2.1 Generation of the Myc-HB-EGF construct 
In order to perform biochemical studies, mammalian expression constructs were 
needed. Although the APP-GFP construct was already available at the laboratory, no HB-EGF 
construct was available to express in mammalian cells.  Therefore, subcloning procedures were 
performed in order to generate a ready to transfect cDNA. The pCMV-Myc plasmid was chosen 
for several reasons: 1) a tag fused to the HB-EGF was needed because, at the time, the anti-
HB-EGF antibody was not available at the laboratory; 2) the Myc epitope has a small size, 
unlikely affecting the tagged protein’s biochemical properties; 3) the MCS in this vector is 
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compatible with the MCS of Clontech’s MATCHMAKERTM Two-Hybrid System Vectors, allowing 
direct subcloning only by using endonucleases. 
5.2.2 Electrophorectic analysis of the Myc-HB-EGF cDNA construct 
The Myc-HB-EGF construct was then created from pACT2-HB-EGF, using standard 
cloning procedures, having the insert been subcloned into the pCMV-Myc vector in frame with 
the Myc coding sequence. The putative Myc-HB-EGF fusion constructs were further subjected 
to restriction fragment analysis using EcoRI and XhoI endonucleases, to confirm the correct 
insertion into the mammalian expression vector. The restriction fragments were then 
separated by 1% agarose gel electrophoresis and the size of the observed fragments was in 
agreement with the expected: approximately 3.8 Kb for the pCMV-Myc vector and ~2,3 Kb for 
the HB-EGF insert (Figure 21). 
 
 
 
 
 
Figure 21 – Restriction fragment analysis of the pCMV-Myc-HB-EGF constructs. Lane M, 1 Kb Plus DNA Ladder. Lanes 
1-5, pCMV-Myc+HB-EGF (3.8 + 2.3 Kb) fragments upon restriction with EcoRI and XhoI. 
5.2.3 Optimization of Myc-HB-EGF transfection 
For the functional cellular studies, we chose the immortalized HeLa cell line. This 
remarkably durable and prolific cell line is a widely used experimental tool for ex vivo assays, 
being of human origin and easy to transfect. 
In order to optimize HeLa cells transfection with the Myc-HB-EGF construct, Myc-HB-
EGF cDNA was transfected for 24h using the TurbofectTM reagent method. Different cDNA 
concentrations and Turbofect:DNA ratios were tested: 1 and 2 µg of Myc-HB-EGF cDNA, and 
1:1 and 2:1 ratios (data not shown). The levels of HB-EGF transfection were evaluated by 
Western blot analysis using the anti-My-tag antibody. As we can notice by observation of 
Figure 22, the TurbofectTM transfection reagent rendered appreciable levels of Myc-HB-EGF 
transfection when using 1 µg and a 2:1 ratio. Therefore, in all subsequent experimental 
analysis these transfection conditions were used. 
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Figure 22 – Pilot experiment for detecting the expression of the transfected Myc-HB-EGF construct. The TurbofectTM 
transfection reagent yielded satisfactory amounts of cDNA transfection. Cells transfected with the pCMV-Myc 
vector were used as control. 
5.2.4 Validation of the APP/HB-EGF interaction by GFP-Trap® Pull-Down 
assay 
Several procedures may be used to validate a novel putative protein-protein 
interaction. Co-immunoprecipitation is a technique based on the formation of antigen-
antibody complexes, most commonly used to prove that two proteins of interest are 
associated. However, for biochemical studies, the GFP-Trap® Pull-Down assays (Chromotek) 
have emerged as a fast and efficient method that enables purification of GFP-fusion proteins 
and their binding partners. Therefore, GFP-Trap® Pull-Down assays were performed to confirm 
the specific interaction between HB-EGF and APP ex vivo and to enable further analysis of the 
physiological relevance of the APP/HB-EGF interaction. 
GFP-Trap® Pull-Down assays were carried out using cellular extracts obtained from 
HeLa cells expressing four different co-transfection conditions: 1) pEGFP-N1 and pCMV-Myc 
empty vectors (EGFP:Myc), 2) APP-GFP and the pCMV-Myc empty vector (APP:Myc), 3) Myc-
HB-EGF and the pEGFP-N1 empty vector (EGFP:HB-EGF), and 4) co-transfection of both APP-
GFP and Myc-HB-EGF constructs (APP:HB-EGF). 24 hours after transfection, cells and the 
respective incubation medium were harvested and subjected to GFP pull-down. Cell lysates 
and precipitates (pull-down) were resolved by 5-20% SDS-PAGE and immunoblots probed with: 
anti-Myc and/or anti-HB-EGF (to detect the pre-proHB-EGF Myc-HB-EGF construct and/or 
endogenous HB-EGF, respectively); and with anti-APP antibodies (anti N-terminus - 22C11; anti 
C-terminus - CT695) for endogenous APP and APP-GFP detection. 
In the first experimental design, 35 mm cell culture plates were used (Figure 23). APP-
GFP was detected in all APP-GFP transfected cell lysates and precipitated samples, which 
means that APP-GFP was successfully pulled-down, although a fainter band was observed for 
the APP-GFP (APP:Myc) pulled-down lane. Endogenous APP was only observed in the lysates 
and not in the pulled-down samples. Immunoblotting with anti-Myc-tag antibody detected the 
35 kDa - 
Myc 
Myc-
HB-EGF 
WB Myc-HB-EGF 
(Ab αMyc-tag) 
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Myc-HB-EGF construct in Myc-HB-EGF lysates, as expected, and in the APP:HB-EGF pulled-
down sample, confirming the interaction with APP.  
 
 
 
 
In order to unravel if APP also binds to endogenous HB-EGF, the GFP-Trap® Pull-Down 
assay was performed in a higher amount of cellular extracts, obtained from overexpressing 
APP HeLa cells plated on 60 mm cell culture plates. First, the APP:Myc-HB-EGF interaction was 
confirmed in co-transfected pulled down samples, runned side-by-side with APP-GFP solely 
transfected samples. Indeed, immunoblotting with the anti-Myc-tag antibody detected the 
Myc-HB-EGF construct (band ~33 kDa) either in the lysate and pull-down lanes of APP-GFP and 
Myc-HB-EGF co-transfected samples. When membranes were probed with the anti-HB-EGF 
antibody, this recognized the recombinant Myc-HB-EGF as expected, but also detected various 
species of endogenous HB-EGF in all cell lysate lanes. Three immunoreactive proteins - of 37, 
35 and 33 kDa, as deduced from co-migration with known standards - were observed in the 
lysates. Further, a much less abundant species of minor MW (31 kDa) was also observed. These 
appear to be various forms of unmodified and post-translationally modified pre-proHB-EGF. 
These various forms of different sizes and representing different degrees of protein 
Figure 23 – Validation of APP/HB-EGF interaction by GFP-Trap pull-down assays. Immunoblot analysis of HeLa cells 
co-transfected with EGFP:Myc, EGFP:HB-EGF, APP:Myc and APP:HB-EGF. A – GFP-Trap pull-down of HeLa cells 
grown in 35 mm cell culture plates. B - GFP-Trap pull-down of HeLa cells grown in 60 mm cell culture plates. HB, HB-
EGF. 
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maturation were already described in cell lysates by other authors (59,61,80,81). All these 
bands were also detected in the APP-GFP pull-downs (and in the co-transfected lane), 
indicating that APP interacts with endogenous pre-proHB-EGF. Unfortunately the anti-HB-EGF 
antibody has a bad signal-to-noise ratio and difficult bands perception in digitalized images. 
Indeed, two more HB-EGF immunoreactive fainter bands appear in cell lysates (data not 
shown): a 25 KDa species that may represent the propeptide truncated form, proHB-EGF, 
being derived from the major full-length pre-proHB-EGF precursor. This species was also 
pulled-down by APP-GFP, being observable in APP-GFP and co-transfection pull-down lanes 
(data not shown).  A sixth HB-EGF immunopositive faint band appeared in the expected size for 
soluble HB-EGF (~20kDa) in cell lysates but was barely detected in the pulled down samples 
and in the conditioned medium (data not shown). Of note, APP-GFP also pulled down 
endogenous APP (lower bands in APP-GFP pull-down lanes), what is not unexpected since APP 
has been reported to dimerize. 
Taken together, these results indicate that APP interacts with the exogenous and 
endogenous pre-proHB-EGF species, and most possibly with the proHB-EGF form. Nonetheless, 
the bands detection was faint using the anti-HB-EGF antibody, and hence this has to be further 
confirmed, including if APP interacts with sHB-EGF. 
5.2.5 APP/HB-EGF subcellular co-localization 
The APP/HB-EGF molecular association might exert diverse effects depending on the 
context or subcellular compartment. In order to address the physiological relevance of the 
APP/HB-EGF interaction, immunocytochemistry studies were performed.  
First, the subcellular distribution of the Myc-HB-EGF construct was analyzed and 
compared to the endogenous HB-EGF, in Myc-HB-EGF transfected cells. The anti-Myc-tag 
(Alexa Fluor 488; green fluorescence) and anti-HB-EGF (Texas Red, red fluorescence) 
antibodies were used. Fluorescence microscopy was carried out using a confocal microscope, 
and cells were randomly selected for analysis.  
As HB-EGF shows bidirectional intracellular trafficking between the plasma membrane 
and ER, it was reported to localize to five different subcellular compartments: the plasma 
membrane, Golgi apparatus, ER, nuclear envelope, and perinuclear vesicles (56). 
Microphotographs revealed that Myc-HB-EGF (in green) presented a predominant subcellular 
distribution in the perinuclear region, in what appeared to be the ER and the Golgi apparatus, 
and in nearby cytoplasmic vesicles. The anti-HB-EGF labeling (in red) revealed a more diffuse 
distribution for the endogenous HB-EGF, being also slightly enriched at the Golgi and present 
in cytoplasmic vesicles distributed throughout the entire cell (Figure 24).  
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As expected for the N-terminally labeled full-length HB-EGF (Myc-HB-EGF), no staining 
could be observed neither in plasma membrane nor in the nuclear envelope. This most 
probably reflects the very rapid prodomain cleavage after synthesis of the precursor, or as 
soon as it reaches the plasma membrane (57). Likewise, very few plasma membrane staining 
could be observed in these cells for the endogenous HB-EGF (labeled with this antibody). 
 
 
 
 
 
 
 
 
Noticeably, low levels of co-localization between the anti-Myc-tag and anti-HB-EGF 
antibodies were observed, with the anti-HB-EGF antibody not recognizing efficiently the 
exogenous Myc-HB-EGF protein in most transfected (myc-positive) cells. This can be due to 
epitope masking by the myc tag in the final three dimensional conformation, a problem that 
did not occurred in the previous denaturing assays (GFP-Trap pull-down). 
Regarding APP-GFP distribution, microphotographs of APP-GFP overexpressing cells 
showed the expected subcellular distribution, with APP localizing mainly in the Golgi apparatus 
and cytoplasmic vesicles, and with only a small fraction being present at the plasma 
membrane. It has been evidenced by previous work  from our laboratory that fluorescently 
tagged APP can be observed in the endoplasmic reticulum (ER), Golgi complex, lysosomal, 
endocytic vesicles and plasma membrane (27,77,82). EGFP alone, by its turn, distributes 
diffusely through the cell cytoplasm and the nucleus, where it is found enriched. 
 
Subsequently, the co-localization between APP and either endogenous or exogenous 
HB-EGF proteins was addressed in HeLa cells co-transfected with APP-GFP and Myc-HB-EGF. 
HB-EGF expression was detected with either the anti-Myc-tag (exogenous) or anti-HB-EGF 
(endogenous) antibodies (Figure 25).  
 
Figure 24 - Analysis of the subcellular distribution of Myc-HB-EGF (in green; anti-Myc-tag antibody) and 
endogenous HB-EGF (in red; anti-HB-EGF antibody). Their co-localization was also evaluated (merge). 
Myc-HB-EGF                                       HB-EGF                                                 Merge 
  SACS/UA 2013 
Unraveling the APP/HB-EGF Interaction  77 
Figure 25 – Immunocytochemistry analysis of APP-GFP (green) co-localization with HB-EGF (red). Upper panel: 
endogenous HB-EGF (anti-HB-EGF antibody). Lower panel: transfected Myc-HB-EGF protein (anti-Myc antibody). 
 
 
 
 
Confocal fluorescence microscopy showed that endogenous HB-EGF presented some 
degree of co-localization with APP-GFP, predominantly at small vesicles distributed throughout 
the cytoplasm, as showed in the magnified ROI (region of interest; Figure 25, upper panel). 
Recombinant HB-EGF protein seemed to co-localize with APP-GFP mainly in the Golgi 
apparatus and nearby vesicles (Figure 25, lower panel). Also, a higher degree of co-localization 
was detected when HB-EGF was overexpressed. Of note, the great majority of APP-GFP 
vesicles do not co-localize with HB-EGF, suggesting highly regulated interactions. The nature of 
the subcellular regions of co-localization, especially the cytoplasmic vesicles, will have to be 
further analyzed by using specific organelle markers. 
5.2.6 Influence of HB-EGF overexpression in APP levels 
The same four conditions used for the first pull-down assay were used to study the 
influence of APP and HB-EGF on each other’s protein levels. To evaluate the effect of HB-EGF 
 
APP-GFP                               HB-EGF                                  Merge                                                  ROI 
APP-GFP                                                Myc-HB-EGF                                       Merge 
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overexpression in endogenous APP levels, these were quantified in HB-EGF transfected 
samples (EGFP:HB-EGF) and compared to vector samples (EGFP:Myc). The analysis of 
exogenous APP levels was performed by quantification of the APP-GFP levels in APP:HB-EGF 
and APP:Myc co-transfected samples (Figure 26). Of note, Ponceau S staining of total proteins 
bands was performed for all assays and used as loading control in the quantitative analysis. 
Regarding the influence of HB-EGF overexpression in endogenous APP levels, we can 
observe that HB-EGF induced a 2.01±0.46 fold increase in endogenous APP. In opposition, HB-
EGF induced a significant decrease in exogenous APP expression when both constructs were 
co-transfected (fold decrease of 0.65±0.06).  
Since an increase in endogenous APP was observed, the mature and immature levels 
of APP were further analyzed in detail in order to understand if HB-EGF was inducing an effect 
specifically on one or on both forms. HB-EGF induced a fold-increase (FI) of 1.87±0.52 in the 
immature endogenous APP, whilst a more significant increase in mature endogenous APP 
expression was detected (FI of 2.82±0.61). Contrasting these results, HB-EGF induced a 
decrease in the amount of mature APP-GFP (0.64±0.11). So, while HB-EGF transfection seems 
to enhance both mature and immature endogenous APP levels, it decreases APP-GFP levels. 
We have further analyzed if HB-EGF overexpression affected the percentage of APP maturation 
and only a slight tendency for the percentage of APP maturation to increase was observed 
either in APP:HB-EGF co-transfected or HB-EGF transfected cells (Figure 26). 
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Figure 26 – Western Blot and quantitative analysis of the influence of HB-EGF overexpression in APP levels, upon 
24h of HeLa cells transfection. Bands a and d, mature and immature endogenous APP. Bands b and c, mature and 
immature APP-GFP forms, respectively. Graphs: upper panel - endogenous APP and APP-GFP fold increase over 
vectors (EGFP:Myc) and APP:Myc, respectively; middle panel - mature and Immature APP fold increase over 
vectors (EGFP:Myc) and APP:Myc, respectively; lower panel - evaluation of % of APP maturation. Data are 
presented as mean ± SEM, upon correction to Ponceau. *p<0,05; **p<0,01; ***p<0,001. n=3-4. 
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Since the simultaneous transfection of HeLa cells with Myc-HB-EGF and APP-GFP led to 
a decrease in the exogenous APP levels, it was relevant to investigate if this decrease would be 
due to a promotion of APP processing into sAPP. Cell medium samples collected for each 
condition were analyzed by Western blotting with the anti-22C11 antibody (Figure 27). After 
soluble APP quantification, evidences showed that HB-EGF overexpression leads to a decrease 
both in endogenous and exogenous APP cleavage, being this decrease more accentuated for 
the APP:HB-EGF co-transfection condition (0.67±0.03 FD; Figure 27).  
 
 
 
 
The differential effects of HB-EGF overexpression on endogenous and exogenous APP 
levels led us to perform a preliminary analysis to evaluate if HB-EGF was in someway 
promoting APP’s half-life. Hence, a cycloheximide (CHX) assay (27) was performed in pCMV-
Myc vector and Myc-HB-EGF transfected cells, treated or not for 1 hr with the protein 
synthesis inhibitor CHX. As we can notice by observing Figure 28, cells exposed to CHX showed 
a significant reduction of the amount of total APP, which was consistent between HB-EGF cells 
and control. Thus, HB-EGF does not increase APP half-life, since this would result in none or 
Figure 27 – Evaluation of the influence of HB-EGF overexpression on soluble APP levels in HeLa cells, upon 24h of 
transfection. Immunoblot: bands a and b, endogenous 751/770 sAPP isoform and exogenous sAPP, 695 isoform, 
respectively. Graphic: ‘Endg sAPP’: effect of HB-EGF transfection on endogenous sAPP levels (EGFP:Myc samples); 
‘Endg+Exog sAPP’: effect of HB-EGF transfection (APP:HB-EGF samples) on endogenous and exogenous sAPP levels 
(APP:Myc samples). *p<0,05; **p<0,01; ***p<0,001. n=5. 
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lower decreases in endogenous APP levels. The possibility of HB-EGF may be inducing APP 
gene expression will be further addressed in the future. 
 
 
5.2.7 Influence of APP overexpression in HB-EGF levels 
The effects of APP overexpression on exogenous HB-EGF levels were also monitored by 
comparing Myc-HB-EGF levels in APP:HB-EGF versus the EGFP:HB-EGF co-transfected samples. 
APP overexpression had a negative influence on the exogenous HB-EGF levels, 
decreasing Myc-HB-EGF levels by 0.75±0.20 when both proteins were overexpressed 
(representative immunoblot in Figure 33. We further intended to analyze the influence of APP-
GFP transfection in endogenous HB-EGF levels, by using the anti-HB-EGF antibody, but this is 
not yet optimized for WB quantification; nonetheless, an increase in endogenous HB-EGF 
levels appears to occur when cells were transfected with APP-GFP (data not shown). 
5.2.8 Influence of APP and HB-EGF overexpression in MAPK/Erk signaling 
It is prior knowledge that the MAPK signaling is a main pathway activated by ligands of 
the EGF family. For this reason it was peremptory to investigate the influence of APP and HB-
EGF/APP interaction in Erk1/2 signaling.  The activation of the Erk1/2 signaling was analyzed 
using both anti-phosphoMAPK (Thr185/Tyr187) and anti-MAPK antibodies, in the previously 
analyzed samples (section 5.2.6). 
Evidences showed that all the three transfection conditions promoted Erk1/2 
phosphorylation, when comparing to control (vector transfected cells). Among those, 
EGFP:HB-EGF transfection induced the higher levels of MAP kinase phosphorylation (3.10 FI). 
APP:GFP followed with a FI of 1.94, and APP:HB-EGF co-expression presented a FI of 1.49 over 
basal levels. Hence, co-transfecting cells with APP:HB-EGF decreased MAPK phosphorylation 
Figure 28 – Immunoblot analysis of HeLa transfected cell lysates. Cells transfected with pCMV-Myc vector or with 
recombinant HB-EGF were treated (+) or not (-) with cycloheximide (CHX) for 1h. Bands a and b, mature and 
immature endogenous APP, respectively. 
CHX: 
a 
b 
WB APP 
(Ab αAPP C-term) 
Myc Myc-
HB-EGF 
Myc Myc-
HB-EGF 
- 135 kDa 
- 100 kDa 
- - + + 
- 35 kDa 
- 25 kDa 
WB HB-EGF 
(Ab αMyc-tag) 
SACS/UA 2013 
82   Luísa Filipe Henriques Martins de Bastos 
by ~30% (0.70 FD) relatively to APP single transfection and around 20% relatively to HB-EGF 
single transfection (0.80 FD) (Figure 29). Concerning MAPK levels, APP and HB-EGF co-
transfection induced a FI of 1.26±0.26, with the remaining conditions not affecting MAPK 
levels.  
When the P-MAPK/MAPK ratio, a measure of MAPK activation, was determined for 
each condition, the higher ratio was obtained for HB-EGF overexpressing cells (FI of 3.35), 
followed by APP-GFP expressing cells (2.36). APP:HB-EGF co-transfection decreased these 
positive effects, only activating MAPK signaling by 1.67 over basal levels (Figure 29). 
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Figure 29 – Evaluation of the effect of APP and HB-EGF transfection on Erk signaling by immunoblot analysis of 
HeLa cells lysates. Upper and Middle: left graphs - P-MAPK and MAPK fold increases in HB-EGF, APP-GFP and 
APP:HB-EGF overexpressing cells, over vectors (EGFP:Myc) levels; right graphs – calculated fold increases of P-
MAPK and MAPK levels by APP:HB-EGF co-transfection, over APP and HB-EGF single transfection levels. Lower 
panel left and right graphs: similar analyses but for the P-MAPK/MAPK ratio. Data are presented as mean ± SEM, 
upon correction to Ponceau. n=2 (P-MAPK levels and P-MAPK/MAPK ratio) and n=3 (MAPK levels). HB, HB-EGF. 
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5.2.9 Influence of APP and HB-EGF overexpression in STAT3 signaling 
Another pathway already described to be activated by EGFR agonists is the STAT3 
pathway. Therefore, the influence of APP and HB-EGF overexpression in STAT3 signaling was 
considered, being analyzed by using both anti-phosphoSTAT3 (Tyr 705) and anti-STAT3 
antibodies. 
Upon 24 h of transfection, no noteworthy effects on STAT3 phosphorylation (P-STAT3) 
were observed in either the APP-GFP, HB-EGF, or the APP:HB-EGF expressing cells. Still, APP 
overexpression drove the most accentuated decrease in STAT3 phosphorylation, with a fold-
decrease of 0.80±0.05. STAT3 levels remained constant at the basal level (Figure 30). Protein 
quantification data were used to determine the P-STAT3/STAT3 ratio, a measure of STAT3 
activation, for each condition. Accordant to the previous observations, the P-STAT3/STAT3 
ratio presented a decrease of about 20% for the APP transfection condition (FD of 0.76±0.06), 
comparing to the vectors transfection. Of note, this effect has been already observed in our lab 
for SH-SY5Y cells (83).  
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Figure 30 - Evaluation of the influence of APP and HB-EGF overexpression on STAT3 signaling by immunoblot 
analysis of Hela cells lysates. Upper and Middle graphs: left - P-STAT3 and STAT3 fold increase in HB-EGF, APP-GFP 
and APP:HB-EGF overexpressing cells, over vectors (EGFP:Myc); right: calculated fold increases on P-STAT3 and 
STAT3 levels in APP:HB-EGF co-transfection conditions over APP and HB-EGF single transfections. Lower graphs: 
similar evaluations for the P-STAT3/STAT3 ratio. Data are presented as mean ± SEM, upon correction to Ponceau. 
*p<0,05; **p<0,01; ***p<0,001. n=4. HB, HB-EGF. 
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5.3 APP Interplay with EGF 
5.3.1 Influence of APP in EGF-induced signaling 
Since APP was able to influence HB-EGF-induced signaling, we further evaluated if it 
had similar effects on EGF-induced signaling. This was conducted in pEGFP-N1 and APP-GFP 
transfected cells, incubated or not with 100 ng/ml of EGF for 30 min. Once again, both Erk and 
STAT3 signaling pathways were analyzed, and fold increases of APP over EGFP, and APP+EGF 
over EGFP+EGF conditions were calculated. 
Again, APP declined STAT3 phosphorylation by approximately 30% in the absence of 
EGF (0.69±0.07 FD), and only by 12% (0,88±0.01 FD) in the presence of EGF (Figure 31). EGF 
itself decreased both P-STAT3 and STAT3 levels (compare EGFP+EGF vs EGFP lanes).  
 
 
 
Figure 31 - Analysis of APP overexpression in STAT3 signaling. Upper panel – immunoblot analysis of P-STAT3 and 
STAT3 levels in HeLa cells transfected for 24 h with EGFP or APP-GFP, unexposed or exposed to 100 ng/ml EGF 
(‘+EGF’). Middle and lower panel – graphic analysis of the fold increases in P-STAT3, STAT3, and P-STAT3/STAT3 ratio 
induced by APP-GFP transfection and EGF incubation (calculated as indicated in the x-axis). Data are presented as 
mean ± SEM, upon correction to Ponceau. *p<0,05; **p<0,01; ***p<0,001. n=3. 
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Contrasting these results, an enhancement of the Erk1/2 signaling was observed in 
response to EGF and to APP. EGF alone induced an enormous surge in P-MAPK levels, as 
expected (compare of EGFP+EGF vs EGFP lanes). For APP, in cells non treated with EGF, a fold 
increase of 1,94±0.24 was obtained, a double increase that is maintained in the presence of 
EGF (2.26±0.15). MAPK protein levels did not suffer considerable alterations. In terms of MAPK 
activation (P-MAPK/MAPK ratio), APP transfection induced a 2,13±0.25 FI in the absence of 
EGF, and a 2,21±0.16 FI in the presence of EGF (Figure 32).  
 
 
 
Figure 32 - Analysis of APP overexpression in MAPK signaling. Upper panel – immunoblot analysis of P-MAPK and 
MAPK levels in HeLa cells transfected for 24 h with EGFP or APP-GFP, unexposed or exposed to 100 ng/ml EGF 
(‘+EGF’). Middle and lower panel – graphic analysis of the fold increases in P-MAPK, MAPK, and P-MAPK/MAPK ratio 
induced by APP-GFP transfection and EGF incubation (calculated as indicated in the x-axis). Data are presented as 
mean ± SEM, upon correction to Ponceau. *p<0,05; **p<0,01; ***p<0,001. n=3. 
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5.3.2 Analysis of the APP/EGF and APP/EGFR interaction by GFP-Trap® 
Pull-Down 
Since the previously obtained results suggested a synergistic effect of APP with EGF in 
MAPK signaling, we further investigated the possibility of EGF and EGFR being two novel APP 
protein partners. With this purpose, immunoblots of the GFP pull-downs (Figure 23, 60 mm), 
were probed with the anti-EGF and anti-EGFR antibodies. 
When blots were probed with the anti-EGF antibody, cell lysates showed three 
immunoreactive EGF proteins corresponding to high molecular weight species ranging 94-110 
KDa. Apparent molecular masses of the different EGF species detected in the immunoblots 
were deduced from co-migration with known standards. Size analysis showed a major species 
of 110 kDa and two minor ones of 103 and 94 kDa (Figure 33). These detected species most 
possibly represent the precursor protein of EGF, namely prepro-EGF.   
 
 
Surprisingly, the detected lower molecular weight 94kDa species was an immunoreactive 
protein that was pulled-down by APP-GFP, which suggests a novel and unexpected interaction 
between APP and pro-EGF (Figure 33). Of note, the performed electrophoresis with 5-20% 
SDS-PAGE did not allow us to detect the lower molecular weight mature 6kDa EGF species, 
either in cell lysates or precipitated samples (data not shown).  
On the other hand, our initial attempt to detect EGFR protein failed because the respective 
antibody was not functioning properly (data not shown). 
Figure 33 – Evaluation of APP binding to EGF by the GFP-Trap pull-down assay. Western Blot analysis of HeLa cells 
grown on 60 mm plates and co-transfected with vectors (EGFP:Myc), APP-GFP:Myc, and APP-GFP:HB-EGF. 
Immunodetection of APP, Myc-HB-EGF and EGF precursor in cells lysates and GFP-pull-downs was accomplished 
with the indicated antibodies (Ab). HB, HB-EGF. 
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5.3.3 APP/HB-EGF- and APP/EGF – induced alterations in cellular 
morphology 
The effects of overexpressing APP-GFP and Myc-HB-EGF fusion proteins, solely or 
simultaneously, in cells morphology was also evaluated by immunocytochemistry procedures. 
Since appreciable effects were also observed in the biochemical analysis with EGF, the 
influence of EGF was also tested, having been generated two distinct sets of conditions. The 
first, aiming the analysis of APP-GFP and Myc-HB-EGF influence on cell morphology, consisted 
in four different transfection scenarios: 1) pEGFP-N1:pCMV-Myc; 2) APP-GFP:pCMV-Myc; 3) 
pEGFP-N1:Myc-HB-EGF, and 4) APP-GFP:Myc-HB-EGF. The second consisted in the analysis of 
cells exposed to EGF stimulation in three different transfection backgrounds: 1) pEGFP-N1; 2) 
APP-GFP and 3) APP-GFP:Myc-HB-EGF. Cells were visualized by fluorescence microscopy, and 
cells length was further quantified. 
Vector-transfected HeLa control cells presented an average cell length of ~53µm. APP 
overexpression (APP:Myc) resulted in cell elongation, with an average of ~65 µm of length. 
Interestingly, Myc-HB-EGF transfection resulted in the most remarkable elongation, with cells 
presenting an average cell length of ~85 µm. On the other hand, APP-GFP and Myc-HB-EGF co-
expressing cells resulted in lengths close to those of APP-GFP expressing cells. 
Concerning the EGF set, a similar increase in cells length as for APP was induced by the 
addition of EGF to the cell medium (EGFP+EGF; ~69 µm), when comparing to vector cells 
(EGFP:Myc). Despite the clear increase in cell elongation induced by EGF exposure, its effect 
was far from the one observed for HB-EGF. Although presenting a lower cell length, HeLa cells 
under EGF treatment exhibited a higher degree of cell plasticity, showing several ruffles 
emerging from the plasma membrane. Consistent with the previous results for HB-EGF, the 
EGF stimulation of APP-GFP expressing cells did not prompted additional cell elongation and 
the cell plasticity seemed to decrease comparing to EGFP+EGF cells. When APP:HB-EGF cells 
were treated with EGF even lower cell lengths were observed, and this represented the closest 
condition to vector cells (~58 µm). 
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Figure 34 – Analysis of APP/HB-EGF- and APP/EGF-induced alterations in cellular morphology. Transfected HeLa 
cells were analyzed for cell length. *p<0,05; **p<0,01; ***p<0,001. n=3 
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6 Discussion 
As previously mentioned, the study of PPIs is a powerful approach for inferring 
information about protein function. With this work we intended to study the interaction 
between the APP and HB-EGF proteins, and initiate the functional characterization of the 
complex through biochemical methods and visual analysis of subcellular distribution and co-
localization.  
Validation of the APP/HB-EGF interaction by yeast co-transformation. The YTH 
system has become one of the most popular and powerful tools to study PPIs, providing a 
sensitive in vivo assay for interaction analysis. From the YTH screen of a human brain cDNA 
library performed in our laboratory, HB-EGF was identified as a novel APP interactor, when 
using full-length APP as bait. Confirmation of the interaction in yeast was here performed by 
co-transformation of AH109 strain and assayed for reporter genes activation. Positive clones 
were obtained as accessed by their ability to grow on SD/QDO selective media and to turn blue 
in the presence of X-α-Gal. Hence, interaction of APP with HB-EGF was confirmed and 
validated by the YTH system. Additionally, HB-EGF was found not to interact with the APP 
intracellular domain (AICD), demonstrating that this region is not responsible for the 
interaction, and indicating that the interaction must occur via the APP N-terminus. Two N-
terminal domains are simultaneously responsible for APP growth promoting activities, MAPK 
activation and heparin/HSPG binding, and may mediate APP binding to HB-EGF: the GFLD 
domain at E1 (10,21) and the RERMS domain at E2 (3,10,13,21). Of note, these two APP 
domains appear to be the relevant biological sites underlying sAPP trophic actions (6,12). 
Interestingly, immediately adjacent to the GFLD domain is a hydrophobic surface patch that 
also constitutes a putative HB-EGF binding site on APP. This has to be confirmed in further 
studies aiming mapping the APP domain responsible for this interaction, for example by using 
APP deletion mutants. 
 
As with all detection methods, the YTH system is known to result in the detection of 
some false positive clones; however, the elimination of such false positives has been greatly 
improved by these recent YTH systems. False positive signals result from cells in which the 
reporter genes are active even though the bait and prey do not interact. There are several 
classes of false positives. For example, false positives may arise from preys that interact with 
DNA upstream of the reporter genes or with proteins that interact with promoter sequences. 
These two classes of false positives can be eliminated by the use of more than one reporter 
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gene under the control of different promoters, as was the case of the present work. Other 
false positives include interactions that occur in the YTH screen but not in a physiological 
context, because the partners are not co-expressed in the same cellular or subcellular 
environments. Hence, the new putative protein interaction found by YTH screening was 
further validated by other method, in order to strengthen the accuracy of PPI data and hence 
increase the knowledge on functional proteomics.  
 
Validation of the APP/HB-EGF interaction by pull-down assays and subcellular co-
localization. The GFP-Trap® Pull-Down is a reliable technique used to validate ex vivo protein 
interactions, and is based on the pull-down of GFP-trapped complexes. To validate the 
APP/HB-EGF interaction and its physiological relevance we attempted to demonstrate the 
complex formation between APP and Myc-HB-EGF, as well as endogenous HB-EGF, in a 
mammalian cell line (HeLa) transfected with APP-GFP and Myc-HB-EGF cDNAs. Immunoblot 
analysis using the anti-Myc-tag that recognizes the Myc-HB-EGF fusion protein, and the anti-
HB-EGF antibody that recognizes the various HB-EGF species, showed that APP interacts with 
both the exogenous and endogenous pro-domain-containing HB-EGF forms. These results are 
in agreement and further extend the results obtained in the YTH, validating the APP/HB-EGF 
interaction. 
Previous studies have shown that the HB-EGF propeptide domain is cleaved rapidly 
after synthesis of the precursor or readily as it reaches the cell surface, with PM-anchored HB-
EGF mainly consisting of ORF63– 208 (proHB-EGF) (37). As previously described, the HB-EGF cDNA 
was cloned into the pCMV-Myc vector, which contains the Myc tag in an N-terminal position 
relatively to the MCS. Therefore, since interaction was evidenced with the anti-Myc-tag 
antibody, we can point out that the APP/HB-EGF interaction is possible to occur as soon as pre-
proHB-EGF is synthetized by ER-bound ribosomes and through its trafficking in the Golgi and 
TGN. Indeed, APP-GFP mainly co-localized with Myc-HB-EGF in the Golgi apparatus and nearby 
vesicles, as expected for two fusion proteins being overexpressed that follow the same 
secretory pathway to be membrane-targeted and medium secreted. 
Facing the impossibility of detecting proHB-EGF (the form generated after prodomain 
cleavage) with the anti-Myc-tag antibody, the anti-HB-EGF antibody was used to evaluate 
whether the interaction also occurred with endogenous HB-EGF and with HB-EGF species 
other than pre-proHB-EGF. Of note, the immunogen used to create this antibody is a synthetic 
peptide derived from human HB-EGF corresponding to the 80-130 aa sequence (HB-EGF 
mature domain), with the antibody recognizing the pre-pro, pro, and soluble HB-EGF species. A 
positive interaction was detected between APP and various HB-EGF endogenous species 
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ranging from 31 to 37 KDa that most likely represent different degrees of post-translationally 
modified pre-proHB-EGF. Additionally, APP appeared to interact with a lower molecular weight 
form of HB-EGF (25 kDa) most possibly corresponding to proHB-EGF, although this needs 
further confirmation.  
Further studies will also address if the mature HB-EGF domain is the region responsible 
for binding APP. As previously reported (57), HB-EGF can be released at a very low rate under 
normal culture conditions, and we have barely detected it in the conditioned medium (data 
not shown). Therefore, the shedding of proHB-EGF under PKC or PMA stimulation will be used 
to ensure the presence of sHB-EGF in detectable levels in the incubation medium. 
Furthermore, a construct corresponding to prodomain-truncated soluble HB-EGF was 
designed, and will be generated and used in subsequent studies to better characterize 
APP/HB-EGF binding. Cell surface protein biotinylation assays will also be pursued to 
specifically test for the interaction with PM-anchored proHB-EGF forms. 
Very interestingly, the immunoblots probed with the CT695 antibody (recognizing the 
C-terminus of APP) detected not only APP-GFP but also endogenous APP in the pulled-down 
samples, which seems to represent APP homodimerization. Cell-bound APP was already 
reported to form dimers, with trans-dimerization promoting cell-cell adhesion and being 
mapped to the E1 and E2 APP regions (10,22). It was further shown that heparin binding to the 
E1 or E2 region would induce APP dimerization (13). As mentioned, heparin is also a HB-EGF 
interactor, and APP heparin-binding domains are involved in APP functions common to HB-
EGF. Thus, the formation of a cis (same PM) or a trans (cell-to-cell) complex between APP, 
proHB-EGF and heparin and/or HPSG, with a role in cell adhesion, appears feasible and is a 
hypothesis that should be pursued. 
 
The APP/HB-EGF molecular association might exert diverse effects depending on the 
context or subcellular compartment. Immunocytochemistry studies using the anti-Myc-tag 
antibody showed the expected higher localization of this pre-proHB-EGF form in the ER and 
Golgi (a structure extensively stained by APP-GFP) compartments, and in nearby larger vesicles 
possibly related to the TGN. A good degree of co-localization with APP-GFP could be observed 
in these regions, consistent with both proteins being processed via the secretory pathway. 
When using the anti-HB-EGF antibody, we could note that endogenous HB-EGF co-localizes at 
a much lesser extent with APP-GFP, with co-localization being occurring predominantly at 
small cytoplasmic vesicles distributed throughout the cell. Further experiments will be 
required to accomplish the identification of these cytoplasmic vesicles, namely to confirm their 
secretory origin. Endogenous HB-EGF also accumulates less at the ER and Golgi than Myc-HB-
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EGF, which was being overexpressed, indicating that HB-EGF is normally readily packaged into 
secretory vesicles under normal conditions. These results suggest that endogenous HB-EGF 
associates with APP at/after TGN sorting and at the cell membrane. Nonetheless, endogenous 
HB-EGF cell surface staining was barely visible and only in a few cells, indicating that in HeLa 
cells, proHB-EGF (and possibly part of the sHB-EGF) must be generated intracellularly. It will be 
interesting to observe if the same occurs in neuronal-like cells such as the SH-SY5Y line. 
Of note, an ICC procedure with both the anti-Myc-tag and anti-HB-EGF antibody 
performed in HB-EGF overexpressing cells, showed that the anti-HB-EGF antibody does not 
recognize efficiently transfected Myc-HB-EGF since very low levels of co-localization between 
this and the anti-myc-tag antibody occurred in Myc-HB-EGF expressing cells. It is possible that 
the newly synthesized Myc-HB-EGF, just before suffering any cleavage and still with the Myc 
tag, has the HB-EGF antibody epitope masked by the tag, impairing at some degree the 
antibody recognition of the recombinant Myc-HB-EGF fusion protein. This only occurred in 
native folding conditions such as in ICC, but not in reducing conditions such as in the WB assay. 
 
Several growth factors and cytokines are synthesized as membrane-anchored proteins, 
and these are not only the precursor forms of soluble factors but also biological active 
molecules. Membrane-anchored forms may have different biological activity from their soluble 
counterparts, acting in a juxtacrine way, and their activity can be regulated by associating 
molecules. There are reported evidences that proHB-EGF may have opposite effects than sHB-
EGF: while this always presents growth-promoting activity, proHB-EGF has the ability to 
suppress the growth of cancer cells through continuous and sustained EGFR phosphorylation 
and up-regulation (37,70). Association with APP might specifically increase some of the proHB-
EGF functions, as it occurs with its association with CD9, which enhance HB-EGF binding to DT 
and its mitogenic activity. Together with integrin α3β1, proHB-EGF and CD9 were found to co-
localize at cell–cell contact sites near adherence junctions, where EGF receptors and APP are 
also localized. APP may stabilize membranar proHB-EGF and deviate it for a cell adhesion 
and/or cell migration role, forming a complex with proHB-EGF, CD9 and integrin α3β1. Indeed, 
APP and integrins interact and are known to be involved in cell adhesion and migration (13,14). 
APP might also direct proHB-EGF for a specific receptor, either ErB1 or Erb4, with different 
physiological outputs (37,42,43,84). 
 
Influence of APP and HB-EGF in each other protein levels. WB analyses showed that 
exogenous HB-EGF and APP-GFP levels decreased when both fusion proteins were co-
transfected, when compared to their ‘solely’ transfection. The observed decay in the 
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exogenous APP levels propelled us to further evaluate mature and immature APP levels. The 
amount of mature APP-GFP was indeed suffering a considerable decline, raising some 
questions. First, it was considered the possibility of HB-EGF being, in someway, impairing the 
exogenous APP maturation process, but the percentage of mature APP-GFP against its total 
amounts did not decreased. Hence, Myc-HB-EGF did not hindered maturation in the secretory 
pathway. A second hypothesis that would suit the current results was the possibility of HB-EGF 
being promoting APP proteolysis to sAPP. However, HB-EGF induced a decrease in soluble APP 
secretion for the cell medium, for both endogenous and exogenous sAPP, allowing us to rule 
out this hypothesis. Further, sAPP levels in APP-GFP samples decreased to a similar extent as 
the full length APP-GFP levels (~65%), pointing the later as the reason for lesser sAPP. 
Concerning the impairment in APP-GFP levels, we can hypothesize that Myc-HB-EGF interferes 
with its vesicular post-TGN trafficking and/or promotes mature APP degradation via the 
lysosomal machinery. This hypothesis remains to be tested but an experiment to address it 
was already designed. Further, these results can also be co-transfection artifacts, resulting 
from less availability and binding to the transfection reagent in co-transfection conditions. This 
is feasible, since APP and HB-EGF have opposite effects on each other endogenous protein 
levels, as described below.  
APP appears to induce a slight increase in endogenous HB-EGF, but this has to be 
further validated in subsequent experiments. Further, HB-EGF overexpression induced an 
increase in total endogenous APP, either immature or mature. The amount of the mature APP 
form was especially increased, confirmed by the higher percentage of APP maturation in HB-
EGF overexpressing cells. In what concerns this effect, we can postulate that HB-EGF is 
retaining mature APP in secretory vesicles and/or at the plasma membrane, so that they can 
act synergistically in cell surface adhesion and interacting with proteins of the extracellular 
matrix, since both appear to be involved in membrane-matrix stabilization.  
Concerning the raise in the endogenous APP levels, two feasible explanations were 
purposed: HB-EGF can be somehow promoting APP’s half-life or, in a neurotrophin-like 
scenario (85,86), promoting APP gene transcription. Through the use of radioactivity-based 
techniques, the half-life of total cellular APP was estimated to be of approximately 1 h (29). 
After exposing cells for 1h to cycloheximide (an inhibitor of protein synthesis), we observed 
that the amounts of endogenous APP suffered a significant and similar decline in both control 
and Myc-HB-EGF expressing cells. This suggests that the increase of endogenous APP is not 
due to an increase in APP’s half-life because, if this was the case, the decrease in APP protein 
levels would not be as accentuated as in control condition (87). Thus, the remarkable 
upregulation in endogenous APP levels is likely due to a positive regulation of APP gene 
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transactivation, potentially through the nuclear translocated HB-EGF C-terminus. As already 
observed for neurotrophins such as NGF and BDNF, APP may sustain long-term signaling for 
HB-EGF. Neurotrophins also lead to increased APP levels (by gene transactivation) and, later 
on, to its cleavage to sAPP and AICD. These topics here addressed will need further 
investigation through mRNA studies and the use of HB-EGF deletion constructs.  
 
Influence of APP and HB-EGF overexpression in Erk and STAT3 signaling. Concerning 
the influence of HB-EGF and APP overexpression in Erk signaling, we could observe that HB-
EGF overexpression led to a 3,10 FI in MAPK activation, which corroborates several previous 
studies reporting that HB-EGF signals preferentially through the MAPK signaling pathway. Very 
interestingly, APP overexpression alone drove the second highest effects on the rate of MAPK 
activation (FI of ~2). While APP:HB-EGF co-transfection still induced an increase in MAPK 
activation over control condition, it decreased the rate of MAPK activation relatively to HB-
EGF, suggesting that APP/HB-EGF interaction does not necessarily leads to MAPK activation. 
Concerning the effects in STAT3 signaling, HB-EGF, either alone or co-expressed with APP-GFP, 
did not affect this pathway. Further, it was realized that APP-GFP overexpression per se slightly 
decreased the rate of STAT3 phosphorylation. 
When APP is associated with pre-pro and proHB-EGF in HeLa cells the Erk signaling is 
not preferentially activated, which may, in part, be due to the induced decrease of soluble APP 
secretion. Indeed, it is previous knowledge that sAPP promotes the Erk signaling activation 
(88,89). Similarly, impairment in soluble HB-EGF secretion may be occurring, which would 
contribute to this scenario, and this will be further pursued. 
 
APP effects on EGF-induced signaling. As expected for EGF itself, it prompted a 
170±20 FI in MAPK phosphorylation, comparing to the basal condition. Consistent with the 
previous obtained results for the influence of APP overexpression in MAPK signaling, also in 
these experiments APP alone was able to again drive a 2-fold increase in MAPK 
phosphorylation. Very interestingly, a remarkable result was obtained when APP 
overexpressing cells were exposed to EGF treatment. APP overexpression led to a ~2,3 FI 
increase in P-MAPK levels, comparing to cells transfected with the EGFP vector and treated 
with EGF. This means that APP acts synergistically with EGF to significantly enhance MAPK 
activation, and hence promoting sEGF-induced Erk signaling.  
The influence of APP in the STAT3 signaling was confirmed by this set of studies, 
resulting in a decrease on STAT3 phosphorylation of approximately 30%; nonetheless, this 
decrease was abolished under EGF stimulation. Therefore, unlike for Erk signaling, APP is not 
  SACS/UA 2013 
Unraveling the APP/HB-EGF Interaction  97 
prone to signal through the STAT3 cascade but may not totally impair it when it is activated by 
other signals. 
 
Analysis of the APP/EGF and APP/EGFR interaction by GFP-Trap Pull-Down. Towards 
analyzing the possibility of APP to interact with two more proteins involved in the EGFR 
signaling pathway, namely EGF itself and EGFR, the immunoblots of the APP:HB-EGF pull-down 
experiments (60 mm) were probed for these two proteins. 
First, the anti-EGF antibody was used and the presence of three immunoreactive 
proteins, ranging from 94-110 kDa, was demonstrated in HeLa cell lysates, which most likely 
represent pre-proEGF and proEGF species with different glycosylation degrees. Similar 
maturation of the membrane-associated proEGF was previously reported in rat kidney (57). 
Further, these authors have described that HeLa cells transiently transfected with pre-proEGF 
cDNA first produce the EGF high molecular weight precursor, proEGF, and that this precursor is 
membrane anchored, being expressed at the cell surface as shown by biotinylation 
experiments (57). Similarly to human HB-EGF, the EGF species detected in HeLa cell lysates are 
most possibly pre-pro and proEGF, found intracellularly and at the cell surface. Of note, data 
reported on mouse EGF are similar to those obtained for mouse HB-EGF and suggests that the 
proEGF is the form that is preferentially found at the cell surface.  
Surprisingly, the 94 kDa immunoreactive species was also clearly detected in APP pull-
down precipitates, evidencing a novel interaction between APP and a proEGF species. Further 
experimental studies will be needed in order to understand what species these bands may 
represent, to confirm this novel interaction, and to study whether the same result is obtained 
for the 6 kDa soluble EGF form. Indeed, this result raises the question if the EGF domain is the 
main region promoting binding to APP, and this has to be further tested. Of note, the HB-EGF 
heparin-binding domain lies mostly N-terminal to the EGF-like domain but partially overlaps 
with this. In addition, it would also be interesting to evaluate if proHB-EGF competes with pro-
EGF for APP.  
Due to the remarkable results obtained with the EGF studies and since HeLa cells 
express endogenous EGFR at physiological levels at the cell surface, this receptor was also 
tested for binding to APP. Unfortunately, our initial attempt to detect EGFR protein failed since 
the antibody was not working properly and failed to recognize the endogenous EGFR protein in 
all tested cell lysates. 
We may hypothesize that while EGFR is a high affinity cell surface receptor for proEGF 
and proHB-EGF, APP functions as a lower affinity receptor for these (and other precursors of 
growth factors and cytokines), regulating their autocrine and juxtacrine roles. Indeed, APP-GFP 
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overexpression was observed to induce a sustained but low response in the MAPK activation 
(2.0 FI), while EGFR activation via sEGF resulted in a fast and robust MAPK activation 
(increased by ~170 times in 30 min). Further, these pathways may compete, since AICD leads 
to a long-term decrease in EGFR levels, and/or APP may signal through EGFR, what needs to be 
further addressed. 
 
APP/HB-EGF- and APP/EGF – induced alterations in cellular morphology. Very 
interestingly, HB-EGF overexpression rendered a significant promotion of cell elongation, with 
cells presenting an average cell length of ~85 µm, comparing to the ~53 µm measured in 
vector transfected cells (Figure 34). While cells treatment with EGF also resulted in cell 
elongation, it was considerably inferior to the one induced by HB-EGF, with EGF main effect 
being to induce cell plasticity. A parallel can be drawn with the effects reported for HB-EGF in 
neurite outgrowth, via activation of the ERK signaling pathway, an effect never been reported 
for EGF (84). 
When APP was co-transfected with HB-EGF, it appears that the cell elongation 
prompted by HB-EGF was inhibited to APP values, similarly to what occurred in Erk activation 
assays. This points out that, besides apparently not signaling through Erk (or STAT3), the 
physiological function of the APP/HB-EGF interaction is probably not to mediate cell 
differentiation. When APP-GFP cells were stimulated with EGF, no significant alteration on cell 
elongation could be observed (Figure 34).  
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7 Conclusions 
We have here first described the interaction between APP and cellular HB-EGF. Taken 
together, results indicate that the HB-EGF binding domain in the APP protein is most likely 
located at the APP N-terminus, most probably at one of the APP heparin-binding motifs 
responsible for APP trophic role. This hypothesis needs further confirmation, together with the 
hypothesis that the prodomain and/or the mature domain on HB-EGF are responsible for APP 
binding. Outstandingly, we also first describe the physical interaction between APP and cellular 
EGF, a widely known mitogenic and trophic factor, strengthening the hypothesis that the EGF 
domain is the region that binds to APP.  
 In a first set of experiments, we have observed that while APP and EGF seem to have a 
synergistic effect in promoting EGF-induced Erk signaling, the same does not occur for APP and 
HB-EGF, that appear to have opposite effects in this respect. Nonetheless, the experimental 
conditions tested were different, and this signaling interference has still to be evaluated in APP 
overexpressing cells exposed to soluble HB-EGF. It will be also important to tests whether the 
APP ‘basal’ effect in MAPK phosphorylation is mediated by its binding to proEGF and/or proHB-
EGF, by e.g. siRNA interfering assays.  
The relevance of these interactions will certainly be further addressed by us. Due to 
their tissue distribution, APP and EGF interaction should be of major importance regulating 
non-brain tissues, while APP and HB-EGF interaction may be of higher functional relevance in 
neuronal tissues, where it is known to be expressed at much higher levels than EGF (44,50). 
APP and HB-EGF role in brain show quite an overlap. In fact, HB-EGF and APP/sAPP have been 
implicated in neuronal survival, glial/stem cell proliferation and differentiation, contributing to 
adult neurogenesis in the dentate gyrus of the hippocampus (49). Importantly, evidences 
suggest that HB-EGF may be one of the important contributors to synaptic plasticity and 
memory formation in the hippocampus, determinant functions also reported for APP, and 
found impaired in AD.  
In summary, our recent findings place HB-EGF and EGF as important players in multiple 
steps of APP signaling, and vice-versa. The identification of novel putative APP interactors such 
as these will always represent a hallmark in molecular biology studies, since they can 
potentially help to understand the biology of APP, and, ultimately, better characterize APP-
related AD pathogenesis.  
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9 Appendix 
Culture media and solutions 
I. Bacterial media 
 
 LB (Luria-Bertani) Medium 
To 950 mL of deionised H2O add:  
LB 25 g  
Agar 15 g (for plates only)  
Shake until the solutes have dissolved. Adjust the volume of the solution to 1 L with deionised 
H2O. Sterilize by autoclaving.  
 SOB Medium 
To 950 mL of deionised H2O add: 
SOB Broth 25.5 g  
Shake until the solutes have dissolved. Add 10 mL of a 250mM KCl (prepared by dissolving 
1.86g of KCl in 100 mL of deionised H2O). Adjust the pH to 7.0 with 5N NaOH. Just prior to use 
add 5 mL of a sterile solution of 2M MgCl2 (prepared by dissolving 19 g of MgCl2 in 90 mL of 
deionised H2O). Adjust the volume of the solution to 1 L with deionised H2O and sterilize by 
autoclaving). 
 SOC Medium  
SOC is identical to SOB except that it contains 20 mM glucose. After the SOB medium has been 
autoclaved, allow it to cool to 60°C and add 20 mL of a sterile 1M glucose (this solution is made 
by dissolving 18 g of glucose in 90 mL of deionised H2O; after the sugar has dissolved, adjust 
the volume of the solution to 1 L with deionised H2O and sterilize by filtration through a 0.22-
micron filter. 
II. Yeast Media  
 
 SD synthetic medium 
To 800 mL of deionised H2O add:  
Yeast nitrogen base without amino acids (DIFCO) 6.7 g 
Agar (for plates only) 15 g 
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Shake until the solutes have dissolved. Adjust the volume to 850mL with deionized H2O and 
sterilize by autoclaving. Allow medium to cool to 60°C and add glucose to 2% (50 mL of a 
sterile 40% stock solution) and 100 mL of the appropriate 10x dropout solution. 
 10x Dropout solution (10x DO)  
This solution contains all but one or more of the following components: 
 
 
10x dropout supplements may be autoclaved and stored for up to 1 year. 
 YPD medium 
To 950 mL of deionised H2O add: 
YPD 50 g 
Agar 15 g (for plates only) 
Shake until the solutes have dissolved. Adjust the volume to 1 L with deionized H2O and 
sterilize by autoclaving. Allow medium to cool to 60°C and add glucose to 2% (50 mL of a 
sterile 40% stock solution). 
 TE Buffer (pH 7.5) 
10 mM Tris-HCl (pH 7.5) 
1 mM EDTA (pH 8.0) 
 10x 
concentration 
(mg/L) 
SIGMA # 
L-Isoleucine 300 I-7383 
L-Valine 1500 V-0500 
L-Adenine hemisulfate salt 200 A-9126 
L-Arginine HCl 200 A-5131 
L-Histidine HCl monohydrate 200 H-9511 
L-Leucine 1000 L-1512 
L-Lysine HCl 300 L-1262 
L-Methionine 200 M-9625 
L-Phenylalanine 500 P-5030 
L-Threonine 2000 T-8625 
L-Tryptophan 200 T-0254 
L-Tyrosine 300 T-3754 
L-Uracil 200 U-0750 
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III. Cell culture Solutions and Immunocytochemistry  
 
 DMEM Medium 
For a final volume of 1 L, dissolve one pack of DMEM powder (with L-glutamine and 
4500 mg glucose/L; Sigma Aldrich) in deionized H2O and add 3.7 g NaHCO3 (Sigma 
Aldrich). Adjust to pH 7.4. Sterilize by filtering through a 0,2 µm filter and store at 4°C. 
 Complete DMEM (HeLa cells)  
For a final volume of 1 L, when preparing DMEM medium adjust to pH 7.4 and before 
sterilizing add: 100 mL (10% v/v) Fetal bovine Serum (FBS; Gibco BRL, Invitrogen).  Notes: FBS is 
heat-inactivated for 30 min at 56°C. For cell maintenance, prior to pH adjustment add 100 
U/mL penicillin and 100 mg/mL streptomycin (100 mL Streptomycin/Penicilin/Amphotericin 
solution (Gibco BRL, Invitrogen)). 
 PBS (1x) 
For a final volume of 500 ml, dissolve one pack of BupH Modified Dulbecco’s Phosphate 
Buffered Saline Pack (Pierce) in deionised H2O. Final composition:  
8 mM Sodium Phosphate 
2 mM Potassium Phosphate 
140 mM Sodium Chloride 
10 mM Potassim Chloride 
 Sterilize by filtering through a 0.2 μm filter and store at 4°C.  
 4% Paraformaldehyde Fixative solution 
For a final volume of 100 mL, add 4g of paraformaldehyde to 25 mL deionised H2O. Dissolve by 
heating the mixture at 58°C while stirring. Add 1-2 drops of 1 M NaOH to clarify the solution 
and filter (0.2 μm filter). Add 50 mL of 2X PBS and ajust the volume to 100 mL with deionised 
H2O.  
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IV. Solutions for proteins manipulation 
SDS-PAGE and Immunoblotting Solutions 
 (4x) LGB (Lower gel buffer)  
To 900 ml of deionised H2O add:  
Tris 181.65 g 
SDS 4 g 
Mix until the solutes have dissolved. Adjust the pH to 8.9 and adjust the volume to 1L with 
deionised H2O. 
 (5x) UGB (Upper gel buffer)  
To 900 ml of deionised H2O add:  
Tris 75.69 g 
Mix until the solute has dissolved. Adjust the pH to 6.8 and adjust the volume to 1 L with 
deionised H2O. 
 30% Acrylamide/0.8% Bisacrylamide 
To 70 ml of deionised H2O add: 
Acrylamide 29.2 g 
Bisacrylamide 0.8 g 
Mix until the solute has dissolved. Adjust the volume to 100 ml with deionised water. Filter 
through a 0.2 μm filter and store at 4°C. 
 10% APS (ammonium persulfate) 
In 10 ml of deionised H2O dissolve 1 g of APS. Note: prepare fresh before use.  
 10% SDS (sodium dodecilsulfate) 
In 10 ml of deionised H2O dissolve 1 g of SDS. 
 Resolving (lower) gel solution for gradient gels (60 ml)  
 5% 20% 
H2O 17,4 ml 2,2 ml 
30% Acryl/0.8% Bisacryl solution 5 ml 20 ml 
LGB (4x) 7,5 ml 7,5 ml 
10% APS 150 μL 150 μL 
TEMED 15 μL 15 μL 
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 Stacking (upper) gel solution (20 ml) 
 3,5% 
H2O 13,2 ml 
30% Acryl/0.8% Bisacryl solution 2,4 ml 
UGB (5x) 4,0 ml 
10% APS 200 μL 
10% SDS 200 μL 
TEMED 20 μL 
 
 (4x) Loading Gel Buffer  
1 M Tris solution (pH 6.8) 2.5 mL (250 mM) 
SDS 0.8 g (8%) 
Glicerol  4 ml (40%) 
β-Mercaptoetanol 2 ml (2%) 
Bromophenol blue 1 mg (0.01%) 
Adjust the volume to 10 ml with deionised H2O. Store in darkness at room temperature. 
 1 M Tris (pH 6.8) solution 
To 150 ml of deionised H2O add:  
Tris base 30.3 g 
Adjust the pH to 6.8 and adjust the final volume to 250 ml.  
 10x Running Buffer 
Tris 30.3 g (250 mM) 
Glycine 144.2 g (2.5 M) 
SDS 10 g (1%) 
Dissolve in deionised H2O, adjust the pH to 8.3 and adjust the volume to 1 L. 
 1x Transfer Buffer  
Tris 30.3 g (250 mM) 
Glycine 144.2 g (192 mM) 
Mix until solutes dissolution. Adjust the pH to 8.3 with HCl and adjust the volume to 800 ml 
with deionised H2O. Just prior to use add 200 ml of methanol (20%). 
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 10x TBS (Tris buffered saline)  
Tris 12.11 g (10 mM) 
NaCl 87.66 g (150 mM) 
Adjust the pH to 8.0 with HCl and adjust the volume to 1L with deionised H2O. 
 10x TBST (TBS+Tween) 
Tris 12.11 g (10 mM) 
NaCl 87.66 g (150 mM) 
Tween 20 5 ml (0.05%) 
Adjust the pH to 8.0 with HCl and adjust the volume to 1L with deionised H2O.  
 Membranes Stripping Solution (500 ml)  
Tris-HCl (pH 6.7) 3.76 g (62.5 mM) 
SDS 10g (2%) 
β-mercaptoethanol 3.5 ml (100 mM) 
Dissolve Tris and SDS in deionised H2O and adjust with HCl to pH 6.7. Add the β-
mercaptoethanol and adjust volume to 500 ml. 
 ECL home-made (250 ml) 
Solution A - ECL luminol solution (Stock solution):  
20 mM luminol (in DMSO) * 1.25 ml (100μM) 
100 mM 4-iodophenol (in DMSO) * 5 ml (2mM) 
0.1 M Tris (pH 9.35) 125 ml (50 mM) 
Adjust volume to 250 ml with deionised H2O.  * Protect from the light; conserve at -20°C 
Solution B – Hydrogen peroxide 
Pull-down solutions 
 Lysis buffer (5 ml) 
50 mM Tris (pH 8) 250 μl of 1M Tris (pH 8) 
25% glycerol  1250 μl 100% glycerol 
0.5% Gepac-ca-630 (NP40)  250 μl 10% NP40 
200 mM NaCl  200 μl 5M NaCl 
β-mercaptoethanol  0,35 μl β-mercaptoethanol 
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1 mM PMSF  50 μl 100 mM PMSF 
Protease inhibitor cocktail  5 μl of protease inhibitor cocktail 
Keep all on ice. 
 Wash buffer (20 ml) 
10 mM Tris (pH 8)  200 μl of 1M Tris (pH 8) 
0.1% Gepac-ca-630 (NP40)  200 μl 10% NP40 
150 mM NaCl  600 μl 5M NaCl 
0.25 mM EDTA  40 μl 0.25M EDTA 
1 mM PMSF  200 μl 100 mM PMSF 
Protease inhibitor cocktail  20 μl of protease inhibitor cocktail 
Keep all on ice. 
 
V. Solutions for DNA manipulation 
 
 50x TAE Buffer Tris base 
Tris base 242 g 
Glacial acetic acid 57.1 mL 
0.5M EDTA (pH 8.0) 100 mL 
 
 TE Buffer (pH 7,5) 
10 mM Tris-HCL pH 7,5 
1 mM EDTA pH 8,0 
 
 6x Loading Buffer (LB) 
Bromophenol blue 0.25% 
Glycerol 30% 
 
 Competent Cell Solutions  
Solution I (1L): 
MnCl2.4H2O 9.9 g  
CaCl2.2H2O 1.5 g   
SACS/UA 2013 
116   Luísa Filipe Henriques Martins de Bastos 
Glycerol 150 g 
KHAc 1M 30 mL  
Adjust the volume of the solution to 1 L with deionised H2O. Adjust pH to 5.8, filter through a 
0.2 μm filter and store at 4°C. 
Solution II (1L): 
0.5M MOPS (pH 6.8) 20 mL  
RbCl 1.2 g 
CaCl2.2H2O 11g 
Glycerol 150 g 
Adjust the volume of the solution to 1 L with deionised H2O. Filter through a 0.2 μm filter and 
store at 4°C. 
 Miniprep Solutions  
Solution I: 
50 mM glucose  
25 mM Tris.HCl pH 8.0  
10 mM EDTA 
 
Solution II: 
0.2 N NaOH  
1% SDS 
 
Solution III: 
3 M potassium acetate  
2 M glacial acetic acid 
 
 Midiprep Solutions  
Cell Resuspension Solution: 
50 mM Tris-HCl (pH 7.5) 
10 mM EDTA 
100 µg/mL RNAase A 
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Cell Lysis Solution: 
0.2 M NaOH 
1% SDS 
 
Neutralization Solution: 
4.09 M Guanidine hydrochloride (pH 4.8) 
759 mM potassium acetate 
2.12 M Glacial acetic acid 
 
Column Wash Solution: 
60 mM potassium acetate 
8.3 mM Tris-HCl (pH 7.5) 
0.04 mM EDTA 
60 % ethanol 
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Plasmids 
 
 
 
pACT2 (Clontech) map and multiple cloning sites. Unique sites are in bold. pACT2 is used 
to generate a hybrid containing the GAL4 AD, an epitope tag and a protein encoded by a cDNA 
in a fusion library. The hybrid protein is expressed at medium levels in yeast host cells from an 
enhanced, truncated ADH1 promoter and is targeted to the nucleus by the SV40 T-antigen 
nuclear localization sequence. pACT2 contains the LEU2 gene for selection in Leu- auxotrophic 
yeast strains. 
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pAS2-1 (Clontech) map and multiple cloning sites. Unique restriction sites are coloured 
blue. pAS2-1 is a cloning vector used to generate fusions of a bait protein with the GAL4 DNA-
BD. The hybrid protein is expressed at high levels in yeast host cells from the full-length ADH1 
promoter. The hybrid protein is targeted to the yeast nucleus by nuclear localization 
sequences. pAS2-1 contains the TRP1 gene for selection in Trp- auxotrophic yeast strains. 
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pCMV-Myc (Clontech) restriction map and multiple cloning sites. Unique restriction sites 
are in bold. pCMV-Myc is a mammalian expression vector with an N-terminal c-Myc epitope 
tag. This vector possesses the ampicillin resistance gene for selection in E. coli. 
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pEGFP-N1 (Clontech) restriction map and multiple cloning sites. Unique restriction sites 
are in bold. pEGFP-N1 is a mammalian expression vector with the EGFP coding sequence 
located in a C-terminal position to the MCS. This vector possesses the kanamicin resistance 
gene for selection in E. coli. 
 
 
 
